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Natural products are chemical compounds produced by plants, animals and 
microorganisms.  These compounds are of great interest for their diverse range of 
structures and biological functions.  As many natural products are produced by their 
organisms in vanishingly small quantities it is often impossible to fully study their 
chemical properties and biological functions without the ability to reliably synthesise 
them in the laboratory.   
Total synthesis is the term given to the synthetic preparation of complex natural 
products from simple, readily-available chemical starting materials.  One method that 
can be used to help develop methods for the total synthesis of natural products is to 
emulate the way in which nature synthesises these compounds inside the living 
organism.  This branch of chemistry, referred to as biomimetic synthesis, aims to 
understand the way complex natural products are formed in nature (biosynthesis) and 
use this knowledge to develop practical laboratory syntheses. 
This thesis describes the biomimetic total synthesis of three natural products, called 
millingtonine, incargranine A and incargranine B, discovered in medicinally important 
plants from China and Southeast Asia.  For each of these natural product targets, we 
analysed how the plant was likely to biosynthesise the compound.  Based on this 
analysis, we were able to develop efficient strategies to prepare all three natural 
products from cheap, commercially-available materials. 
As part of our studies into the biosynthesis of millingtonine, incargranine A and 
incargranine B, we proposed that these, along with several other natural products, were 
likely formed in nature through a web of interconnected biosynthetic pathways.  
Successful synthetic investigations in the laboratory allowed us to demonstrate the 
relationships between these natural products as well as identifying several new 









Biomimetic synthesis is the branch of synthetic organic chemistry which attempts to 
learn from nature into order to solve the challenges of chemical synthesis.  This thesis 
describes application of biomimetic principles to the total synthesis of three 
phenylethanoid alkaloid natural products: incargranine B; millingtonine and 
incargranine A.  Chapter 1 provides a general introduction to the area.  Specific 
introductions can be found at the start of each chapter. 
Chapter 1 introduces the concept of biomimicry and provides a brief overview of the 
development of the underlying concepts and terminology.  The major biosynthetic 
pathways involved in the production of incargranine B, millingtonine and incargranine 
A (shikimic acid, ornithine alkaloids) are also introduced.   
Chapter 2 discusses the synthesis of incargranine B.  Biosynthetic analysis of this 
dimeric alkaloid led us to question its structural assignment and suggest a structural 
revision.  This speculative reassignment was validated through a biomimetic total 
synthesis of our proposed structure.  Incargranine B was successfully prepared in a 
longest linear sequence of six steps, forming three new rings, four bonds and three 
contiguous stereocentres in a single biomimetic domino condensation/Mannich/SEAr 
sequence. 
Chapter 3 describes the synthesis of millingtonine.  We proposed that millingtonine is 
biosynthetically related to incargranine B through a divergent/re-convergent network 
of pathways.  Synthetic exploration of this hypothesis culminated in the total synthesis 
of millingtonine and discovery of an unanticipated biosynthetic intermediate, dia-
millingtonine, which we propose as a previously unidentified natural product.  .  
Chapter 4 details the synthesis of incargranine A.  Incorporating dia-millingtonine into 
our biosynthetic hypothesis allowed the development of a four step bioimimetic total 
syntheses of incargranine A which was scaled-up to provide over one gram of natural 
product. 
Chapter 5 summarises the work presented and provides a perspective on its 
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1 GENERAL INTRODUCTION 
1.1 BIOMIMETIC SYNTHESIS 
This chapter provides a general introduction to the field of biomimetic chemistry, 
specific introductions can be found at the start of chapters 2, 3 and 4.  A perspective, 
containing a review of literature relevant to this work can be found in chapter 5.  Note 
that, unless otherwise specified, reactions in this thesis were carried out at room 
temperature. 
1.1.1 The Development of Biomimetics 
Biomimetics, biomimicry, bionics and bio-inspired are all terms used to describe a 
simple underlying concept – learning from nature in order to solve problems.  Using 
nature as a source of innovation has been a fundamental feature of human development 
throughout history.  Innumerable examples of important innovations which, either 
definitely, or probably, resulted from observations of nature can be found.  For 
example, even simple innovations such as the fishing net can be viewed as probably 
inspired by observing spiders’ webs, while the observation of many swimming 
creatures presumably led people to experiment with artificial fins and flippers to aid 
with swimming and diving.1  Further examples of a more deliberate and considered 
use of nature as a source of inspiration, one could look to Leonardo da Vinci’s studies, 
albeit theoretical, of birds in an attempt to design a flying machine,2 or the many 
architectural works of Antoni Gaudí, or possibly the most well-known example of 
biological inspiration in use today, Velcro® which was invented by the Swiss engineer 
George de Mestral inspired by the burdock burr.3 
Despite the ubiquity of looking to nature for inspiration, biomimetics as a coherent 
field of endeavour is very young.  Although many people, across a wide range of fields, 
have articulated the concepts of biomimetics and proposed various definitions and 
names for these ideas over time, the birth of the field of biomimetics can generally be 
traced back to the late 1950s and the work of Jack Steele and Otto Schmitt.1,2,4  Steele, 
a medical doctor working for the US Airforce, is credited with coining the term 




on natural systems, or whose properties resemble those of natural systems or are 
analogous to them.”4  At a similar time, Otto Schmitt had begun to develop the concept 
he would later call biomimetics, initially describing it as an often neglected corollary 
to conventional biophysics.  In 1957 he noted that, conventionally, biophysics was 
considered to be a physics approach to biological problems, but it could also be 
considered as a biological approach to the problems of engineering and physics.5  It 
was to describe this corollary to conventional biophysics, the use of thinking from 
biology to tackle the problems of physical sciences and engineering, that Schmitt 
coined the term ‘biomimetic’ in 1969.5 
 
1.1.2 The Development of Biomimicry in Organic Chemistry  
As in other fields, the use of biomimetic thinking in chemistry far predates the 
development of a separate discipline or terminology.  The first examples of biomimetic 
thinking can be found nearly eighty years before the first use of the term ‘biomimetic 
chemistry’.6–8  In the 1890s John Collie, provided the foundation for what would later 
become known as polyketide chemistry through a series of arguably biomimetic 
studies.  Collie successfully demonstrated the capacity of linear polyketides, such as 
diacetylacetone (1.2), to form a wide range of cyclic and aromatic structures through 
sequences of simple condensation reactions.7–9   
 
Scheme 1.1: Collie's early polyketide studies7,8 
In particular, in probably the first reported example of a biomimetic synthesis of a 




by treatment with barium hydroxide to give diacetylacetone (1.2), which on 
subsequent acidification yielded orcinol (1.1) (Scheme 1.1).7 
Collie subsequently noted that, by varying the conditions, the linear polyketide 
intermediate could be intercepted to produce a wide range of different products.  For 
example, if the crude diacetylacetone (1.2) was not acidified and was allowed to stand 
under basic conditions for an extended time, the dimeric napthol (1.4) was produced 
instead of orcinol (1.1).8  These observations led Collie to hypothesise that many 
natural products could be assembled through the sequential build-up of polyketide 
chains which could then undergo a range of cyclisations and other modifications such 
as hydration, dehydration, decarboxylation or incorporation of ammonia to give a great 
diversity of structures.8–10  Despite these ideas being largely overlooked at the time,11,12 
they are remarkably close to our current understanding of polyketide biosynthesis.9,13  
Although Collie’s work was not deliberately biomimetic in the sense that he did not 
start out with the intention of imitating nature, his thinking shows a lot of features 
which people such as Otto Schmitt would later identify as biomimetic.  While 
acknowledging that laboratory synthesis was much less sophisticated than nature, 
Collie noted “Although, however, the actual reactions taking place in plants are 
different from those in the laboratory, still much may be done by studying, in the 
laboratory, reactions which might quite conceivably occur in plants”.10  As well as 
highlighting the potential to learn more about nature by studying fundamental 
chemistry in the laboratory, Collie also noted the possibility of using our understanding 
nature’s synthetic approach to benefit synthetic chemistry, saying “I think, therefore, 
that when it is possible to show that by merely using the simplest kind of change, 
namely condensation, acetyl groups will produce pyridine, benzene and naphthalene 
derivatives, we have imitated nature in a remarkable manner”.8 
The next, and probably most famous, landmark in the development of biomimetic 
chemistry is Sir Robert Robinson’s 1917 synthesis of tropinone (1.5).14  Despite being 
a truly remarkable synthesis in many ways and often being cited as the first example 
of biomimetic synthesis,15 it is probable that, like Collie’s early work, this was not 
designed to be biomimetic.16  In some ways the approach taken by Robinson can be 




explaining his approach to the problem, Robinson notes “an inspection of the formula 
of tropinone discloses a degree of symmetry…By imaginary hydrolysis at the points 
indicated by the dotted lines, the substance may be resolved into succindialdehyde, 
methylamine and acetone, and this observation suggested a line of attack of the 
problem” (see Scheme 1.2).14   
 
Scheme 1.2: Robinson's synthesis of tropinone (1.5)14 
By following this analysis almost exactly, Robinson was able to develop a synthesis 
of tropinone (1.5) via a three component condensation of succindialdehyde, 
methylamine and acetone dicarboxylic acid (which he found gave higher yields than 
acetone) (Scheme 1.2).14   
As in the case of Collie’s work, the biomimetic aspect of Robinson’s tropinone (1.5) 
synthesis arguably came subsequent to the successful laboratory synthesis.16  In a 
paper submitted some 10 days later, Robinson proposed a biosynthetic hypothesis for 
a range of pyrrolidine and piperidine alkaloids, including tropinone (1.5).17  To a great 
extent this biosynthetic proposal was inspired by and mirrored his successful synthesis 
of tropinone (1.5).18  In making his biosynthetic proposal Robinson commented on the 
potential of synthetic chemistry to provide insight into natural processes, noting “the 
synthesis of tropinone recently described, on account of its simplicity, is probably the 
method employed by the plant”.17  Robinson, like Collie, also rejected the idea that the 
chemistry of nature and that of the laboratory were so different that one could not be 
understood in terms of the other, commenting that people had tended to assume “that 




substances, the properties of which have been investigated with considerable care, to 
undergo transformations which cannot be induced in the laboratory … it is probable 
that this aspect has been exaggerated”.17 
Collie and Robinson’s ground-breaking early work provided great advances in 
synthetic chemistry, laid the foundations for understanding several biosynthetic 
pathways and, most importantly, highlighted that the chemistry used by nature was not 
necessarily out of the reach of the synthetic chemist.  Despite this, neither of them 
attempted to conceptualise or define their work as part of a distinct biomimetic field 
of endeavour.  It was not until the early 1960s that Eugene van Tamelen made the first 
attempt to identify and define biomimetic chemistry as a separate area of study.19  In 
his 1961 review, van Tamelen noted that a small, but important body of work had 
developed where attempts had been made to synthesise natural products in a manner 
which could plausibly occur in nature.  He proposed that syntheses of this type should 
be termed ‘biogenetic-type.’  He defined a biogenetic-type synthesis as one which was 
“designed to follow, in at least its major aspects, biosynthetic pathways proved, or 
presumed to be used in the natural construction of the end product.”19  There are 
several key aspects of van Tamelen’s definition.  Firstly, it refers to deliberately 
seeking inspiration from nature in the design of a synthetic route; however, this may 
take the form of testing a hypothetical biosynthetic pathway.  Secondly, in van 
Tamelen’s biogenetic-type synthesis, the focus is on the key intermediates and overall 
strategy used by nature.  As a result, it is not necessary that every step in a synthesis 
match those proposed to occur in nature and key intermediates may be prepared by 
conventional synthetic techniques.  Slight changes may also be made to key 
intermediates to improve reactivity or selectivity in the absence of enzymatic control 
in the laboratory synthesis.  Finally, as the emphasis is on strategy, the precise reagents 
and conditions are not considered important.  It is not necessary, or even desirable, that 
the synthesis be conducted under physiologically reasonable conditions.  In relation to 
the last two features, van Tamelen draws a distinction between biogenetic-type and 
physiological-type syntheses, noting “biogenetic-type syntheses are thus to be 
distinguished from ‘physiological-type’ syntheses, in which not only plausible bio-
organic substitutes are employed, but also specific conditions of temperature, pH, 




the emphasis of biogenetic-type synthesis is on strategy and synthetic practicality, 
physiological-type synthesis has a greater emphasis on testing biosynthetic hypotheses 
and as such requires that all the intermediates and reaction conditions are plausible in 
a natural system.19 
Van Tamelen provided a very practical and detailed definition of the philosophy of 
biomimicry as applied specifically to organic synthesis; however, he does not link 
these ideas to the discussion around the emerging fields of biomimetics and bionics, 
nor does he offer a broader concept of biomimetic chemistry in general.  This task fell 
to Ronald Breslow, who in 1972 attempted the first general definition of ‘biomimetic 
chemistry’, saying “biomimetic chemistry is the branch of organic chemistry which 
attempts to imitate natural reactions and enzymatic processes as a way to improve the 
power of organic chemistry.”6  It is worth noting that while both van Tamelen and 
Breslow’s definitions are useful and both fit with Otto Schmitt’s explanation of the 
philosophy of biomimetics, each is understandably coloured by their own areas of 
interest.  Van Tamelen’s definition, developed in the context of total synthesis, 
focusses on using biological thinking to solve problems of synthetic strategy;whereas 
Breslow, working to develop enzyme mimics, proposed a definition which focusses 
on using biological thinking to solve the problem of developing new reagents and 
reactions. 
Despite the slight difference in focus, van Tamelen and Breslow’s definitions can often 
be seen operating together in a single piece of work.  An excellent example of this can 
be found in Chapman’s 1971 synthesis of (±)-carpanone (1.6).20  Brophy and the 
isolation team proposed that (±)-carpanone (1.6) was likely to be the product of an 
oxidative dimerization of the co-isolated natural product, carpacin (1.7), via a ββ-
coupling followed by an intramolecular Diels-Alder reaction.21  Chapman, drawing on 
this biosynthetic hypothesis was able to successfully synthesise (±)-carpanone (1.6) 
from demethylcarpacin (1.8) using a Pd(II) mediated oxidative coupling to give the 
proposed biosynthetic intermediate (1.9), which readily gave the natural product 





Scheme 1.3: Chapman's 1971 synthesis of (±)-carpanone (6)20 
The success of this synthesis highlights many of the best features of biomimetic and 
biogenetic-type chemistry as discussed by van Tamelen and Breslow.  The synthetic 
strategy used by Chapman is based on a plausible biosynthetic pathway, albeit one 
which was speculative.  Taking inspiration from this biosynthetic hypothesis gave 
Chapman the confidence to attempt a very ambitious approach, relying on achieving a 
completely diastereoselective oxidative coupling/Diels-Alder sequence.  In order to 
execute this strategy in a synthetically practical way, Chapman was not confined to the 
precise conditions of the postulated biosynthesis.  He was able to make use of modified 
starting materials (demethylcarpacin (1.8), vs carpacin (1.7)), prepared using 
conventional techniques, while also taking advantage of reagents and conditions not 
used in nature (e.g. PdCl2).  All of these features align well with van Tamelen’s 
biogenetic-type synthesis, providing a remarkably short and efficient route to a 
complex natural product; however, in order to achieve this, Chapman also developed 
and demonstrated a new and highly selective ββ-phenolic coupling mediated by a two 
electron oxidant (Pd), providing new nature-inspired methodology to enhance the 
power of organic chemistry, in the way Breslow envisaged. 
 
1.1.3 Terminology and Definitions  
Having provided a brief overview of some of the key points in the development of 
biomimetics in chemistry, it is now worth considering the scope of modern biomimetic 




From the relatively few, but often remarkable early examples, to a large and diverse 
field, biomimetic chemistry has experienced a massive growth in recognition and 
popularity.  A quick visualisation of this growth can be seen in Figure 1.1, where the 
number of results in a Scifinder® search for biomimetic chemistry papers is shown 
from the first uses of this terminology in the 1960s until the present day.22 
 
Figure 1.1: Scifinder® search results showing number of publications including the concepts 
"biomimetic", "biogenetic-type" or "bio-inspired"23 
In order to understand the huge diversity of work being conducted under the umbrella 
of biomimetic chemistry, it is useful to conceptualise biomimicry in chemistry as 
existing along a spectrum.  A representation of such a spectrum is shown in Figure 
1.2, extending from biosynthetic studies at one extreme, to bio-inspired work at the 
other. 
Globally biomimetic chemistry can be defined as imitating nature’s approach to 
chemical problem solving.  It is important to note, as Otto Schmitt did, that this is “not 
so much a subject matter as point of view.”5  It is the use of biological thinking to 
address chemical problems; however, the information flow in this process can be 
bidirectional.  As Schmitt in relation to physics5 and Breslow in relation to chemistry24 
have commented, attempting to imitate nature can simultaneously provide novel 
solutions to problems while improving our understanding of the natural systems we 




























Figure 1.2: A conceptual spectrum of biomimetic chemistry 
In order to account for this two directional information flow, the spectrum of 
biomimetic chemistry proposed in Figure 1.2 is extended to include biosynthetic 
studies.  This is intended to cover work which is aimed directly at elucidating 
biosynthetic pathways, for example feeding experiments with isotopically labelled 
substrates or in vitro studies using isolated enzymes.  Moving right, along the 
spectrum, are studies which fall into van Tamelen’s physiological-type, where 
reactions are conducted in the laboratory without the aid of enzymes, but follow the 
exact postulated substrates and intermediates under biologically plausible conditions.  
Approaching the midpoint of the spectrum is the area where the vast majority of 
biomimetic synthesis will fall.  Whether a synthesis falls more towards the biosynthetic 
or bio-inspired end of the spectrum will depend on what proportion of the steps are 
imitating the biosynthesis and to what extent it was necessary to deviate from 
biologically plausible substrates and conditions in order to achieve an effective 
laboratory synthesis.  Moving right, towards the bio-inspired end of the spectrum, is 
the region containing Breslow’s conception of biomimetic chemistry – drawing 
inspiration from nature’s reagents to design new reagents and reactions which can 
mimic to some extent the properties of enzymes.  And finally, at the far end of the 
spectrum is work which is bio-inspired.  This is intended to cover work where 
knowledge of natural processes has played some role, but the connection is very broad.  
One example of this might be where a transformation, broadly known in nature is used 
(e.g. C-H activation), but which has not been fitted into any cohesive biosynthetic 
hypothesis in relation to the system under consideration, or the use of a very general 
synthetic strategy found in nature (e.g. terpene cyclase/oxidase synthetic strategies).25–
27 
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A good example of the interplay between different areas along this spectrum is 
Johnson’s 1971 synthesis of progesterone (1.10).28 (see Scheme 1.4).  Stork and 
Eschenmoser provided the initial speculative biosynthetic hypothesis, proposing that 
the steroid framework could be formed in nature from squalene (1.11) via a concerted 
cyclisation cascade (‘the Stork-Eschenmoser hypothesis’)29,30 This proposal was 
further developed and supported by van Tamelen’s biosynthetic studies using isolated 
enzymes and isotopic labelling to demonstrate the intermediacy of squalene 2,3-oxide 
(1.12) in the syntheses of lanosterol, cholesterol and fusidic acid.31,32  Johnson was 
then able to use the improved understanding of the biosynthetic pathway to form the 
basis of a ‘biogenetic-type’ synthesis of progesterone (1.10).  Johnson aimed to 
emulate the strategy of concerted polyene cyclisations used by nature; however, for 
synthetic utility, he used the modified substrate 1.13 with an A-ring already in place.  
This allowed him to successfully emulate the key cyclisation cascade, forming a 
steroid-like framework 1.14 in one step, which could then be elaborated to give 
progesterone (1.10).28  The success of the laboratory synthesis then arguably lends 
further support to application of the Stork-Eschenmoser hypothesis in relation to 
progesterone biosynthesis, although, as van Tamelen pointed out, great care must be 
taken when drawing such inferences.19 
 




1.2 PHENYLETHANOID NATURAL PRODUCTS 
1.2.1 Shikimic Acid Biosynthesis: Phenylpropanoid and Phenylethanoid 
Natural Products 
The phenylethanoids are a diverse and widely distributed group of plant secondary 
metabolites characterised by the presence of a C6C2 moiety.  Like the closely related 
phenylpropanoids (which feature a C6C3 moiety), the phenylethanoids are products of 
the shikimic acid biosynthetic pathway (see Scheme 1.5), with mixed C6C2/C6C3 
glycosides commonly occuring.33   
The shikimic acid pathway (Scheme 1.5) starts with the formal aldol coupling of the 
glycolysis product, phosphoenolpyruvate (PEP) (1.15), with erythrose-4-phosphate 
(1.16), from the pentose phosphate cycle, to give 3-deoxy-D-arabino-heptulosonate-
7-phosphate (1.17).34,35  3-Dehydroquinate (E2) synthase then mediates the conversion 
of 1.17 to 3-dehydroquinate (1.18) via a five step sequence.  The C(5) alcohol is 
initially oxidised, followed by enolisation and E1cB-type elimination of phosphate.  
Subsequent reduction of the C(5) ketone, ring opening and aldol addition  form the 
cyclohexane ring to give 3-dehydroquinate (1.18).35–38  3-dehydroquinate (1.18) is then 
dehydrated to give 3-dehydroshikimate (1.19), which is subsequently reduced to give 
shikimic acid (1.20), the first key intermediate in the shikimic acid pathway.  In plants 
these two steps are catalysed by a single bifunctional 3-dehydroquinate dehydratase-
shikimate dehydrogenase enzyme (E4).35  Shikimic acid (1.20) is phosphorylated by 
Shikimate kinase/ATP (E5) to give shikimic acid 3-phosphate (1.21), which is then 
converted to 5-enolpyruvylshikimate-3-phosphate (1.22) via the 5-
enolpyruvylshikimate 3-phosphate synthase (E6) mediated addition of an 
enolpyruvate moiety from PEP (1.15).  The next key intermediate, chorismic acid 
(1.23) is formed via a chorismate synthase (E7) mediated 1,4-eliminatation of 
hydrogen phosphate from 1.22.  Chorismic acid (1.23) serves as an important branch 
point, where the biosynthetic pathway diverges to ultimately give tryptophan on the 





Scheme 1.5: The shikimic acid biosynthetic pathway to the phenylethanoids and phenylpropanoids 
The phenylethanoids and phenylpropanoids are products of the tyrosine/phenylalanine 
branch of this biosynthesis.  Along this branch, chorismic acid (1.23) undergoes a 
chorismate mutase (E8) mediated formal Claisen rearrangement to give prephenic acid 
(1.24).  Several pathways may then operate to convert prephenic acid (1.24) to tyrosine 
(1.25) and phenylalanine (1.26); however, overall they all involve transamination to 
install the amino group, decarboxylation and aromatisation.34,35  At this point the 
biosynthesis of phenylpropanoids and phenylethanoids diverge.  In the case of the 
phenylpropanoids, tyrosine (1.25) and phenylalanine (1.26) feed directly in as the C6C3 
building blocks necessary to produce the diverse range of phenylpropanoid natural 
products.  Alternatively, decarboxylation of tyrosine (1.25) or phenylalanine (1.26) 






1.2.2 Alkaloid Biosynthesis: Ornithine Derived Natural Products 
Alkaloids are nitrogen containing natural products primarily found in plants, which are 
commonly classified based on the nature/source of the amine containing moeity.34  
There are several main sources of alkaloid building blocks.  The shikimic acid pathway 
provides one important source of alkaloid building blocks, the aromatic amino acids, 
in particular tyrosine (1.25) and L-tryptophan (1.27).  These feed into the isoquinoline  
and the indole alkaloids, respectively (Figure 1.3).34,35   
 
Figure 1.3: Some important alkaloid building blocks 
Another important source of nitrogen containing moieties in alkaloid synthesis are the 
non-proteogenic amino acid L-ornithine (1.28) and L-lysine (1.29).  These provide 
simple non-aromatic building blocks which are commonly incorporated into other 
biosynthetic pathways, in particular, giving the pyrrolidine alkaloids (in the case of L-
ornithine (1.28)) and the piperidine alkaloids (in the case of L-lysine (1.29)) (Figure 
1.3).  Biosynthetically L-ornithine (1.28) supplies a C4N unit, which is then 
incorporated into other biosynthetic pathways (e.g., polyketide) to produce a diverse 






Scheme 1.6: Biosynthesis of the pyrrolidine alkaloid C4N unit34 
L-Ornithine (1.28), derived primarily from L-glutamic acid (1.30) in plants, enters the 
secondary metabolism through an initial pyridoxal phosphate dependant 
decarboxylation by ornithine decarboxylase (E1) to give the diamine putrescine (1.31) 
(Scheme 1.6).34,39  Putrescine (1.31) then undergoes an S-adenosyl methionine (SAM) 
mediated methylation to give methyl putrescine (1.32).  Diamine oxidase (E2) 
mediated oxidative deamination of methyl putrescine (1.32) gives the amino-aldehyde 
1.33, which undergoes an intramolecular condensation to give the Δ1-
methylpyrrolinium cation 1.34 (Scheme 1.6).  It is this pyrrolinium cation 1.34 which 
feeds into further pyrrolidine alkaloid biosynthesis as a source of a discrete C4N 
unit.34,39–41  
 
1.3 PRIOR WORK: BIOMIMETIC TOTAL SYNTHESIS INCARVIDITONE 
AND INCARVILLEATONE 
As part of my undergraduate research into the synthesis and biosynthesis of 
phenylethanoid dimers, we undertook a biomimetic total synthesis of the racemic 
natural product (±)-incarviditone (1.35a).  (±)-Incarviditone (1.35a) was isolated in 
2009 by Zhang and co-workers from Incarvillea delevayi.42  Zhang proposed the 
structure 1.35a on the basis of spectroscopic analysis and comparison with the known 
and co-isolated natural product (±)-rengyolone (1.39).  Zhang also noted that (±)-
incarviditone (1.35a) was likely to be formed biosynthetically from (±)-rengyolone 




biosynthesis of (±)-incarviditone (1.35a) from a phenylethanoid glycoside natural 
product, such as salidroside (1.36),33,43 is shown in Scheme 1.7.  
 
Scheme 1.7: Our postulated biosynthesis of incarviditone (1.35a)44 
Oxidative dearomatisation of salidroside (1.36) provides cornoside (1.37) which, upon 
cleavage of the glycosidic bond, reveals the putative aglycone (1.38).43  Aglycone 
(1.38) then spontaneously undergoes an intramolecular oxa-Michael reaction to afford 
(±)-rengyolone (1.39).43  Dimerization of (±)-rengyolone (1.39) could then occur 
through an initial oxa-Michael addition to give 1.40, followed by an intramolecular 
Michael addition to form (±)-incarviditone (1.35a).  This hypothesis involves a 
selectively homochiral dimerization to afford a single diastereomeric product as a 
racemate (Scheme 1.7).  This apparent selectivity in a presumably non-enzyme 
mediated reaction intrigued us. Therefore, we embarked upon a biomimetic synthesis 
of (±)-incarviditone (1.35a). 
Although the notable reversibility of oxa-Michael reactions presented an area of 
concern,45,46 the likelihood that our oxa-Michael adduct (1.40) would be trapped 
through an essentially irreversible carbo-Michael reaction gave us confidence to begin 
exploring our synthetic approach.  To explore our proposed domino Michael strategy 
we first required access to (±)-rengyolone (1.39).  The synthesis of (±)-rengyolone 
(1.39) from the commercially available phenol 1.41 had been reported by several 
groups.  Generation and addition of singlet oxygen, either using photosensitisers or 




(1.39) obtained.43,47,48  In our hands this strategy gave low yields (10-20%) and proved 
difficult to scale-up, so this approach was abandoned.44  With a need for larger 
quantities of (±)-rengyolone (1.39), we elected to explore an alternative synthetic 
route.  The known TBS protection and subsequent PIDA oxidation of phenol 1.4149 
provided a reliable and scalable route to para-quinol 1.43 (Scheme 1.8A),44 which 
could be viewed as a synthetic equivalent of cornoside (1.37).   
 
Scheme 1.8: Total synthesis of (±)-incarviditone (1.35b) and (±)-incarvilleatone (1.48)44 
Pleasingly, when deprotected with TBAF, para-quinol 1.43 afforded (±)-rengyolone 
(1.39) in high yield, providing a practical route to multi-gram quantities of our 
dimerisation precursor (Scheme 1.8A).44  
Attempts to dimerise (±)-rengyolone (1.39) under acid or iminium catalysis were 
unsuccessful, probably due to the poor nucleophilicity of the tertiary alcohol.44 




(CH2Cl)2 was sufficient for the dimerization of (±)-rengyolone (1.39). Treatment of 
one gram of (±)-rengyolone (1.39) with 10 mol% K2CO3 in (CH2Cl)2 at 70 °C for 18 
h provided (±)-incarviditone (1.35b) in 19% yield, along with a racemic heterochiral 
dimer 1.48 in 23 % yield (Scheme 1.8B). Subsequently, Zhang and co-workers 
reported the isolation of dimer 1.48 from Incarvillea younghusbandii, naming it (±)-
incarvilleatone (1.48).50  The successful prediction of a natural product ((±)-
incarvilleatone (1.48)) lends substantial support to the suggestion that our synthesis 
did truly parallel that used in nature.   Re-examination of the NOESY NMR data for 
synthetic (±)-incarviditone (1.35b), raised questions about Zhang’s original structural 
assignment, so a sample of the natural product was derivatised and an X-ray crystal 
structure obtained.  This allowed the structure of (±)-incarviditone to be revised to 
1.35b.  This re-assignment was further supported by a subsequent total synthesis (±)-
incarviditone (1.35b), by Wu and Tang.51 
Following the structural revision of (±)-incarviditone (1.35b) and the serendipitous 
synthesis of (±)-incarvilleatone (1.48) we were able to revise and expand our proposed 
biosynthetic pathway towards (±)-incarviditone (1.35b) and (±)-incarvilleatone (1.48) 
from (±)-rengyolone (1.39) (see Scheme 1.8).  Two competing pathways, one 
homochiral and one heterochiral, operate in the dimerization of (±)-rengyolone (1.39).  
In the homochiral case, the dimerization proceeds via an initial syn oxa-Michael 
addition, to give intermediate 1.44, which is trapped by an intramolecular Michael 
addition to give (±)-incarviditone (1.35b).  Similarly, the heterochiral dimerization 
proceeds via an initial syn oxa-Michael addition to give adduct 1.45 which undergoes 
a further Michael addition to give intermediate 1.46.  As a result of the different 
geometry of the heterochiral intermediate 1.46 (compared to 1.35b) C(8) and C(7ʹ) are 
brought into close proximity, allowing the final aldol addition of enolate 1.47 to give 
(±)-incarvilleatone (1.48) (Scheme 1.8B). 
The success of our initial exploration into the total synthesis of dimeric phenylethanoid 
natural products serves to highlight many of the benefits of approaching the synthesis 
of complex natural products from a biomimetic perspective.  By drawing inspiration 
from the likely biosynthesis of (±)-incarviditone (1.35b), we were able to develop a 




incarviditone (1.35b) in four steps from commercially available material.  As a unique 
result of taking a biomimetic approach, we were able to successfully synthesise the 
correct structure of (±)-incarviditone (1.35b), despite targeting the originally proposed 
structure 1.35a.  The serendipitous synthesis of (±)-incarvilleatone (1.48) 
demonstrates the power of biomimetic synthesis to predict the existence of as yet 
unidentified natural products.  And finally the simultaneous synthesis of both natural 
products supported the idea that they are both formed in nature from (±)-rengyolone 
(1.39), allowing us to develop a coherent biosynthetic hypothesis for both (±)-




2 TOTAL SYNTHESIS OF INCARGRANINE B 
2.1 INTRODUCTION 
2.1.1 Isolation and Structural Assignment 
 
Figure 2.1: Zhang's structural assignment of incargranine B 
Incargranine B (2.1a) was isolated from Incarvillea mairei var. grandiflora in 2010 by 
Zhang and co-workers.52  On the basis of HR-MS and 1D NMR data Zhang determined 
the molecular formula and identified the presence of two sugar and two phenylethanol 
moieties.52  Extensive analysis of 2D NMR data led Zhang and co-workers to propose 
that the two phenylethanol moieties were linked to form a highly unusual indolo-[1,7]-
napthyridine structure (see Figure 2.1).52  Finally, the relative stereochemistry at C(8), 
C(8a) and C(4a) was determined using ROESY.  In particular, the lack of ROESY 
correlations between H(8)/H(8a) and H(8a)/H(4a) led Zhang to propose the trans, 
trans relationship shown (structure 2.1a, Figure 2.1).  
This novel alkaloid structure, which stood as the only example of this framework in 
the literature, was a particularly appealing synthetic target for our research group.  
Consideration of the potential biosynthetic origins of this indolo-[1,7]napthyridine 
framework led us to question the validity of this proposed structure. Zhang’s 
incargranine B structure (2.1a) formulated as a dimer containing two shikimic acid 
derived phenylethanoid (C6C2) units, two glucose units and two ornithine derived C4N 
units (Figure 2.1).   Despite the apparent dimeric nature of this compound, the alkaloid 
portion of the molecule was present as a single C8N2 fragment, rather than two discrete 
C4N pyrrolidine units; as would be anticipated in conventional ornithine alkaloid 




dimerisation very difficult, with any potential biosynthetic pathway to the proposed 
structure 2.1a necessitating the cleavage and formation of an unusually high number 
of bonds.  Although this clearly does not constitute evidence against the proposed 
structure (2.1a), it prompted us to speculate that a, potentially, biosynthetically more 
plausible structure might account for the characterization data reported by Zhang.53 
 
2.1.2 Biosynthetic Speculation and Proposed Structural Reassignment 
 
Figure 2.2: Our proposed incargranine B structure 
We considered that a structure, such as 2.1b, where all of the biosynthetic building 
blocks (sugars, C6C2 and C4N units) were retained intact might represent a 
biosynthetically more plausible alternative to the structure proposed by Zhang (cf. 
Figure 2.1, structure 2.1a. and Figure 2.2, structure 2.1b).  A possible biosynthesis of 
our proposed structure of incargranine B (2.1b) is shown in Scheme 2.1. 
A diamine such as 2.2 (Scheme 2.1), featuring an ornithine derived putrescine 
fragment, C6C2 fragment and glucose unit, could undergo an oxidative deamination, 
to give the amino-aldehyde 2.3.  This could then undergo an intramolecular 
condensation to provide the enamine 2.4 which would be expected to exist in 
equilibrium with the iminium ion 2.5.  The enamine/iminium pair (2.4 and 2.5) could 
dimerise via an initial enamine-Mannich addition, giving the intermediate iminium ion 
2.6.  This intermediate iminium ion 2.6 could then be trapped by SEAr (electrophilic 
aromatic substitution) to give our proposed alternative structure for incargranine B 





Scheme 2.1: Potential biosynthesis of our proposed incargranine B structure (2.1b)53 
 
2.2 SYNTHETIC APPROACH AND LITERATURE PRECEDENT 
In order to test our proposed structural revision and investigate the chemical feasibility 
of our biosynthetic hypothesis, we undertook a biomimetic total synthesis of our 
proposed structure of incargranine B (2.1b).  Our retrosynthetic plan is shown in 
Scheme 2.2.  For synthetic utility we elected to assemble the dipyrrolo-quinoline 
aglycone (2.7) first, with the intention of using a late stage double glycosylation to 
attach the two β-glucose units (Scheme 2.2).  The aglycone 2.7 would be prepared 
through a proposed biomimetic dimerisation of the enamine 2.8 and iminium ion 2.9.  
It was anticipated that these species would be highly reactive and potentially 
impractical to prepare and isolate separately, so we elected to focus on the preparation 
of a suitable precursor which could be used to readily generate the enamine/iminium 





Scheme 2.2: Retrosynthetic analysis of our proposed incargranine B structure (2.1b) 
We envisaged a range of approaches to access the enamine/iminium ion (2.8/2.9): the 
intramolecular condensation of an amino-aldehyde, such as 2.10; the partial reduction 
of a lactam, such as 2.11; the oxidation of a pyrrolidine, such as 2.12; cross-coupling 
of an aryl bromide such as 2.13 with dihydropyrrole.  It was anticipated that these 
dimerisation precursors (2.10, 2.11, 2.12), or variously protected analogues, could 
readily be prepared from the commercially available 4-aminophenylethanol (2.15).  
Three dimerisation strategies – oxidation, reduction and condensation – were 
supported by literature precedent,40,41,54–58 so these became the initial focus of our 
synthetic efforts.   
Subsequent to our completion of this work, Dong, Tan, Liu and co-workers 
demonstrated an alternative approach to the synthesis of dipyrrolo-quinoline 
frameworks through the gold catalysed cyclisation of amino-alkynes such as 2.14.59 
When we embarked on this synthesis; however no literature precedent for this type of 





2.2.1 Previous approaches to dipyrrolo-quinoline frameworks 
A small number of approaches to the synthesis of dipyrrolo-quinoline frameworks 
exist in the literature, primarily utilising the oxidative or reductive approaches 
mentioned above. 
 
Scheme 2.3: Swan and Wilcock's reductive dimerisation54 
Swan and Wilcock have explored the reductive dimerisation of a range of lactams, 
leading to the formation of dipyrrolo-quinoline structures.54  By treating lactam 2.16 
with a sub-stoichiometric quantity of LiAlH4 at room temperature, they were able to 
isolate two diastereomeric dimers in a 1:1 ratio with 19% overall yield (Scheme 2.3).54  
Swan and Wilcock identified the dimeric products as the dipyrrolo-quinoline 2.20, 
although they were not able to assign the relative stereochemistry of each 
diastereomer.  They propose that partial reduction of the lactam 2.16 gives the 
hemiaminal 2.17, elimination would then provide the iminium ion 2.19 with 
subsequent deprotonation giving the enamine 2.18.  Swan and Wilcock suggested the 
enamine 2.18 and iminium ion 2.19 could dimerise either through a stepwise (i.e. 
Mannich/SEAr sequence) or cycloaddition type process to give the observed mixture 
of products (2.20).54  Subsequently, several other groups have repeated these 






Scheme 2.4: Fleming's PhMe2SiLi mediated reductive dimerisation55,60 
An alternative reductive approach was described by Fleming and co-workers as part 
of investigations into the reactivity of phenyldimethylsilyllithium (Scheme 2.4).  
Fleming found that treatment of the lactam 2.21 with two equivalents of 
phenyldimethylsilyllithium at −78 °C, followed by warming to −20 °C gave the two 
dimers 2.26 and 2.27 in 31% and 16% yields respectively, along with a substantial 
amount (42%) of unreacted starting material (2.21).55   
Although the overall reaction is analogous to those described by Swan and Wilcock, 
the unusual nature of the silyllithium reagent led Fleming to propose a very different 
dimerisation mechanism.  Fleming noted that the high nucleophilicity of the 
silyllithium made it unlikely that an iminium ion could be involved in the 
dimerisation.55  By varying conditions it was possible to isolate a range of other 
products, including the dimer 2.24, which was confirmed as a viable intermediate in 
the formation of the dipyrrolo-quinolines 2.26 and 2.27.   Fleming proposed that 
addition of the first equivalent of silyllithium to the lactam 2.21, followed by Brook 
rearrangement and α-elimination of dimethylphenyl silane oxide61 could yield the 
carbene 2.22.  Addition of enolate 2.23 to this carbene 2.22, followed by protonation 
of the resulting carbanion would give the intermediate dimer 2.24.  Subsequent 
addition of a second equivalent of silyllithium to intermediate 2.24 followed by Brook 
rearrangement/α-elimination of would give the carbene 2.25, which Fleming 
suggested, could give the observed dimeric products 2.26 and 2.27 via an 





Scheme 2.5: Suschitzky's DEAD mediated oxidative dimerisation56 
Suschitzky and co-workers, described two oxidative approaches to dipyrrolo-quinoline 
frameworks as part of studies on the oxidation of N,N-dialkylanilines.56  The first 
approach involved a diethyl azodicarboxylate (DEAD) mediated oxidation of cyclic 
N,N-dialkylanilines, such as N-phenylpyrrolidine (2.28).  Addition of N-
phenylpyrrolidine (2.28) to DEAD followed by rearrangement gave hydrazine 2.29.  
Thermolysis of hydrazine 2.29 by refluxing in xylene was then found to give the 
dipyrrolo-quinoline dimers 2.26 and 2.27 in 28% and 22% yields respectively 
(Scheme 2.5).  On heating, hydrazine 2.29 eliminates diethyl hydrazodicarboxylate to 
give the enamine 2.30 and iminium ion 2.31, which Suschitzky suggested were likely 
to dimerise via a Diels-Alder type process with a slight selectively for the endo dimer 
(2.26).56 
 




The second oxidative approach described by Suschitzky relied on the ozone mediated 
oxidation of N-phenylpyrrolidine (2.28).  Treatment of N-phenylpyrrolidine (2.28) 
with ozone at 0 ºC gave a mixture of the dipyrrolo-quinolines 2.26 and 2.27 in a 41% 
combined yield (the two dimers were identified as matching those produced under the 
DEAD conditions, but separate yields for each diastereomer were not reported).56  
Along with the dimers 2.26 and 2.27 a 19% yield of lactam 2.21 was also obtained.  
This result was rationalised following the mechanism outlined in Scheme 2.6.  
Addition of ozone to N-phenylpyrrolidine 2.28 gives the N-ozonide 2.32 which 
decomposes to give the iminium ion 2.31.  In the presence of excess ozone, iminium 
ion 2.31 could be further oxidised to produce the lactam 2.21.  Alternatively the 
iminium ion 2.31 could be deprotonated to give the enamine 2.30, dimerising to give 
the dipyrrolo-quinolines 2.26 and 2.27.56 
 
Scheme 2.7: Komatsu's Cu(II) mediated oxidative dimerisation62 
Another approach relying on the oxidation of N-phenylpyrrolidine 2.28 was described 
by Komatsu and co-workers.62  They found that treatment of N-phenylpyrrolidine 2.28 
with catalytic Cu(II) (2.5 mol%) under an O2 atmosphere resulted in the formation of 
the dimers 2.26 and 2.27, presumably via the formation of the enamine 2.30 and 
iminium ion 2.31.62  Yields were generally low; however, the use of Et3N as an additive 
increased the yield of dimer 2.27, from 8% to 15% and the yield of dimer 2.26 from 
5% to 11%.  Unusually, these conditions were reported to favour the cis-anti 
diastereomer 2.27 over the cis-syn 2.26.62  
 
2.2.2 Other Relevant Pyrroline Dimerisation Literature 
In addition to the examples of dipyrrolo-quinoline syntheses discussed above, it is 
useful to briefly consider some of the literature on the formation of simpler Δ1 and Δ2-






Scheme 2.8: Leonard and Cook's pyrrolidine oxidation studies57 
Leonard and Cook investigated the formation of enamines and their corresponding 
pyrrolinium ions through the mercuric acetate oxidation of various substituted 
pyrrolidines and found the extent to which the monomeric enamine or pyrrolinium 
products were isolable, compared to various dimeric and trimeric products, depended 
significantly on the degree of substitution (see Scheme 2.8).57   For the simplest 
example investigated, N-methylpyrrolidine (2.33), mercuric acetate oxidation gave the 
dimer (2.34) and trimer (2.35) in a 1:1 ratio, with none of the enamine (Δ2-pyrroline 
2.36) or Δ1-pyrrolinium (2.37) observed (Scheme 2.8).57  Only when heavily 
substituted pyrrolidines such as 2.38 were used was it possible to isolate either the 
enamine (2.39) or Δ1-pyrrolinium (2.40) products. 
 
Scheme 2.9: Swan and Wilcock's study on N-alkyl lactam reduction54 
Swan and Wilcock have demonstrated results paralleling those of Leonard and Cook, 
by the reduction of a range of N-alkyl lactams.54  Swan and Wilcock found the Red-
Al reduction of lactam 2.41 provided the same dimeric and trimeric products as were 
obtained by oxidation of the pyrrolidine 2.33 (refer to Scheme 2.8).  Once again, 





Scheme 2.10: Wagner and Leete's condensation approach40,58 
The third approach we considered to access our key enamine and iminium was the 
intramolecular condensation of an amino-aldehyde.  Unlike the reductive and 
oxidative strategies, there was no literature precedent for using this approach to 
generate dipyrrolo-quinolines; however, some work had been done on the formation 
and reactivity of simple N-alkyl pyrrolines.  Both Wagner58 and Leete40 have 
demonstrated the synthesis of N-methylpyrrolinium (2.37) as the chloride salt through 
the acidic deprotection of acetal 2.42 to the aldehyde 2.43, which undergoes an 
intramolecular condensation to give the pyrrolinium chloride 2.37 in good yield with 
only a trace amount of the dimer 2.44 (Scheme 2.10).40,63  
 
2.3 AGLYCONE SYNTHESIS 
2.3.1 Dimerisation Precursors 
Based on our survey of the literature, we concluded that three of the strategies 
(oxidation, reduction, condensation) we had identified were viable (see Scheme 2.2).  
For the condensation strategy, it was anticipated that a suitable acetal protected amino-
aldehyde 2.10a would provide the most synthetically practical precursor. 
 




For the reductive approach, the lactam 2.11 was selected as a practical precursor and 
for the oxidative approach, the pyrrolidine 2.12 appeared to be a viable and readily 
accessible precursor.  With this in mind we decide to prepare suitable precursors for 
all three approaches (Figure 2.3). 
 
Scheme 2.11: Synthesis of precursors for reductive and oxidative dimerisation 
Each of these precursors were successfully prepared on gram scale from the 
commercially available aniline 2.15.  Pyrrolidine 2.12 was readily accessed by a 
double alkylation of aniline 2.15 with 1,4-dibromobutane in good yield.  Lactam 2.11 
could also be readily prepared in 1 step by solvent free condensation of aniline 2.15 
with γ-butyrolactone (2.45) under microwave irradiation (Scheme 2.11).   
The final dimerisation precursor, acetal 2.10a was prepared as shown in Scheme 2.12.  
Bromo-acetal 2.48 was prepared following a known 2 step procedure from 
commercially available ethyl 4-bromobutyrate 2.46 (Scheme 2.12A).64  Partial 
reduction of the ester 2.46 with DIBAL-H gave the aldehyde 2.47, which due to its 
instability, was not purified but directly converted to the acetal 2.48 by treatment with 
ethylene glycol and catalytic p-TsOH.  The acetal 2.10a could then be accessed by 
alkylation of aniline 2.15 with bromo-acetal 2.48 in the presence of NaI and iPr2NEt.  
Although achieving selective mono-alkylation was an area of concern, it was found 
that by using an excess of aniline 2.15 it was possible to obtain excellent yields of the 
desired mono-alkylated product 2.10a, with only small quantities of the, easily 





Scheme 2.12: Synthesis of precursor for condensation dimerisation 
 
2.3.2 Dimerisation Studies 
With precursors for all three dimerisation strategies in hand, we turned our attention 
to investigating our proposed biomimetic dimerisation.  Although the high degree of 
similarity to our biosynthetic proposal made the condensation strategy an attractive 
avenue of exploration, the stronger literature precedent for the oxidative and reductive 
routes led us to investigate these conditions first.  We considered the oxidative 
conditions, although having good literature precedent, less attractive as they required 
harsh reaction conditions,56 or gave low yields.62  As a result, we elected to initially 
investigate dimerisation through reduction of lactam 2.11. 
Due to their simplicity, we initially decided to investigate the dimerisation of lactam 
2.11 under Swan and Wilcock’s LiAlH4 conditions.   
 




Treatment of lactam 2.11 with a solution of LiAlH4 in THF pleasingly gave a mixture 
of diastereomeric dimers, along with a small amount of the over-reduced pyrrolidine 
2.12.  The NMR data for the mixture of dimeric products matched well with previously 
reported dipyrrolo-quinolines, leading us to conclude the products were the desired 
dimers 2.7.  Unfortunately this initial success proved unreproducible, with all 
subsequent attempts giving primarily unreacted lactam 2.11 and pyrrolidine 2.12.  
Thus the reductive approach was abandoned. 
Following the promising, but unreliable results from the reductive dimerisation of 
lactam 2.11, we decided to move on and investigate the deprotection and condensation 
of acetal 2.10a.  We decided to start our investigations using the conditions described 
by Leete40 and Wagner.58  Thus acetal 2.10a was treated directly with 2M aqueous 
HCl at room temperature to deprotect the acetal and hopefully trigger the 
condensation/dimerisation sequence (Scheme 2.14).  Pleasingly, on treatment with 2M 
HCl, the acetal 2.10a appeared to deprotect smoothly, allowing the isolation of the 






Scheme 2.14: Acidic deprotection and dimerisation of acetal 2.10a 
Separation of the products by HPLC gave the cis-anti diastereomer 2.7a in 18% yield 
and the cis-syn diastereomer 2.7b in a 32% yield.  Both structures were confirmed by 
single crystal x-ray analysis (see Scheme 2.14 and experimental section 6.9).53  These 





oxygen.  This was attributed to facile autoxidation, presumably at the benzylic methine 
position C(8), so samples were stored in the presence of a trace quantity of 2,6-di-tert-
butyl-4-methylphenol (BHT) as an anti-oxidant and handling in solution was kept to a 
minimum. 
 
Figure 2.4: Comparison of the 500MHz 1H-NMR spectra of incargranine B (top) and synthetic 
aglycone 2.7a (bottom) 
Comparison of the NMR data for both of the dipyrrolo-quinoline aglycones 2.7a and 
2.7b to NMR spectra for incargranine B (2.1a), kindly provided by Professor Zhang, 
identified the cis-anti diastereomer 2.7a as a very close match to the natural product.  
The similarities in the 1H-NMR spectra of aglycone 2.7a and incargranine B, taking 
into account the expected differences due to the absence of the glucose units, strongly 
suggested that dimer 2.7a represented the true aglycone structure of incargranine B 
(see Figure 2.4). 
 
2.4 GLYCOSYLATION 
With a reliable route to our proposed aglycone established, it was necessary to perform 
a double glycosylation in order to complete the total synthesis and obtain definitive 
confirmation of the proposed structural revision.  Due to the challenging nature of 
achieving a double β-selective glycosylation, we elected to screen conditions on 





2.4.1 Model Glycosylation Studies 
In selecting from the wide range of glycosylation procedures described in the literature 
two considerations were of primary importance: choice of sugar protecting group and 
activation/coupling method.  As incargranine B (2.1a) contains two β-glucose units, 
achieving very high β-selectivity was necessary to avoid the potentially problematic 
separation of several diastereomers.  The need for β-selectivity was most easily 
addressed by selecting a glycosyl donor with protecting groups capable of 
neighbouring group participation (e.g. esters).65  In addition to high selectivity, we also 
required a high yielding glycosylation in order to obtain practical yields of the bis-
glycoside.  To address these issues we decided to start the glycosylation screen using 
an acetate protected sugar, comparing two alternative glycosylation procedures: the 
Schmidt tricholoroacetimidate66,67 method; and the Koenigs-Knorr glycosyl halide 
method65,67,68. 
 
Scheme 2.15: Synthesis of OAc glycosyl tricholoracetimidate (2.50) and OAc glycosyl bromide (2.51) 
Glycosyl donors for both methods were prepared on multi-gram scale from 
commercially available α-D-glucose pentaacetate (2.49) following literature 
procedures (Scheme 2.15).  The Schmidt type glycosyl donor 2.50 was prepared in 
two steps via a selective anomeric deprotection with BnNH2, followed by 
tricholoracetimidate formation.69,70  The Koenigs-Knorr glycosyl donor 2.51 was 





Scheme 2.16: Schmidt type glycosylation of aryl bromide (2.13) using a Pd(II) activator 
The commercially available aryl bromide 2.13 was chosen as a suitable model 
phenylethanoid substrate to test these glycosylation conditions.  Initial attempts at 
glycosylation using the Schmidt donor 2.50 proved unsuccessful using a range of 
Lewis acid activators.  Using TMSOTf69 gave exclusively the transesterification 
product 2.53, while AgOTf72 and Amberlyst®73 gave primarily recovered starting 
material.  Nguyen’s Pd(II) activated conditions74 showed some promise, giving a 56% 
yield of the glycoside 2.52, along with 40% of the transesterification product 2.53 
(Scheme 2.16).  Unfortunately subsequent efforts to optimise these conditions were 
unable to satisfactorily reduce the amount of transesterification, which could lead to 
low yields and purification difficulties when applied to our bis-glycosyolation.  As a 
result, attention was switched to the Koenigs-Knorr glycosylation. 
Koenigs-Knorr glycosylation was initially attempted on the model aryl bromide 2.13 
by treatment with the glycosyl bromide 2.51 activated with Ag2CO3.
75  Pleasingly 
these conditions gave slightly improved yields of the glycoside 2.52 (57-61%) 
compared to the Schmidt glycosylation and could be scaled up to give substantial 





Scheme 2.17: Koenigs-Knorr glycosylation of aryl bromide (2.13) and lactam (2.11) 
A preliminary test of these glycosylation conditions on the aglycone 2.7a was 
attempted; however, no trace of glycoside was observed.  As a result, we decided to 
conduct a second model glycosylation under these conditions, hoping that lactam 2.11 
would serve as more realistic model substrate.  Treatment of lactam 2.11 with glycosyl 
bromide 2.51 and Ag2CO3 initially seemed promising, giving a 66% yield of what 
appeared to be the desired glycosidic product.  Unfortunately, on closer examination 
of the NMR data, it was found that the sole product was the orthoester 2.54 (Scheme 
2.17).   
The problems of transesterification (e.g. to give 2.53) and orthoester formation (e.g. to 
give 2.54) prompted us to reconsider the utility of an acetate protected glycosyl donor.  
As it was necessary that any alternative protecting group also offered similarly high β-
selectivity, we investigated bulkier ester groups in the hope that this would suppress 
unwanted orthoester formation and transesterification.76,77  Pivaloyl (trimethyl acetyl) 
groups have been successfully used to suppress the formation of orthoester and 
transesterification products, while still providing excellent β-selectivity.72,78–80  With 
this in mind we prepared pivaloyl protected glycosyl donors for both the Koenigs-





Scheme 2.18: Synthesis of OPiv glycosyl trichloroacetimidate (2.56) and OPiv glycosyl bromide 
(2.57) 
Both glycosyl donors were prepared from penta-O-pivaloyl glucose 2.55 based on 
literature procedures (Scheme 2.18).  The pivaloyl protected Schmidt donor 2.56 was 
prepared in two steps via a selective anomeric deprotection with hydrazine acetate, 
followed by trichloroacetimidate formation.81  Similarly the Koenigs-Knorr donor 2.57 
was prepared in one step by the treatment of penta-O-pivaloyl glucose 2.55 with 
HBr/AcOH (Scheme 2.18). 
 
Scheme 2.19: Test Koenigs-Knorr and Schmidt glycosylations using OPiv glycosyl donor 
As the lactam 2.11 had proved the more challenging model substrate, it was used in 




glycosyl donors (2.56, 2.57).  The lactam 2.11 was subjected to both Koenigs-Knorr 
and Schmidt glycosylation conditions, using the glycosyl bromide 2.57 and 
trichloroacetimidate 2.56 respectively (Scheme 2.19).  Under Koenigs-Knorr 
conditions the only product was the orthoester 2.58, despite the added steric bulk 
provided by the pivaloyl groups.  Although it was found that treatment of the orthoester 
with trimethylsilyl trifluoromethanesulfonate (TMSOTf) prompted rearrangement to 
the glycoside 2.59, the Schmidt-type glycosylation proved superior.  Treatment of the 
lactam 2.11 with trichloroacetimidate 2.56, activated using TMSOTf, gave clean 
conversion directly to the desired glycoside 2.59 in excellent yields and complete β-
selectivity.  These conditions proved reliable on the model system 2.11, so we decided 
to move forward with their application to the aglycone 2.7a. 
 
2.4.2 Glycosylation of Incargranine B Agylcone 
Having developed robust, high yielding, β-selective glycosylation conditions on our 
model monomeric phenylethanoid substrate, we turned our attention to the more 
challenging bis-glycosylation of the aglycone 2.7a.   
The synthetic aglycone (±)-2.7a was subjected to our optimised glycosylation 
conditions, using the pivaloyl protected Schmidt donor 2.56 and TMSOTf as an 
activator.  Adding a small amount of CH3CN was found to substantially improve 
results, due to poor solubility of the aglycone (±)-2.7a in CH2Cl2.  Pleasingly under 
these conditions the desired bis-glycoside 2.60 was obtained in a 28% yield following 
purification by HPLC.  Although this yield was substantially lower than expected from 
our model studies, we felt it was still an impressive result given the notable difficulties 
of late-stage bis-glycosylations of natural products72 and the sensitivity of our specific 





Scheme 2.20: Glycosylation of aglycone 2.7a to give incargranine B (2.1b)53 
The final step in the synthesis of our proposed incargranine B structure 2.1b was the 
global deprotection of the sugars.  Accordingly the protected glycoside 2.60 was 
treated with LiOH, as described by Wegner,72 to give the fully deprotected glycoside 
2.1b in near quantitative yield (Scheme 2.20).53  On close analysis of high-field 13C-
NMR spectra it was apparent that glycoside 2.1b was a mixture of diastereomers, as 
would be expected.  All attempts at standard chromatographic (e.g. flash column, 
HPLC) separation of these diastereomers proved unsuccessful.  In desperation we 
turned to chiral HPLC and were finally were able to separate these compounds.  
Analysis using chiral HPLC confirmed that 2.1b was the anticipated 1:1 mixture of 
diastereomers.  Although Professor Zhang had kindly provided us with low resolution 
pdf copies of the processed NMR spectra for natural incargranine B, neither the 
original FID data, nor an authentic sample of natural incargranine B was available, 
making a conclusive comparison with our synthetic material impossible.  Despite this 
we found that all reported data for our synthetic material (2.1b), including optical 
rotation (synthetic [𝛼]𝐷
20 = −16.7 (c=0.275 MeOH), natural [𝛼]𝐷
20 = −12 (c=0.257 
MeOH)) were a good match for natural incargranine B (see section 6.3.17, 6.3.18).  As 
a result, we were able to confidently reassign the structure of incargranine B to the 




likely to exist in nature as a mixture of diastereomers.53  However, without access to 
an authentic sample of natural incargranine B (2.1b) for direct comparison, this 
conclusion must remain tentative. 
 
2.5 CONCLUDING REMARKS 
Consideration of the biosynthetic origins of a novel natural product, incargranine B, 
led us to propose that the originally proposed indolo-napthyridine structure (2.1a) was 
incorrect.  Further biosynthetic speculation led us to suggest a dipyrrolo-quinoline 
structure (2.1b) as a plausible alternative.  We were able to successfully validate this 
proposal through a concise biomimetic total synthesis, shown in Scheme 2.21.  
 
Scheme 2.21: Total synthesis and structural revision of incargranine B (2.1b)53 
Incargranine B (2.1b) was prepared in six steps from commercially available materials, 
making use of a biomimetic domino condensation/Mannich/SEAr sequence to 
assemble the core framework in a single synthetic operation.  The synthesis of 
incargranine B (2.1b) as a nearly inseparable pair of pseudo-enantiomeric 
diastereomers suggests that incargranine B is likely to exist in nature as a mixture of 
diastereomers.  It is interesting to note that several other natural products have been 
isolated from other Bignoniaceae plants as mixtures of pseudo-enantiomeric 




dimeric alkaloid, millingtonine (3.1),83 which is discussed in greater detail in chapter 
3. 
 
Figure 2.5: Examples of other pseudo-dimeric Bignonia natural products82,83 
These pseudo-enantiomeric natural products can be viewed conceptually (although not 
necessarily biosynthetically) as consisting of a racemic aglycone which is ‘resolved’ 
into a pair of diastereomers by the addition of the enantio-pure sugar units (see Scheme 
2.22).  
 
Scheme 2.22: Pseudo-enantiomeric diastereomeric natural products 
In the case of dimeric natural products, such as incargranine B (2.1b) and millingtonine 
(3.1) the pairs of pseudo-enantiomeric diastereomers could arise in two ways: either 
as the result of a non-selective glycosylation of a racemic aglycone (e.g. 2.7a); or a 




the sugars exert no stereochemical influence (Scheme 2.22).  It is also interesting to 
consider that, if incargranine B (2.1b) is formed through a non-enzymatic dimerisation, 
a second pair of pseudo-enantiomers would likely be formed (corresponding to the cis-
syn core stereochemistry), which may represent an, as yet, undiscovered natural 
product (i.e. dia-incargranine B 2.63).  Unfortunately all attempts to form dia-
incargranine B (2.63), synthetically, through glycosylation of the aglycone 2.7b have 
so far proved unsuccessful (However, dia-incargranine B 2.63 was prepared later 











3 TOTAL SYNTHESIS OF MILLINGTONINE 
3.1 ISOLATION AND BIOSYNTHETIC ANALYSIS 
 
Figure 3.1: Biosynthetic analysis of millingtonine (3.1) 
Millingtonine (3.1) was isolated in 1996 by Yamasaki and co-workers from 
Millingtonia hortensis,83 an important medicinal plant in Southeast Asia, as part of a 
series of studies into Millingtonia phenylethanoid natural products.82,83  Millingtonine 
(3.1) was isolated as an inseparable mixture of two diastereomeric alkaloids, featuring 
a novel tetracyclic framework.  On the basis of HR-MS and NMR data, along with 
detailed structural analysis of its deglycosylation products, Yamasaki assigned 
millingtonine to structure 3.1 (Figure 3.1).83  Conceptually, but not biosynthetically, 
millingtonine (3.1) can be considered to consist of a racemic aglycone core that is 
‘resolved’ into two pseudo-enantiomeric diastereomers by the attachment of a pair of 
β-D-glucopyranosyl units (see chapter 2.5).  Yamasaki noted that this phenomenon 
had also been observed in other Millingtonia phenylethanoid glycosides (Figure 
3.2).82,83 
 
Figure 3.2: Examples of other pseudo-enantiomeric Millingtonia natural products82 
Biosynthetically, millingtonine (3.1) can been seen as comprising, two β-D-glucose 




C4N unit (Figure 3.1). No detailed biosynthetic pathway towards millingtonine (3.1) 
has been proposed and, as commented upon by the isolation team, “the mechanism of 
insertion of this (C4N) unit between the two C6C2 units is unknown.”
83  This 
combination of a unique structural framework and intriguing biosynthetic questions 
made millingtonine (3.1) an appealing target for biomimetic investigation. 
Our previous work on the synthesis and biosynthesis of other phenylethanoid natural 
products ((±)-incarviditone (1.35b), (±)-incarvilleatone (1.48) and incargranine B 
(2.1b)) provided some clues as to a plausible biosynthetic hypothesis for millingtonine 
(3.1).     
 
Scheme 3.1: Proposed biosynthetic network linking (±)-incarviditone (1.35b), (±)-incarvilleatone 




We considered that (±)-incarviditone (1.35b), (±)-incarvilleatone (1.48), incargranine 
B (2.1b) and millingtonine (3.1) could all be linked through a common biosynthetic 
network, shown in Scheme 3.1.  We propose that diamine 2.2, which we originally 
proposed as the biosynthetic precursor to incargranine B (2.1b) (see chapter 2), could 
represent a common biosynthetic precursor for all four natural products via a 
divergent/re-convergent network of biosynthetic pathways. 
In the divergent portion of the network, diamine 2.2 could undergo an oxidative 
dearomatisation (Scheme 3.1, pathway 1) to give imine 3.2, hydrolysis of which would 
provide cornoside (1.37).  It has previously been demonstrated that deglycosylation of 
cornoside (1.37) results in an intramolecular oxa-Michael cyclisation to form (±)-
rengyolone (1.39).47,82  Our previous studies have shown that homochiral domino-
Michael dimerisation of (±)-rengyolone (1.39) gives (±)-incarviditone (1.35b), while 
a similar heterochiral dimerisation gives (±)-incarvilleatone (1.48) (see chapter 1.3).44  
Alternatively, if diamine 2.2 were to undergo an oxidative deamination (Scheme 3.1, 
pathway 2), this would give amino-aldehyde 2.3.  As we have previously shown (see 
chapter 2) this type of amino-aldehyde readily forms the enamine 2.4 and iminium ion 
2.5 through an intramolecular condensation.53  This enamine/iminium ion pair 2.4/2.5 
can then dimerise to give incargranine B (2.1b) through a domino Mannich/SEAr 
sequence.53 
These two divergent pathways from the diamine 2.2 (Scheme 3.1, pathways 1 and 2) 
could potentially re-converge, providing a biosynthetic route to millingtonine (3.1) 
(Scheme 3.1, pathway 3).  An enamine-Michael addition of the enamine 2.4 to 
cornoside (1.37) would provide an intermediate iminium ion 3.3, which could be 
trapped via an intramolecular oxa-Mannich addition to give millingtonine (3.1).  In 
this proposal, it would be expected that the two diastereomers of millingtonine (3.1) 
would be a result of a lack of stereocontrol in the dimerisation process, rather than a 





3.2 PREVIOUS SYNTHETIC WORK 
There has been one previous total synthesis of millingtonine (3.1), reported in 2012 by 
the research groups of Ley, Kirschning and Baxendale.72  The Ley-Kirschning-
Baxendale strategy relied on the initial construction of the tricyclic core of 
millingtonine (3.1) using a Ueno-Stork cyclisation, attachment of the phenylethanol 
moiety via Buchwald-Hartwig coupling and final late-stage double glycosylation 
(Scheme 3.2). 
 
Scheme 3.2: Ley, Kirschning and Baxendale’s total synthesis of millingtonine (3.1)72 
The synthesis started with the preparation of protected para-quinol 3.4 from 
commercially available material in 59% yield over four steps.  Cbz-enamine 3.5, 
prepared in one step from commercially available N-Cbz 2,5-dihydropyrrole, was 
treated with bromine to give the corresponding bromonium/iminium ion.  Oxa-
Mannich addition of para-quinol 3.4 to this Cbz-iminium ion gave bromide 3.6.  This 
intermediate bromide 3.6 was not isolated, but directly treated with AIBN/Bu3SnH to 
initiate the Ueno-Stork cyclisation and give the desired tricyclic core of millingtonine 
3.7a in a 63% yield, along with a 23% yield of the unwanted cis-syn diastereomer 3.7b.  
This core fragment 3.7a was then coupled with the aryl bromide 3.8 under Buchwald-




stage of the synthesis involved the tetrabutylammonium fluoride (TBAF) deprotection 
of both primary alcohol groups in 3.9, followed by bis-glycosylation to reach the 
natural product.  Deprotection of silylether 3.9 proceeded smoothly; however, the bis-
glycosylation proved extremely challenging, giving low yields, poor selectivity and 
unwanted orthoester products under a range of conditions.  Reasonable yields of the 
desired bis-β-glycoside were eventually achieved using trichloroacetimidate 3.10, 
activated with AgOTf.  This was then subjected to a two-step global deprotection to 
give millingtonine (3.1) in 22% yield from 3.9 (Scheme 3.2).72  Overall, this approach 
allowed Ley, Kirschning and Baxendale to complete the first total synthesis of 
millingtonine (3.1) in a longest linear sequence of twelve steps (sixteen total) from 
commercially available materials, with an overall yield of 6.2%.  The execution of a 
total synthesis of this alkaloid was an impressive achievement, with the intermediate 
structures en-route to millingtonine (3.1) reported to be “exceedingly prone” to 
rearrangement reactions.72  With this in mind, we hoped that by drawing on our 
biosynthetic analysis and learning from our previous work on similar dimeric 
phenylethanoid natural products, we could develop a new, more step-economical, 
biomimetic synthetic strategy towards millingtonine (3.1). 
 
3.3 SYNTHETIC APPROACH 
Inspired by our biosynthetic hypothesis, we planned to form millingtonine (3.1) 
through a pseudo-dimerisation between a protected glycosidic enamine such as 3.11 
and a similarly protected cornoside 3.12 (Scheme 3.3).  We anticipated that protected 
cornoside 3.12 could readily be accessed from phenol glycoside 3.13.43,47  We hoped 
that the enamine 3.11 could be prepared in-situ using a similar strategy to those 
contemplated in our synthesis of incargranine B (2.1) (see chapter 2): i.e. the 
deprotection/condensation of an acetal 3.14; the reduction of a lactam 3.15; or the 





Scheme 3.3: Retrosynthetic analysis, showing our planned route to millingtonine (3.1) 
In particular, we hoped that an approach similar to the condensation strategy we had 
successfully employed in the synthesis of incargraine B (2.1b, see chapter 2) would 
provide practical access to the enamine fragment 3.11.  Ultimately, we anticipated that 
these enamine precursors could be readily prepared from the commercially available 
aniline (2.15).  Yamasaki had previously noted that millingtonine (3.1) aglycone 
undergoes various cyclisations and rearrangements on cleavage of the glycosidic 
bonds,83 indicating that a late-stage glycosylation of an unprotected aglycone would 
not be a viable option.  Ley, Kirschning and Baxendale had functionality masked 
during their late-stage glycosylation; however, they found this approach problematic.72    
To avoid these problems, we planned to prepare both the enamine and p-quinol 
building blocks as a suitably protected glycosides (e.g. 3.12 and 3.14, 3.15, 3.16).   
 
3.4 MODEL STUDIES TOWARDS THE MILLINGTONINE 
FRAMEWORK 
3.4.1 Condensation Based Cross-Dimerisation 
In investigating our proposed route to millingtonine (3.1), we decide to start by 
exploring the key cross-dimerisation between simplified enamine and para-quinol 




already on-hand from our previous biomimetic studies.  Accordingly we chose to use 
the acetal 2.10a, readily prepared as previously discussed (see chapter 2.3.1),53 as an 
enamine precursor and the p-quinol 1.43, which could be easily prepared on multi-
gram scale,44 as a model for cornoside (3.12).  It was hoped that subjecting acetal 2.10a 
to our previously developed deprotection-condensation conditions53 would form the 
enamine 2.8 which, in the presence of the p-quinol 1.43, would trigger the biomimetic 
cross-dimerisation to give the millingtonine framework (3.17) (Scheme 3.4).  
Unfortunately subjecting a mixture of acetal 2.10a and p-quinol 1.43 to a range of 
acidic conditions proved unsuccessful.  Excess TFA or HCl resulted exclusively in 
formation of the incargranine B type dimers 2.7a and 2.7b, with no trace of cross-
dimerisation, while catalytic TFA, HCl or camphorsulfonic acid (CSA) gave no 
reaction.  Attempts to favour the cross-dimerisation by using excess p-quinol 1.43 or 
the slow addition of the acetal 2.10a similarly only showed formation of dimers 2.7a 
and 2.7b. 
 
Scheme 3.4: Attempts at enamine/p-quinol cross-dimerisation under acidic conditions 
Despite initially unpromising results, we decided to more carefully investigate the 
deprotection-condensation strategy in the hope that the conditions could be tuned to 
allow cross-dimerisation. The work of Christophersen and co-workers investigating 
the behaviour of 4-aminobutanal (3.18) in aqueous solution84 provided some hope that 




Christophersen found that 4-aminobutanal (3.18) produced complex mixtures of 
cyclic, open-chain and trimeric species, with the proportions of each depending 
significantly on pH (Scheme 3.5).84  At low pH (between pH 1 and pH 6) a complex 
mixture was observed, with the major components being the protonated hemiaminal 
3.19 and pyrrolinium 3.20 along with a small amount of the aldehyde 3.18.  At higher 
pH (greater than pH 7) the mixture was comprised almost exclusively of the pyrroline 
3.21, with a small amount of the trimer 3.22.84   
 
Scheme 3.5: Christophersen's NMR studies on the structural equilibrium of 4-aminobutanal in 
aqueous solution84  
With this in mind, we set about exploring the behaviour of the acetal 2.10a by NMR 
spectroscopy under carefully controlled acidic conditions, in the hope that we could 
identify conditions under which the enamine 2.8 was the major species present 
(Scheme 3.6).   
 
Scheme 3.6: Our NMR studies on the deprotection and condensation of acetal 2.10a 
Samples of acetal 2.10a were treated with varying quantities of either HCl, or TFA in 
a range of solvents and monitored by 1H-NMR spectroscopy to track the deprotection 
and condensation of the aldehyde.  Uniformly it was found that treatment with sub-
stoichiometric quantities of acid resulted exclusively in protonation of the aniline, as 
observed by a progressive downfield shift of the aromatic proton signals in 2.10a as 
the quantity of acid was increased (see Figure 3.3).  Solutions of the protonated acetal 




periods of time or heating.  On the addition of a small excess of acid (1.1 equiv.), the 
slow formation of the dimers 2.7a and 2.7b was observed, with complete conversion 
taking approximately four days at room temperature; however, neither the enamine 2.8 
nor iminium ion 2.9 were detectable under these conditions (Scheme 3.6). 
 
 
Figure 3.3: 500MHz 1H-NMR spectra of acetal 2.10a with 0, 0.1, 0.5 and 1.0 equiv. TFA 
These studies had revealed that acetal 2.10a was significantly more resistant to acidic 
deprotection than we had anticipated.  As a result, it appeared to be necessary to use 
fairly strongly acidic conditions to affect the deprotection.  We considered that this 
may have the undesired side-effect of significantly promoting the formation of the 
iminium ion 2.9, leading to very fast and essentially irreversible dimerisation.   To try 
to address this problem we decided to explore alternative methods of generating the 





Scheme 3.7: Synthesis and testing of amino-alcohols as condensation precursors 
One alternative approach we envisaged to accessing the enamine 2.8 was oxidation of 
an amino-alcohol such as 3.23 to give the corresponding amino-aldehyde, triggering 
the same intramolecular condensation sequence contemplated previously.  This would 
have the advantage of potentially generating the enamine 2.8 under less acidic 
conditions than those required for the deprotection of the acetal 2.10a.  To test this, 
the amino-alcohol 3.23 was prepared by alkylation of aniline 2.15 with the bromide 
3.24, followed by TBAF deprotection (Scheme 3.7).  A simpler model system,   
amino-alcohol 3.27, was also prepared in a similar fashion from aniline 3.26 by 
alkylation with bromide 3.24 followed by TBAF deprotection (Scheme 3.7).  Both of 
these amino-alcohols 3.23 and 3.27 were then subjected to buffered and un-buffered 
oxidative conditions.  Treatment of amino-alcohols 3.23 or 3.27 with Dess-Martin 
periodinane (DMP) led to decomposition.  IBX oxidation of amino-alcohol 3.23 
showed predominantly unreacted starting material when monitored by 1H-NMR 
spectroscopy, with small amounts of pyrrole 3.25 and pyrrolidine 2.12 detectable by 
GC-MS analysis.  Similar attempts at IBX oxidation of amino-alcohol 3.27 gave 





Scheme 3.8: synthesis and testing of amino-esters as condensation precursors 
In light of the unreliable results provided by attempts to form the amino-aldehyde 
under oxidative conditions, we decided to investigate partial reduction of an ester, such 
as 3.28 as an alternative route.  It was hoped that partial reduction of the ester 3.28 
with DIBAL-H would give the amino-aldehyde, resulting in condensation and 
formation of the enamine 2.8 under strongly basic conditions, which would suppress 
iminium ion formation.  Accordingly, ester 3.28 was prepared by mono-alkylation of 
aniline 2.15 with ethyl 4-bromobutyrate 2.48 (Scheme 3.8).  The ester 3.28 was then 
subjected to DIBAL-H conditions, giving varying mixtures of the over-reduced 
pyrrolidine 2.12 and small quantities of the dimers 2.7a and 2.7b.  Attempts to optimise 
this reaction proved unsuccessful, with reliable yields of the dimers (2.7) being elusive 
and no trace of the desired enamine 2.8 detectable.   
 
3.4.2 Oxidative Cross-Dimerisation 
Having concluded that the condensation approach was not a viable way of achieving 
cross-dimerisation, we decided to investigate oxidative methods of generating the key 
enamine fragment (2.8) and promoting cross-dimerisation.  Although we had 
originally contemplated oxidative conditions to generate the enamine/iminium ion pair 
needed for our synthesis of incargranine B (2.1b) (see chapter 2.2), the majority of 
conditions had been considered unattractive for practical reasons such as the use of 





Scheme 3.9: Bohle85 and Klussman’s86 Cu catalysed amine α-functionalisation 
An attractive alternative to these approaches was presented by Bohle85 and 
Klussman.86  They demonstrated the use of either CuBr or CuCl2 catalysed oxidations 
to generate iminium ions (3.30) from the tetrahydroisoquinoline 3.29, which could 
then undergo addition of various nucleophiles to give α-functionalised products 3.31 
(Scheme 3.9).   
 
Scheme 3.10: Attempts at oxidative cross-dimerisation 
We hoped that oxidation of the pyrrolidine 2.12 under Bohle85 or Klussman86 
conditions would provide access to the iminium ion 2.9 and enamine 2.8 pair under 
relatively mild conditions.  This equilibrium mixture of enamine/iminium ion (2.8/2.9) 
would then hopefully be trapped by addition of the model p-quinol 1.43 to give the 
desired millingtonine framework 3.17.  Unfortunately all attempts to oxidise the 
pyrrolidine 2.12 either by treatment with CuBr/tBuOOH or CuCl2/O2 resulted 
primarily in decomposition, with trace formation of the incargranine B/dia-
incargranine B aglycones (2.7a/2.7b).  Similar results were observed when the 





3.4.3 Alternative Strategies to Access the Millingtonine Framework 
In light of the lack of success encountered trying to assemble the millingtonine core 
through cross-dimerisation under oxidative or condensation based conditions, we 
decided to investigate alternative synthetic strategies.   
 
Scheme 3.11: Proposed β-elimination approach to enamine 2.8 
We considered one alternative approach was to generate the desired enamine 2.8 
through elimination of water from a β-hydroxy amine such as 3.32.  Hopefully, 
subjecting the β-hydroxy amine 3.32 to suitable elimination conditions would give 
enamine 2.8 directly, then treatment of this enamine 2.8 with a p-quinol, such as 1.43, 
would provide access to the millingtonine framework 3.17 (Scheme 3.11).   
 
Scheme 3.12: Preparation of β-hydroxylamine 3.32 and attempted acidic elimination 
Accordingly, the β-hydroxy amine 3.32 was prepared by alkylation of aniline 2.15 
with 1,4-dibromo-2-butanol 3.33 and the elimination investigated (Scheme 3.12).  
Unfortunately, it was found that treatment with stoichiometric acid resulted solely in 
protonation of the aniline, while exposure to excess acid merely resulted in 





Scheme 3.13: Alternative retrosynthetic analysis of the millingtonine framework 3.17 
Another retrosynthetic approach to the model millingtonine framework 3.17 is shown 
in Scheme 3.13.  We considered the possibility that the millingtonine model 3.17 could 
be accessed using analogous disconnections to those employed in the Ley-Kirschning-
Baxendale synthesis (see section 3.2).72  Thus, millingtonine model 3.17 could be 
formed by Buchwald-Hartwig coupling of the tricyclic fragment 3.34 with a suitable 
aryl bromide, such as 2.53.  The tricyclic framework would be assembled by domino 
enamine-Michael/oxa-Mannich addition of a Δ2-pyrroline 3.35 to the model p-quinol 
1.43.  If this approach proved promising on the model system, we anticipated that we 
could adapt it to access the natural product by replacing the p-quinol 1.43 with 
protected cornoside (3.12) and the use of an aryl bromide glycoside (see chapter 2.4.1). 
 
Scheme 3.14: Poupon's 1 step biomimetic synthesis of nitraramine (3.36)87 
Some support for the use of free Δ2-pyrroline as a nucleophile came from Poupon’s 
biomimetic synthesis of nitraramine (3.36) (Scheme 3.14).87  In this remarkable, one-
step biomimetic synthesis, Poupon used the trimer 3.37 as a source of the enamine Δ2-
piperidene 3.38.  Two molecules of this Δ2-piperidene 3.38 could then undergo 
nucleophilic addition to glutaraldehyde (3.39), initiating a domino sequence of 





Scheme 3.15: Proposed synthesis of the tricyclic core of millingtonine 
We aimed to make use of a similar approach to form the model tricyclic core of 
millingtonine 3.34.  We hoped that the known pyrroline trimer 3.22 could be used as 
a source of the Δ2-pyrroline 3.40 in an analogous fashion to Δ2-piperidene trimer 3.37.  
Enamine-Michael addition of the pyrroline 3.40 to a p-quinol such as 1.43 would then 
give the iminium ion intermediate 3.41 which could be trapped through an 
intramolecular oxa-Mannich addition to give the desired tricyclic framework 3.34 
(Scheme 3.15).   
Nomura and co-workers have previously described the synthesis of the pyrroline 
trimer 3.22 by the oxidation of pyrrolidine (3.41) with catalytic AgNO3 and 
peroxodisulphate.88,89   
 
Scheme 3.16: Synthesis of Δ1-pyrroline(3.21)/trimer (3.22) and Michael addition to p-quinol 1.43 
Accordingly, following Nomura’s procedure, we treated pyrrolidine with 
AgNO3/Na2S2O8 under basic conditions to give a mixture of the trimer 3.22 and 




p-quinol 1.43 in CHCl3 in the hope of triggering the desired enamine-Michael/oxa-
Mannich sequence.  Unfortunately, the only isolable product from this reaction proved 
to be the oxazolidine 3.43, which presumably formed through an initial aza-Michael 
addition of the Δ1-pyrroline 3.21 to the p-quinol 1.43 to give the iminium ion 3.42, 
followed by an intramolecular oxa-Mannich addition to give 3.43.  It was unclear 
whether the undesired reactivity was caused by the contamination of the trimer 3.22 
with Δ1-pyrroline 3.21, or simply indicative that no significant quantity of the Δ2-
pyrroline 3.40 could be formed from the trimer 3.22; however, as it proved impossible 
to obtain pure trimer 3.22, this approach was abandoned. 
 
3.4.4 N-Aryl Enamines through Alkene Isomerisation 
As discussed above, extensive screening of conditions following oxidation, reduction 
and condensation strategies to generate a suitable N-aryl enamine and promote cross-
dimerisation proved unsuccessful.  Under all conditions explored, it appeared that the 
domino Mannich/SEAr reaction sequence, en-route to the incargranine B frameworks 
(e.g. 2.7a and 2.7b), are too fast for cross-dimerisation to compete.  Our inability to 
detect any signs of either N-aryl enamine or N-aryl iminium species in these reactions 
further supported the conclusion that, under any conditions where the formation of 
both species was possible, very rapid dimer formation would prevent the build-up of 
the N-aryl enamine.  As a result, we concluded that the only window of opportunity 
for cross-dimerisation would be the generation of an N-aryl enamine under conditions 
which essentially precluded the formation of highly electrophilic iminium species. 
We considered that one possible strategy to access an N-aryl enamine in the absence 
of the corresponding iminium ion would be the isomerisation of a suitable 2,5-
dihydropyrrole (such as 3.44).  A promising approach was presented by Grubbs and 
co-workers, who reported observing the formation of the enamine 3.45 as an unwanted 
isomerisation product following ring-closing metathesis of diallyl aniline 3.46 
(Scheme 3.17).90  Grubbs found that treatment of diallyl aniline 3.46 with the Grubbs 
first generation catalyst (Grubbs I) under normal metathesis conditions initially gave 




extended reaction times; however, substantial isomerisation to the 2,3-dihydropyrrole 
3.45 was observed (Scheme 3.17)90 
 
Scheme 3.17: Grubbs observation of N-aryl enamine formation through metathesis/isomerisation90 
To explore the possibility of using this approach to access suitable N-aryl enamines 
for cross-dimerisation, we decided to first attempt to replicate the results reported by 
Grubbs.  Diallyl aniline 3.46 was readily prepared by dialkylation of aniline 3.26 with 
allyl bromide (Scheme 3.18).  It was found that treatment of diallyl aniline 3.46 with 
5 mol% of Grubbs I catalyst rapidly promoted ring-closing metathesis at room 
temperature, giving quantitative conversion to the 2,5-dihydropyrrole 3.44 
(determined by NMR spectroscopic analysis compared to an internal standard, see 
chapter 6.4.10).  Subjecting either diallyl aniline 3.46 or the dihydropyrrole 3.44 to 
extended reaction times at 40 °C, as described by Grubbs, gave an unexpected result.  
Following ring-closing metathesis, no sign of isomerisation to the enamine 3.45 could 
be observed, with prolonged reactions giving slow formation of a 1:1 mixture of the 
pyrrole 3.47 and pyrrolidine 3.48.  It is worth noting that the 1:1 mixture of the pyrrole 
3.47 and pyrrolidine 3.48 produces NMR signals which could be misinterpreted as 
belonging to the enamine 3.45; however, comparison of NMR data and co-spiking 
experiments (Scheme 3.18) confirmed that these were the only products formed.  Re-
analysis of the data reported by Grubbs and co-workers showed that it also matched 
these results. 
 




Although this result proved a disappointing setback, we remained convinced that the 
best approach to form N-aryl enamines was the isomerisation of a suitable 2,5-
dihydropyrrole (such as 3.44).  The Grubbs conditions, despite not providing a route 
to the enamine 3.45, provided a convenient method to prepare a range of 2,5-
dihydropyrroles which we could then use to explore alternative isomerisation 
conditions.  
 
Scheme 3.19: Two procedures for the synthesis of 2,5-dihydropyrrole (3.49) 
Accordingly, the phenylethanol 2,5-dihydropyrrole 3.49 was prepared following a 
similar two-step procedure (Scheme 3.19).  Commercially available aniline 2.15 was 
diallylated using allyl bromide to give diallyl aniline 3.50 in excellent yield on multi-
gram scale.  Ring-closing metathesis using 5 mol% Grubbs I at room temperature 
smoothly converted the diallyl aniline 3.50 into 2,5-dihydropyrrole 3.49.  Although 
this two-step approach provided convenient access to 2,5-dihydropyrrole 3.49, it 
proved difficult (and costly) to scale-up the metathesis to multi-gram scale.  To avoid 
these issues, an alternative one-step procedure was developed in which the aniline 2.15 
was alkylated with (Z)-1,4-dichlorobutene91 3.51, to give the dihydropyrrole 3.49 
directly in excellent yield on multi-gram scale (Scheme 3.19). 
With access to multi-gram quantities of a suitable dihydropyrrole (3.49), we turned 
our attention to developing conditions to effect the isomerisation to the N-aryl 
enamine.  Isomerisations of alkenic amines to give enamines has been reported under 
a range of conditions including: strong base such as n-BuLi or KOtBu;92 Wilkinson’s 
catalyst;72 and catalytic Fe(CO)5.
93  Unfortunately, all attempts to use these conditions 
to effect the isomerisation of the 2,5-dihydropyrrole 3.49 proved unsuccessful.  The 





94 only showed partial conversion to the pyrrole 3.25 
(~40% by NMR analysis) after 18 hours, with no sign of enamine formation (Scheme 
3.20).  Treatment with catalytic Pd(OAc)2/dppp
95 gave a modest yield of the dimers 
(2.7a/2.7b), which indicated that the enamine 2.8 was probably being formed during 
the reaction; however, it was not possible to identify or isolate the enamine 2.8 under 
these conditions, so they were also abandoned.  
 
Scheme 3.20: Attempted Pd catalysed isomerisation of 2,5-dihydropyrrole 3.49 
A promising result came from the commercially available rhodium hydride complex 
Rh(H)(CO)(PPh3)3.  Based on conditions reported by Stille and Becker
93 the 2,5-
dihydropyrrole 3.49 was heated in either d8-toluene or CD2Cl2 in the presence of 5 
mol% Rh(H)(CO)(PPh3)3, giving complete consumption of starting material.  Initial 
analysis of the 1H-NMR spectrum of the reaction mixture suggested the major product 
could be the desired enamine 2.8, identified by the presence of a 1,4-disubstituted aryl 
system and a doublet at 5.05 ppm, initially believed to correspond to the enamine (2.8) 
H(2) signal.  However, attempts to react this material with the model p-quinol 1.43 
proved unsuccessful.  This prompted a closer analysis of the in-situ 1D and 2D NMR 
spectra of this isomerisation reaction, leading us to conclude that the major product 
was likely to be the dimeric macrocycle 3.52.  Unfortunately, all attempts to isolate 
and purify the macrocycle 3.52 proved unsuccessful, with the only isolable products 





Scheme 3.21: Rhodium hydride catalysed isomerisation of 2,5-dihydropyrrole 3.49 
These results suggested that, although the conditions Rh(H)(CO)(PPh3)3 appeared 
promising, they were unlikely to be compatible with the presence of an unprotected 
hydroxyl group in the substrate.  In order to remove potential issues with this 
functional group intolerance, we decided to develop the isomerisation chemistry using 
2,5-dihydropyrrole 3.44 as a simplified model system.   
 
Scheme 3.22: Synthesis of simplified model 2,5-dihydropyrrole (3.44) 
Accordingly the 2,5-dihydropyrrole 3.44 was prepared following the previously 
outlined procedures.  Aniline 3.26 was diallylated with allyl bromide to give diallyl 
aniline 3.46, which could be converted to the 2,5-dihydropyrrole 3.44 through ring 
closing metathesis.  Alternatively the 2,5-dihydropyrrole 3.44 could be prepared via 
dialkylation of aniline 3.26 with cis-1,4-dichlorobutene91 3.51 on multi-gram scale 




With the simplified model 2,5-dihydropyrrole 3.44 in hand, we moved to re-examine 
the rhodium hydride mediated isomerisation.  Following Stille’s conditions,93 the 2,5-
dihydropyrrole 3.44 was initially treated with 5 mol% Rh(H)(CO)(PPh3)3 at 70 ºC in 
C6D6 and the reaction monitored by 
1H-NMR spectroscopy.  Pleasingly, under these 
conditions, it was found that the 2,5-dihydropyrrole 3.44 isomerised readily to give the 
desired enamine 3.45 in approximately 30 minutes (Scheme 3.23).  Attempts to isolate 
and purify the enamine 3.45 led to decomposition, so characterisation was carried out 
in-situ using 1D and 2D NMR spectroscopy.  Yields of enamine 3.45 proved variable, 
so a screen of conditions was undertaken in an attempt to optimise the isomerisation.  
It was found that d8-PhMe, C6D6 and CD2Cl2 were the most suitable solvents and that 
rigorous degassing improved both yields and reliability.  The isomerisation proceeded 
smoothly at room temperature in CD2Cl2, giving yields of 54-71%, although reaction 
times were increased to ~ 4 hours.  Reaction monitoring by 1H-NMR spectroscopy at 
room temperature showed that enamine concentrations peaked at ~ 4 hours, followed 
by slow decomposition.  It was found that reaction times could be reduced to ~ 1-1.5 
hours by heating to 40 ºC without any drop in yield, while attempts to reduce catalyst 
loadings below 5 mol% resulted in incomplete consumption of starting material.  As a 
further test of these optimised isomerisation conditions, the phenylethanol model 2,5-
dihydropyrrole 3.53 was prepared through TBS protection of the dihydropyrrole 3.49 
under standard conditions.   
 
Scheme 3.23: Synthesis of two model enamine systems 
The protected 2,5-dihydropyrrole 3.53 was treated with 5 mol% Rh(H)(CO)(PPh3)3, 




section 6.4).  The N-aryl enamines, such as 3.54, could be readily identified by the 
presence of distinctive doublets of triplets at 6.69 ppm and 4.96 ppm in the 1H-NMR 
spectrum.  These signals showed mutual coupling (J = 4.6 Hz) and strong 1H-1H COSY 
cross-peaks, allowing them to be assigned as the H(2)/H(3) alkenic protons (see 
Figure 3.4). 
 
Figure 3.4: 500MHz 1H-NMR spectra showing the in-situ formation of enamine 3.54 
 
3.4.5 Model Cross-Dimerisation Studies 
Having secured reliable access to suitable N-aryl enamines, we began to investigate 
their use in cross-dimerisation reactions.  Although it was possible to use a 
phenylethanoid model system (enamine 3.54 and p-quinol 1.43), we elected to initially 
explore a simplified model system, making use of the aniline enamine 3.45 and methyl 
p-quinol 3.55 which could be readily prepared in 1 step (Scheme 3.24).96  Initial 
attempts to achieve cross-dimerisation with this model system proved unsuccessful 
under a range of conditions.  Treatment of a freshly prepared solution of the enamine 
3.45 with the model p-quinol 3.55 at room temperature resulted only in slow 




or using excess p-quinol simply increased the rate of decomposition and homo-dimer 
formation.  Attempts to conduct the isomerisation of the dihydropyrrole 3.44 in the 
presence of p-quinol 3.55 returned only starting material.  Considering that the 
enamine 3.45 was potentially less nucleophilic than we had anticipated, we explored a 
range of Lewis acids in the hope of activating the p-quinol Michael acceptor 3.55.  
Strong Lewis acids such as TMSOTf, BCl3 and AlCl3, were unsuitable, causing 
immediate decomposition of the p-quinol 3.55.  Treatment of p-quinol 3.55 with mild 
Lewis acids, such as LiBr and LiCl, caused promising deshielding of the β-alkenic 
positions, as observed by 1H-NMR spectroscopy.  These Lewis acids; however, were 
only compatible with THF as a solvent, which proved to be unsuitable for the 
formation of the enamine 3.45.  LiPF6 and CeCl3 gave only rapid decomposition of the 
enamine 3.45 with no signs of cross-dimer 3.56 formation.  Binol phosphoric acids 
had previously been reported as catalysts for Michael additions to p-quinol systems;97 
however, attempts to use the phosphoric acid 3.57 to promote cross-dimerisation also 
proved unsuccessful.  Attempts to use the Ledwith-Weitz aminium salt 3.5898 as a 
radical-cation catalyst to promote cross-dimerisation were unsuccessful, with 
complete decomposition of the enamine 3.45 observed in all cases. 
 
Scheme 3.24: Screen of conditions for model cross-dimerisation 
Despite unpromising results with the Ledwith-Weitz salt 3.58, the possibility of using 
a radical-cation mediated approach to the cross-dimerisation remained attractive.  A 




3.45 to a suitable redox catalyst could produce the iminium radical 3.59.  Mannich-
type addition of the p-quinol 3.55 to the iminium 3.59 would give the carbon-centred 
radical 3.60, which could be trapped through a rapid 5-exo-trig cyclisation, to give the 
cross-dimer 3.56.  By generating an electrophilic iminium radical 3.60, the oxa-
Mannich addition to form the C−O bond would occur first, hopefully avoiding the 
apparently poor nucleophilicity of the enamine 3.47 and electrophilicity of the p-quinol 
3.55.  This approach would also be analogous to the Ueno-Stork cyclisation 
successfully employed in the Ley-Kirschning-Baxendale synthesis (see section 3.2),72 
providing good precedent for its viability.   
 
Scheme 3.25: Radical-cation cross-dimerisation strategy 
Yoon and co-workers have described the preparation and use of Ru(bpz)3 (3.61) and 
Ru(bpy)3 (3.62) as photoredox catalysts to promote Diels-Alder reactions on a range 
of substrates including enamines, such as N-vinyl carbazole 3.65.99,100  As these 
catalytic systems had been shown to promote the formation of radical cations from 
enamines under mild conditions, we considered they might prove competent catalysts 
for promoting our cross-dimerisation through a radical-cation pathway.  Accordingly 
Ru(bpz)3(BArF)2, Ru(bpy)3(PF6)2 and MV(PF6)2 (3.64) were prepared following 
literature procedures99,100 and their use in the model cross dimerisation investigated.   
As a test of the catalytic system, Yoon’s reported Diels-Alder addition of N-vinyl 
carbazole 3.65 to 2,4-dimethyl-1,3-pentadiene 3.66 to give adduct 3.67 was repeated.  




light, the adduct reported by Yoon 3.67 could be identified in the 1H-NMR spectrum 
(Scheme 3.26). 
 
Scheme 3.26: Yoon's photoredox catalysts and test Diels-Alder reaction 
Having confirmed the activity of our catalysts, we set about testing their application to 
our model cross-dimerisation.  Unfortunately, it was found that subjecting the enamine 
3.45 and p-quinol 3.55 to either Yoon’s Ru(bpz)3(BArF)2
100 or Ru(bpy)3(PF6)2/ 
MV(PF6)2
99 photoredox catalysis conditions led exclusively to decomposition of the 
enamine 3.45 without any dimer formation. 
 




In an attempt to further explore the reactivity of our model system, attempts were made 
to react enamine 3.45 and p-quinol 3.55 with different coupling partners under Yoon’s 
Ru(bpz)3(BArF)2 mediated conditions (Scheme 3.27).  Accordingly, the Diels-Alder 
addition of enamine 3.45 to 2,4-dimethyl-1,3-pentadiene 3.66 was attempted in the 
presence of Ru(bpz)3(BArF)2; however, once again only rapid decomposition of the 
enamine was observed.  Similarly, attempts to promote the cross-dimersation of the 
commercially available enamine 3.70 with p-quinol 3.55 also resulted in 
decomposition. 
Disappointed by the lack of success encountered with radical-cation cross-
dimerisation, we turned our attention back to methods of activating the p-quinol to 
nucleophilic addition.  Success came while exploring the use of iminium ion catalysis 
to activate the p-quinol 3.55.  It was found that, while addition of L-proline to a mixture 
of enamine 3.45 and p-quinol 3.55 resulted in decomposition, surprisingly the use of 
pyrrolidine resulted in the formation of the cross-dimeric product 3.56 in 16% yield, 
along with a substantial amount of the homo-dimers 2.26/2.27 (Scheme 3.28).   
 
Scheme 3.28: Successful pyrrolidine mediated cross-dimerisation 
Pleasing though this result was, optimising the reaction to favour the cross-dimer 3.56 
proved difficult.  On close examination of the reaction by 1H-NMR spectroscopy 
several peculiar features became apparent.  On addition of p-quinol 3.55 and 
pyrrolidine, consumption of both the enamine 3.45 and the p-quinol 3.55 occurred 
much faster than the formation of either the homo (2.26/2.27) or cross-dimeric (3.56) 
products.  This suggested the formation of an intermediate which then slowly 




identified in the NMR spectra.  In addition, consumption of the p-quinol 3.55 occurred 
much faster than that of the enamine 3.45, suggesting a possible side-reaction. 
To probe these peculiar observations, control reactions were conducted on both 
enamine 3.45 and p-quinol 3.55 (Scheme 3.29).  On treatment with pyrrolidine at room 
temperature, the p-quinol 3.55 could be seen to undergo rapid aza-Michael addition to 
give the adduct 3.71, which decomposed when isolation was attempted.  Treatment of 
a freshly prepared solution of the enamine 3.45 with pyrrolidine at room temperature 
resulted in slow formation of the aminal 3.72.  Although this aminal 3.72 appeared 
quite stable in solution, attempts at isolation resulted in decomposition. 
 
Scheme 3.29: Pyrrolidine addtion products from p-quinol (3.55) and enamine (3.45) 
 
This additional insight into some of the species formed under our cross-dimerisation 
conditions suggested some possible avenues for optimisation.  Formation of the cross-
dimer 3.56 appeared to correspond to a reduction in the concentration of both enamine 
3.45 and aminal 3.72, making it difficult to determine which was an intermediate in 
cross-dimerisation (see Figure 3.5).  Rapid formation of the aza-Michael adduct 3.71 
appeared to represent a problem.  Aza-Michael addition to the p-quinol 3.55 did not 
seem to form part of a productive pathway, as the formation and disappearance of the 
aza-Michael adduct 3.71 over the course of the reaction did not correlate with the either 






Pre-formation of the aminal 3.72 prior to addition of p-quinol 3.55 provided a possible 
method for testing the intermediacy of the aminal 3.72 in the cross-dimerisation.  An 
additional benefit of pre-forming the aminal 3.72 was the possibility of reducing the 
amount of excess pyrrolidine present, hopefully limiting unproductive formation of 
the aza-Michael adduct 3.71.  Pleasingly, it was found that addition of p-quinol 3.55 
to a pre-formed solution of the aminal 3.72 at room temperature gave the cross-dimer 
3.56 in comparable yield, confirming the aminal 3.72 as a viable intermediate. 
 
 
Figure 3.5: Concentrations of quinol (3.55) quinol adduct (3.71), enamine (3.45), aminal (3.72) 
and dimer (3.56) over the course of a pyrrolidine mediated dimerisation reaction.  Concentrations 






























Scheme 3.30: Methyl hemiaminal (3.73) formation from 2,5-dihydropyrrole 3.44 
To further probe the behaviour of the 2,5-dihydropyrrole 3.44 under the rhodium 
hydride conditions, we decided to test if substitution of an alcohol for pyrrolidine 
would result in hemiaminal formation.  Accordingly, 2,5-dihydropyrrole 3.44 was 
treated with MeOH and 5 mol% Rh(H)(CO)(PPh3)3 at 40 ºC to give the hemiaminal 
3.73 in quantitative yield (determined 1H-NMR spectroscopic analysis compared to an 
internal standard) (Scheme 3.30). 
 
Scheme 3.31: Optimised model cross-dimerisation 
Addition of pyrrolidine prior to the rhodium hydride catalysed isomerisation of the 
2,5-dihydropyrrole 3.44 was found to give the aminal 3.72 directly.  Gratifyingly, the 
use of a slight excess of pyrrolidine resulted in quantitative formation of the aminal 
3.72 (determined by 1H-NMR spectroscopy compared to an internal standard) after 2 
hours at 40 °C.  Treatment of this aminal 3.72 solution with excess (3 equiv.) p-quinol 
3.55 gave the cross-dimer 3.56b in 37% isolated yield, along with a 21% combined 
yield of the homo-dimers 2.26/2.27 and an unexpected p-quinol dimer 3.74 in 23% 




On close examination of the NMR data it became apparent that we had originally miss-
assigned the stereochemistry of the cross-dimeric product 3.56.  NOESY analysis 
showed the product had a cis-syn-cis configuration (3.56b) instead of the expected cis-
anti-cis (3.56a) (Scheme 3.32). 
 
Scheme 3.32: Isomerisation of model cross-dimer 3.56b 
This was a significant concern, as millingtonine (3.1) possesses the cis-anti-cis 
stereochemistry, which was not obtained from the model cross-dimerisation.  
Thankfully, treatment of the cis-syn-cis dimer 3.56b with TFA resulted in clean 
isomerisation to what appeared to be the desired cis-anti-cis structure (3.56a) (as 
determined by 1H-NMR spectroscopy) (Scheme 3.32).  Presumably this occurs 
through a retro-oxa-Mannich/enamine epimerisation/oxa-Mannich sequence. 
 
Scheme 3.33: Possible explanation of the role of pyrrolidine in enamine cross-dimerisation 
One possible mechanistic explanation for the role of the aminal 3.72 in the cross-
dimerisation process would be as a reservoir for enamine 3.45 (Scheme 3.33).  Slow 
loss of pyrrolidine from aminal 3.72 could ensure a low steady-state concentration of 
the enamine 3.45 in the reaction mixture, limiting homo-dimerisation and providing a 
reactivity window for cross-dimerisation.  However, although this explanation 




how cross-dimerisation is promoted.  In the absence of pyrrolidine, enamine 3.45 does 
not appear to be sufficiently nucleophilic to undergo cross-dimerisation with p-quinol 
3.55; however, aminal 3.72 is sufficiently reactive to give the cross-dimer 3.56b. 
 
Scheme 3.34: Possible mechanism for the cross-dimerisation of aminal 3.72 and p-quinol 3.55 
An alternative explanation of the role of the aminal 3.72 is shown in Scheme 3.34.  It 
is likely more favourable for the endocyclic C–N bond of aminal 3.72 to cleave, in 
preference to the exocyclic C–N bond, to give the acyclic iminium ion 3.76 (Scheme 
3.34).  Therefore, the problematic N-aryl iminium species 3.75 is present at lower 
concentration.  Deprotonation of the acyclic iminium 3.76 would give the enamine 
3.77, which would be expected to be more nucleophilic than the N-aryl enamine 3.45.  
The acyclic enamine 3.77 would then have a sufficient window of opportunity to react 
with para-quinol 3.55 to give the Michael-addition product 3.78.  Finally, an aza-
Mannich/oxa-Mannich sequence with loss of pyrrolidine would give the cross-dimer 
3.56b (Scheme 3.34). 
 
Scheme 3.35: Synthesis of p-quinol dimer 3.74 
The formation of the p-quinol dimer 3.74 as an unexpected side product, while not 
representing a particular problem, suggested one reason an excess of p-quinol 3.55 was 




p-quinol dimer 3.74 could also readily be formed through treatment of the p-quinol 
3.55 with 20 mol% pyrrolidine at 70 ºC, giving good yields of the dimer 3.74 (Scheme 
3.35).  
 
Scheme 3.36: Two possible mechanisms for the formation of p-quinol dimer 3.74 
Two possible mechanisms for the formation of dimer 3.74 are presented in Scheme 
3.36.  In the first (Scheme 3.36A) base-mediated intermolecular oxa-Michael addition 
would initially form the dimer 3.79.  Subsequent intra-molecular Michael addition 
would give the second enolate 3.80 which could then undergo a final intramolecular 
Michael addition to give the observed dimer 3.74 (Scheme 3.36A).  Alternatively, the 
dimerisation could proceed via a pyrrolidine catalysed Rauhut-Currier101 mechanism 
(Scheme 3.36B).  Initial aza-Michael addition of pyrrolidine to p-quinol 3.55 would 
give the pyrrolidine adduct 3.71.  This could then undergo Michael addition to a second 
molecule of p-quinol 3.55, to give the dimer 3.81.  E1cB elimination of pyrrolidine 
would form dimer 3.82, which could then undergo intramolecular oxa-Michael 
addition to give the tricyclic intermediate 3.80.  This can then undergo a final Michael 




The Rauhut-Currier mechanism appeared more likely for two reasons.  Firstly, the 
prior observation that the aza-Michael adduct 3.71 is rapidly formed on treatment of 
p-quinol 3.55 with pyrrolidine and secondly, attempts to promote this reaction using 
K2CO3
44 as a non-nucleophilic base proved unsuccessful, returning only unreacted p-
quinol 3.55. 
 
3.5 SYNTHESIS OF MILLINGTONINE 
3.5.1 Synthesis of Tetra-O-Pivaloyl Cornoside (3.12) 
Having developed reliable methodology for the formal cross-dimerisation of N-aryl 
enamines with p-quinols to give the millingtonine (3.1) framework, we set about 
applying it to the total synthesis of millingtonine itself (3.1).  The first step in this 
process was to access suitably protected cornoside 3.12.  It was anticipated that a 
similar strategy to that used for the synthesis of the OTBS model p-quinol 1.4344 could 
be applied to make protected cornoside 3.12 from protected salidroside 3.13.  
Accordingly, O-pivaloyl salidroside 3.83 was prepared in three steps from the 
commercially available phenol 1.41 (Scheme 3.37).  A previously described double 
TBS protection of the phenol 1.41 followed by selective mono-deprotection using 
I2/MeOH
102 gave the OTBS phenol 3.83 in good yield on gram scale.  Using our 
previously optimised glycosylation conditions,53 the OTBS phenol 3.83 was treated 
with trichloroacetimidate 2.56 activated with TMSOTf.  Pleasingly, with the use of 
extended reaction times, phenol 3.83 was found to smoothly undergo glycosylation 
and subsequent desilylation to give pivaloyl salidroside 3.13 directly in good yields 
and with complete β-selectivity (Scheme 3.37).  Finally, hypervalent-iodine oxidation 
of salidroside 3.13 gave the desired O-pivaloyl protected cornoside 3.12 on gram scale 





Scheme 3.37: Synthesis of tetra-O-pivaloyl cornoside 3.12 
To test the compatibility of O-pivaloyl protected cornoside 3.12 with the cross-
dimerisation conditions, a model dimerisation was conducted using the 2,5-
dihydropyrrole 3.44.  Accordingly, O-pivaloyl cornoside 3.12 was added to a freshly 
prepared solution of aminal 3.72 to give a 31% yield of the desired cross-dimer 3.85 
as an inseparable mixture of pseudo-enantiomeric diastereomers (d.r. ~ 1:1 determined 
by 13C-NMR spectroscopy) (Scheme 3.38). 
 
Scheme 3.38: Test cross-dimerisation using O-pivaloyl cornoside 3.12 
3.5.2 Synthesis of the Dihydropyrrole Glycoside 
With O-pivaloyl cornoside 3.12 in hand and test cross-dimerisation results 
demonstrating its compatibility with our dimerisation strategy, we turned to the 
preparation of a suitable 2,5-dihydropyrrole glycoside.  Attempts to glycosylate either 
the 2,5-dihydropyrrole 3.49 or the diallyl aniline 3.50 resulted in decomposition 
(Scheme 3.39), so it was concluded that installation of the β-glucose unit would have 





Scheme 3.39: Failed glycosylation strategies 
With this in mind, the commercially available aniline 2.15 was selectively N-Boc 
protected under standard conditions to give the protected aniline 3.86.  With the 
nitrogen protected, aniline 3.86 could be subjected to our optimised glycosylation 
conditions.53  Pleasingly, treatment with trichloroacetimidate 2.56 and TMSOTf at 
room temperature was found to give β-selective O-glycosylation followed by N-
deprotection, giving the desired aniline glycoside 3.87 directly in excellent yield on 
gram scale.  The glycoside 3.87 was subjected to our standard dialkylation conditions 
in an attempt to form the 2,5-dihydropyrrole 3.88.  Surprisingly, treatment of aniline 
3.87 with (Z)-1,4-dichlorobutene 3.51 in the presence of NaI/iPr2NEt was found to give 
only the pyrrole 3.89 in 45% yield, with no sign of dihydropyrrole 3.88.   
Detailed examination of this dialkylation reaction using the model 2,5-dihydropyrrole 
3.44 found that decomposition, substantially to N-phenylpyrrole, occurred when the 
2,5-dihydropyrrole 3.44 was exposed to excess 1,4-dichlorobutene 3.51 in the 
presence of NaI.  Although the reason for this decomposition was unclear, it appeared 
good results could be obtained by ensuring no excess  1,4-dichlorobutene 3.51 was 
present.  With this in mind, the glycoside 3.87 was treated with a sub-stoichiometric 
amount (0.8 equiv.) of 1,4-dichlorobutene 3.51, giving the desired 2,5-dihydropyrrole 





Scheme 3.40: Synthesis of 2,5-dihydropyrrole glycoside 3.88 
 
3.5.3 Dimerisation and Completion of the Synthesis 
With practical quantities of both glycoside dimerisation precursors (3.12 and 3.88) in 
hand, we turned our attention to the biomimetic cross-dimerisation and completion of 
our millingtonine (3.1) synthesis.  Treatment of the 2,5-dihydropyrrole glycoside 3.88 
with pyrrolidine in the presence of 5 mol% Rh(H)(CO)(PPh3)3 gave quantitative 
conversion to the aminal 3.90 after 1.5 hours at 40 ºC (yield determined by 1H-NMR 
spectroscopy compared to an internal standard).  Confirmation of the anticipated 
product structure was obtained by in-situ 1D and 2D NMR spectroscopic analysis prior 
to carrying the material forward.  Treatment of aminal 3.90 with excess O-pivaloyl 
cornoside 3.12 at room temperature gave the desired O-pivaloyl dia-millingtonine 
(3.91) in a 50% yield as the expected 1:1 mixture of pseudo-enantiomeric 
diastereomers (Scheme 3.41).  In addition, the homo-dimer O-pivaloyl incargranine B 
(2.60)53 and its previously unknown diastereomer, dia-incargranine B (3.92), were also 





Scheme 3.41: Synthesis of dia-millingtonine (3.91) 
Having successfully demonstrated the cross-dimerisation, giving access to the kinetic 
product, O-pivaloyl dia-millingtonine (3.91), all that remained to complete the 
synthesis was isomerisation to the thermodynamic cis-anti-cis isomer and sugar 
deprotection.  Accordingly, O-pivaloyl dia-millingtonine (3.91) was treated with TFA 
at room temperature, giving smooth isomerisation to the desired cis-anti-cis isomer, 
O-pivaloyl millingtonine (3.93).  The octa-O-pivaloyl deprotection was achieved by 
treatment with LiOH following a previously reported procedure53,72 to give 50 mg of 
millingtonine (3.1) in good yields (Scheme 3.42).  All data for our synthetic 
millingtonine (3.1) matched that previously reported for both natural83 and synthetic72 





Scheme 3.42: Synthesis of millingtonine (3.1) 
 
3.6 CONCLUDING REMARKS 
In this chapter, we had proposed a divergent/re-convergent biosynthetic pathway to 
account for the synthesis of four structurally diverse natural products, (±)-
incarviditone (1.35b), (±)-incarvilleatone (1.48), incargranine B (2.1b) and 
millingtonine (3.1).  Through purely synthetic investigations, we have been able to 
probe the feasibility of this proposed biosynthetic network.  The successful completion 
of the biomimetic total synthesis of millingtonine (3.1) has provided several insights, 
which have allowed us to further develop and refine our originally proposed 
biosynthetic network.  The formation of O-pivaloyl incargranine B (2.60) and O-
pivaloyl dia-incargranine B (3.92) during the synthesis of millingtonine (3.1), lends 
support to our previous proposal (see chapter 2.5) that dia-incargranine B (2.63) 
represents an undiscovered natural product.  The discovery that the kinetic cis-syn-cis 
product, dia-millingtonine (3.93/3.94) is initially formed from the proposed 
biomimetic cross-dimerisation, leads us to propose that dia-millingtonine (3.94) is also 
an, as yet unidentified, natural product and biosynthetic precursor to millingtonine 





Scheme 3.43: Speculation as to the biosynthetic origin of dia-millingtonine (3.94) 
It is interesting to consider whether our proposed mechanism for the pyrrolidine 
mediated cross-dimerisation (see Scheme 3.34) might have a parallel in the 
biosynthetic formation of dia-millingtonine (3.94).  We speculate that pyrrolidine 
might be fulfilling a similar role to pyridoxal phosphate (PLP) (3.95) in an interrupted 
oxidative deamination of diamine 2.2 as shown in Scheme 3.43.  PLP, (3.95) following 
enzyme Schiff-base formation to give the internal aldimine, could undergo 
transaldimination with diamine 2.2, giving the external aldimine 3.96.  Isomerisation 
could then lead to the enamine 3.97 which would undergo Michael addition to 
cornoside (1.37) to give the imine 3.98.  An aza-Mannich/oxa-Mannich sequence with 
loss of pyridoxamine phosphate (3.99) would then provide dia-millingtonine (3.94). 
In addition to the biosynthetic insights gained from this biomimetic investigation, 
consideration of the potential biosynthetic origins of millingtonine (3.1) have allowed 




approach, we have been able to assemble a challenging diglycosidic natural product in 
a longest linear sequence of only seven steps, which compares favourably to Ley, 
Kirschning and Baxendale’s twelve step synthesis72.  Central to the development of 
this successful synthesis was the use of transition-metal hydride catalysis to access an 
otherwise unstable biomimetic intermediate, an approach we envisage will prove 
applicable to other biomimetic studies. The future isolation of the cis,syn,cis-isomer 
of millingtonine, namely dia-millingtonine (3.94), from the natural environment would 
represent a new case of ‘natural product anticipation’ – an essentially unique benefit 






4 TOTAL SYNTHESIS OF INCARGRANINE A 
4.1 INTRODUCTION 
 
Figure 4.1: Biosynthetic analysis of incargranine A (4.1) 
Incargranine A (4.1) was isolated by Zhang and co-workers in 2009 from Incarvillea 
mairer var. grandiflora as part of their on-going interest in novel natural products from 
the Incarvillea genus of the Bignoniaceae family.107  Little is known about the 
biological function or activity of incargranine A (4.1).  With no reported total synthesis 
and isolation yielding only 0.0000002 % by weight from the whole dried plant, an 
efficient synthesis would provide a valuable contribution to further investigations into 
the properties of this novel alkaloid.  The structure of incargranine A (4.1) contains a 
synthetically challenging, tetracyclic core containing six contiguous stereogenic 
centres; however, we hoped that consideration of the likely biosynthesis of this 
compound would help us design an efficient synthetic strategy.   
Zhang did not speculate as to the biogenesis of incargranine A (4.1); however, retro-
biosynthetic analysis combined with our previous work on related phenylethanoid 
natural products44,53 provided clues as to its potential origins.  The biosynthetic 
analysis, shown in Figure 4.1, indicated that incargranine A (4.1) is likely comprised 
of two shikimic acid derived C6C2 units linked through an ornithine derived C4N 
moiety.  Insight into the manner in which nature links these units to give this complex 
framework came from consideration of the likely biogenesis of the related 
Bignoniaceae natural products (±)-incarviditone (1.35b), (±)-incarvilleatone (1.48), 







Scheme 4.1: Proposed biosynthesis of Incarvillea and Millingtonia natural products 
Building on our proposed biosynthetic network linking these four natural products to 
a common diamine precursor (2.2) through a divergent/re-convergent series of 
pathways, we speculated that incargranine A (4.1) might also be a product of this 
biosynthetic network.  The expanded biosynthetic network, including incargranine A 
(4.1) is shown in Scheme 4.1.  As previously discussed, two divergent pathways 




dearomatisation to imine 3.2, hydrolysis of which affords cornoside (1.37).  
Subsequent deglycosylation/oxa-Michael cyclisation gives (±)-rengyolone (1.39) 
which can undergo dimerisation to give (±)-incarviditone (1.35b) and (±)-
incarvilleatone (1.48).   
Alternatively, pathway 2 involves initial oxidative deamination to aldehyde 2.3, 
condensation to enamine 2.4 and protonation to give iminium ion 2.5.  This enamine 
2.4 and iminium ion 2.5 can then dimerise through a Mannich/SEAr sequence to give 
incargranine B (2.1b).  These two divergent pathways could re-converge at several 
different points to provide the pseudo-dimeric natural products millingtonine (3.1) and 
incargranine A (4.1).   
Based on our biomimetic synthesis of millingtonine (3.1) we proposed that an 
interrupted oxidative deamination of diamine 2.2 could form a pyridoxamine 
phosphate (PMP) enamine such as 4.2.  This enamine could then undergo Michael 
addition to cornoside (1.37), along re-convergent pathway 3, followed by an aza-
Mannich/oxa-Mannich sequence with loss of PMP to give dia-millingtonine (3.94) 
(see chapter 3.6 for details).  Isomerisation of dia-millingtonine (3.94) to the 
thermodynamic cis-anti-cis stereochemistry then provides millingtonine (3.1).   
Alternatively, if the enamine 4.2 intersected with pathway 1 at a later point, this could 
result in an enamine-Michael addition to (±)-rengyolone (1.39), followed by loss of 
PMP/aza-Mannich addition to give the iminium ion 4.3 (pathway 4).  Intramolecular 
Mannich addition could then trap this iminium ion 4.3, giving incargranine A (4.1). 
 
4.2 SYNTHETIC APPROACH 
To investigate the chemical viability of our postulated biosynthesis we undertook a 
short biomimetic total synthesis of incargranine A (4.1).  We hoped to make use of the 
cross-dimerisation methodology developed during the total synthesis of millingtonine 
(3.1) to allow us to rapidly access this additional natural product from building blocks 




The retrosynthetic plan for incargranine A (4.1) is shown in Scheme 4.2.  Following 
our previously developed enamine cross-dimerisation methodology, we planned to 
form incargranine A (4.1) from a suitably protected aminal (4.4) and (±)-rengyolone 
(1.39) through a biomimetic enamine-Michael/aza-Mannich/Mannich reaction 
sequence.  We anticipated the protected aminal 4.4 could be prepared in-situ from a 
protected 2,5-dihydropyrrole 4.5 using the previously established rhodium 
hydride/pyrrolidine conditions.  Protected 2,5-dihydropyrrole 4.5 would be made from 
2,5-dihydropyrrole 3.49, which we had on hand from previous work on millingtonine 
(3.1, see chapter 3) and could be readily prepared from the aniline 2.15.  (±)-
Rengyolone (1.39) could be readily prepared from the commercially available phenol 
1.41 via the p-quinol 1.43 using previously described chemistry (see chapter 1.3).44 
 
Scheme 4.2: Retrosynthetic plan for incargranine A (4.1) 
 
4.3 SYNTHESIS OF INCARGRANINE A 
4.3.1 Initial Attempts 
The first step in implementing our planned synthesis of incargranine A (4.1) was the 
preparation of a suitable aminal (4.4).  From previous work, it was apparent that a free 
primary alcohol was likely to be incompatible with the rhodium hydride catalysed 





Scheme 4.3: Synthesis of aminal 4.6 
 
To avoid this potential issue we decided to make use of the TBS protected 2,5-
dihydropyrrole 3.53, which had been previously prepared from 2,5-dihydropyrrole 
3.49 (Scheme 4.3).  It was found that treatment of this TBS 2,5-dihydropyrrole 3.53 
with Rh(H)(CO)(PPh3)3/pyrrolidine gave smooth conversion to the desired aminal 4.6 
in a 66 % yield (determined in-situ by 1H-NMR spectroscopy compared to an internal 
standard, see Figure 4.2). 
 
 
Figure 4.2: Formation of aminal 4.6 from dihydropyrrole 3.53. Monitored in-situ by 500MHz 1H-
































Scheme 4.4: Synthesis of (±)-rengyolone (1.39)44 
(±)-Rengyolone (1.39) had previously been prepared via a three step route from phenol 
1.41.44  Selective mono-protection of phenol 1.41, followed by hypervalent iodine 
oxidation gave the OTBS p-quinol 1.43 in good yields on multi-gram scale.  A final 
deprotection of p-quinol 1.43 using tetrabutylammonium fluoride (TBAF) gave (±)-
rengyolone (1.39) following spontaneous intramolecular oxa-Michael addition 
(Scheme 4.4). 
 
Scheme 4.5: Cross-dimerisation between (±)-rengyolone (1.39) and dihydropyrrole 3.53 
With access to both dimerisation precursors, we set about investigating the key 
biomimetic cross-dimerisation.  2,5-Dihydropyrrole 3.53 was treated with 5 mol% 
Rh(H)(CO)(PPh3)3, followed by pyrrolidine to give a solution of the desired aminal 
4.6 in CD2Cl2.  Treatment of this freshly prepared solution of aminal 4.6 with (±)-
rengyolone (1.39) was found, after 10 days, to give the unexpected hemi-aminal cross-
dimer 4.7 in 12% yield (Scheme 4.5).     
Proposed mechanisms for the formation of dimer 4.7 and incargranine A (4.1) from 
this cross-dimerisation are shown in Scheme 4.6.  The acyclic enamine 4.8, formed 
from aminal 4.6, undergoes Michael addition to (±)-rengyolone (1.39) to give the 
iminium ion intermediate 4.9.  Two competing pathways could then operate from 




observed hemi-aminal cross-dimer 4.7 presumably forms in a similar way to dia-
millingtonine (3.91, see chapter 3.5.3).  An aza-Mannich/oxa-Mannich sequence, with 
expulsion of pyrrolidine would then give the hemi-aminal 4.7 (Scheme 4.6).  In 
contrast, an aza-Mannich/Mannich sequence to form a C−C bond between C(5) and 
C(1ʹʹ) (Scheme 4.6), would be required for the formation of the incargranine A 
framework. 
 
Scheme 4.6: Possible mechanisms for the cross-dimerisation of aminal 4.6 and (±)-rengyolone 1.39 
Although this test had demonstrated the viability of an aminal cross-dimerisation with 
(±)-rengyolone (1.39), several issues presented themselves with respect to using this 
strategy to access the incargranine A framework.  (±)-Rengyolone (1.39) appeared to 
be a comparatively unreactive Michael acceptor in the cross-dimerisation − taking over 
a week to give consumption of starting material, while comparable reactions with p-
quinols were generally complete in under 24 hours.  In addition, the low yield of cross-
dimer even after prolonged reaction times, was not a promising start to the 
development of an efficient synthesis.  Finally, the isolation of the hemi-aminal dimer 
4.7 as the sole cross-dimeric product, with no sign of the desired incargranine A 






4.3.2 Revised Biosynthetic Hypothesis and Synthetic Strategy 
Taking into account the poor reactivity of (±)-rengyolone (1.39) in the dimerisation 
process and the formation of the hemi-aminal dimer 4.7 in preference to incargranine 
A (4.1), we contemplated the possibility of an alternative, two-part biosynthetic 
pathway to incargranine A (4.1).  We considered that incargranine A (4.1) might be 
formed through an initial dimerisation to give dia-millingtonine (3.94), followed by a 
rearrangement sequence, leading to incargranine A (4.1).  This proposal found support 
in Yamasaki’s work on rearrangement products formed from millingtonine (3.1) 
(Scheme 4.7).83 
 
Scheme 4.7: Deglycosylation and rearrangement of millingtonine (3.1)83  
As part of structural elucidation work, Yamasaki and co-workers subjected 
millingtonine (3.1) to enzymatic deglycosylation.  Treatment of millingtonine (3.1) 
with β-glucosidase was found to give a mixture of two rearranged products, 4.12 and 
4.13.  These were presumably formed by a double deglycosylation to give the aglycone 
4.10.  This aglycone 4.10 could then undergo an intramolecular oxa-Michael addition 




the iminium ion 4.11.  This could then rearrange via an oxa-Michael/Mannich 
sequence to form the C(5)−C(1ʹʹ) bond and give the dimer 4.12.83   
Interestingly the rearranged product 4.12 is a diastereomer of incargranine A (4.1) 
where the difference in stereochemistry is a result of the anti-relationship between the 
C(2)/C(2ʹʹ) substituents.  As a result, we speculated that incargranine A (4.1) could 
potentially form biosynthetically from dia-millingtonine (3.94) (the cis-syn-cis 
diastereomer of millingtonine through an analogous deglycosylation/retro-oxa-
Mannich/oxa-Michael/Mannich sequence (Scheme 4.8). 
 
Scheme 4.8: Revised biosynthetic hypothesis for incargranine A (4.1) 
One implication of this biosynthetic proposal, if correct, is that incargranine A (4.1) 
would be formed as a racemic mixture.  Zhang and co-workers did report an optical 
rotation value for natural incargranine A (4.1); however, the small magnitude of [𝛼]𝐷
22 
= +2 (c = 0.175, CHCl3)
107, suggested it may have been isolated in racemic form.   
 
Scheme 4.9: Alternative retrosynthetic plan for incargranine A (4.1) 
Inspired by our revised biosynthetic hypothesis, we envisaged that incargranine A 
(4.1) could be formed by deprotection and re-arrangement of a hemi-aminal such as 




accessed from p-quinol 1.43 and 2,5-dihydropyrrole 3.53 using the cross-dimerisation 
conditions we had previously optimised during the synthesis of millingtonine (3.1, see 
chapter 3).  This approach would allow the use of a more reactive p-quinol Michael 
acceptor, hopefully alleviating the sluggish reactivity observed with (±)-rengyolone 
(1.39).  The diastereoselective rearrangement necessary to convert the hemi-aminal 
4.15 to incargranine A (4.1) would potentially be challenging; however, Yamasaki’s 
work on millingtonine (3.1) suggested it should be achievable.   
In accordance with this revised synthetic plan, we set about the synthesis of a suitable 
TBS protected hemi-aminal cross-dimer.  Pleasingly, further investigations into the 
rhodium hydride catalysed aminal formation revealed that the conditions were 
compatible with the presence of an unprotected primary alcohol (cf. chapter 3.4.4).  As 
a result, it was possible to make use of the 2,5-dihydropyrrole 3.49, which could be 
readily prepared in a single step on multi-gram scale (Scheme 4.10, also see chapter 
3.4.4).  Treatment of 2,5-dihydropyrrole 3.49 with 5 mol% Rh(H)(CO)(PPh3)3 in the 
presence of pyrrolidine (1.1 equiv.) gave quantitative conversion to the aminal 4.16 
(determined by 1H-NMR spectroscopy in-situ or by aliquot compared to an internal 
standard) after 2 hours at 40 °C.  This procedure was readily scaled up, allowing the 
formation of 2 grams of aminal 4.16 in a single batch (Scheme 4.10). 
 




Addition of p-quinol (1.43) (2.5 equiv.) to a freshly prepared solution of the aminal 
4.16 gave the desired hemi-aminal cross-dimer 4.17 in excellent yield on multi-gram 
scale after 27 hours at room temperature.  As expected, the cross-dimer 4.17 possessed 
the kintetically favoured cis-syn-cis stereochemistry necessary for the formation of 
incargranine A (4.1) (see Schemes 4.7 and 4.8).  Along with the cross-dimer, a small 
amount (11%) of the p-quinol dimer 4.18 was also obtained, presumably resulting from 
the pyrrolidine mediated Rauhut-Currier101 dimerisation sequence discussed 
previously (see chapter 3.4.4). 
With access to substantial quantities of the cross-dimer 4.17 in hand, we began to 
investigate the proposed deprotection-rearrangement sequence.  From previous work 
on the synthesis of millingtonine (3.1) it was known that hemi-aminal dimers, such as 
4.17, were prone to isomerisation to the cis-anti-cis stereochemistry under acidic 
conditions (see chapter 3.5.3).  As retention of the C(2)-C(2ʹʹ) syn configuration was 
required, it was anticipated that common acidic deprotection conditions108 would be 
unsuitable.  Tetrabutylammomium fluoride (TBAF) appeared to offer a suitable 
method for cleaving the TBS ether without risking acid mediated isomerisation.108  
Accordingly, the TBS cross-dimer 4.17 was subjected to standard TBAF conditions in 
the hope of triggering the deprotection and rearrangement to incargranine A (4.1).  
Surprisingly, although incargranine A (4.1) was not identified under these conditions, 
the diol 4.14 was isolated in a 10% yield along with a 56% yield of the oxa-Michael 





Scheme 4.11: Deprotection of hemi-aminal dimer 4.17 and rearrangement to incargranine A (4.1) 
It was observed that a small amount of incargranine A (4.1) was formed from diol 4.14 
when left in solution in methanol.  Pleasingly, on heating to 40 °C in CD3OD slow 
rearrangement occurred, giving a 33% yield of incargranine A (4.1) after 2 days.  All 
spectroscopic data was consistent with our synthetic material being racemic 
incargranine A (4.1).107   
All attempts to similarly rearrange the oxa-Michael product 4.19, including heating to 
reflux in MeOH, EtOH or MeCN returned only starting material.  Treatment with TFA 
appeared to give isomerisation from the syn to anti configuration, with no sign of 
further rearrangement, while treatment with LiOH in refluxing MeOH/H2O gave slow 
decomposition.  Attempts to induce a one-pot deprotection by treating the TBS dimer 
4.17 with TBAF at elevated temperatures were similarly unsuccessful.   
As the diol 4.14, which appeared to be the only viable precursor to incargranine A 
(4.1), was isolated in impractically low yields from the TBAF deprotection of the TBS 
dimer 4.17, we elected to investigate alternative deprotection conditions in the hope of 
optimising the synthesis.  Vaino and Szarek have reported the use of iodine in 
methanol as a very mild method for cleaving TBS ethers.109  In the hope that more 
mild deprotection conditions might increase the yield of the diol 4.14, the TBS dimer 





Scheme 4.12: I2/MeOH mediated incargranine A (4.1) formation 
Exposure of TBS dimer 4.17 to 10 mol% I2 in methanol was found, surprisingly, to 
give clean conversion directly to incargranine A (4.1), with none of the diol 4.14 or 
oxa-Michael product 4.19 observed.  Pleasingly, these conditions were readily scaled 
up to give more than one gram of incargranine A (4.1) in 84% yield.  The mechanism 
of the I2/MeOH deprotection is unclear,
109 so it is difficult to speculate as to why these 
conditions so effectively promoted the rearrangement to incargranine A (4.1).  Vaino 
and Szarek suggest the combined effects of Lewis acidic species and small quantities 
of HI may be responsible for effective desilylation109 and it is plausible that a similar 
combination of factors may promote the retro-oxa-Mannich/oxa-Michael/Mannich 
rearrangement sequence to give incargranine A (4.1). 
 
4.4 CONCLUDING REMARKS 
This chapter has provided a showcase for the power of biosynthetic considerations in 
inspiring highly efficient synthetic strategies to access challenging natural product 
structures.  Retro-biosynthetic analysis of incargranine A (4.1) revealed its structural 
and biosynthetic similarities to several other phenylethanoid natural products: (±)-
incarviditone (1.35b); (±)-incarvilleatone (1.48); incargranine B (2.1b) and 
millingtonine (3.1).  Drawing on our biomimetically-informed understanding of how 
these compounds are assembled in nature, we were able to propose a biosynthetic 





Scheme 4.13: Gram scale total synthesis of incargranine A (4.1) 
 
Inspired by this hypothesis, we were able to develop a very concise synthetic strategy 
for the total synthesis of incargranine A (4.1).  In a longest linear sequence of just four 
steps from commercially available materials, five new bonds, three new rings and six 
contiguous stereocentres were assembled in a completely diastereoselective manner, 
giving incargranine A (4.1) in 56% overall yield (Scheme 4.13).  This synthesis could 
readily be scaled up to give gram quantities of incargranine A (4.1), serving to 
demonstrate the utility and scalability of the rhodium hydride/pyrrolidine mediated 
dimerisation methodology.   
In light of the success of our biomimetic synthesis, we have been able to refine our 
biosynthetic hypothesis for incargranine A (4.1).  We propose that dia-millingtonine 
(3.94) may be the direct biosynthetic precursor to both millingtonine (3.1) and 
incargranine A (4.1).  The revised biosynthetic hypothesis for incargranine A (4.1) is 
shown in Scheme 4.14.   
In this revised proposal, the pyridoxamine (PMP) enamine 3.97 (see chapter 3.6 for 
the proposed formation of this species) undergos Michael addition to cornoside (1.37) 




pyridoxamine phosphate (3.99) gives the cis-syn-cis dimer, dia-millingtonine (3.94).  
Isomerisation of dia-millingtonine (3.94) to the cis-anti-cis stereochemistry gives 
millingtonine (3.1).   
 
Scheme 4.14: Biosynthetic hypothesis for millingtonine (3.1) and incargranine A (4.1) 
Alternatively, deglycosylation of dia-millingtonine (3.94) could give the racemic 
aglycone (±)-4.14.  A retro-oxa-Mannich reaction would form the iminium ion 4.20, 
which can then undergo an oxa-Michael/Mannich reaction sequence to give 
incargranine A (4.1).  On the basis of this biosynthetic proposal, and the small 
magnitude of the optical rotation reported for natural incargranine A (4.1) (see 




racemic natural product.  Unfortunately, no authentic sample of incargranine A (4.1) 






5 CONCLUSIONS AND PERSPECTIVES 
5.1 SUMMARY OF WORK PRESENTED 
The work presented in this thesis has detailed a series of biomimetic investigations 
culminating in the total synthesis of three dimeric and pseudo-dimeric phenylethanoid 
alkaloids, all isolated from members of the Bignoniaceae family of plants. 
Chapter 2 discussed the biosynthetically driven total synthesis and structural revision 
of incargranine B (2.1b) (Scheme 5.1).  Difficulties determining the likely biogenesis 
of the highly unusual, originally proposed structure for this natural product led to a 
speculative structural reassignment.  A concise biomimetic total synthesis confirmed 
the proposed structural revision and identified that incargranine B (2.1b) was likely to 
exist as a mixture of pseudo-enantiomeric diastereomers.  Overall, this synthesis 
required six steps from commercially available starting materials.  The majority of the 
new molecular complexity was generated through a biomimetic domino 
condensation/Mannich/SEAr reaction sequence, forming six new bonds, three new 
rings and three new stereocentres in a single synthetic operation.  
 
Scheme 5.1: Total synthesis of incargranine B (2.1b)53 
Chapter 3 details work culminating in the total synthesis of the pseudo-dimeric natural 
product millingtonine (3.1) (Scheme 5.2).  A biomimetic synthetic strategy was 
developed, relying on a formal enamine-Michael/oxa-Mannich dimerisation.  The 
realisation of this synthesis required the development of a novel rhodium hydride 
mediated N-aryl aminal synthesis; allowing a practical, one-pot aminal 




a longest linear sequence of seven steps, compared to the previous synthesis by Ley, 
Kirschning and Baxendale which required 12 linear steps.72  Overall, six new bonds, 
two new rings and four contiguous stereocentres were formed to give the natural 
product as a 1:1 mixture of pseudo-enantiomeric diastereomers. 
 
Scheme 5.2: Total synthesis of millingtonine (3.1) 
In chapter 4, the extension of our rhodium hydride/pyrrolidine cross-dimerisation 
methodology, to the synthesis of incargranine A (4.1) is described.  Following this 
approach, incargranine A (4.1) was accessed through a biomimetic enamine-
Michael/aza-Mannich/oxa-Mannich dimerisation sequence, followed by retro-oxa-
Mannich/oxa-Michael/Mannich rearrangement.  Five new bonds, three new rings and 
six contiguous stereocentres are formed diastereoselectively in just four steps from 
commercially available material.  The practicality of this synthesis was further 
demonstrated by its scale-up to provide over one gram of material from a single 
synthetic sequence. 
 






Prior to the commencement of the total syntheses of incargranine B (2.1b), 
millingtonine (3.1) and incargranine A (4.1), we hypothesised an interconnected 
network of biosynthetic pathways linking these three natural products, along with (±)-
incarviditone (1.35b) and (±)-incarvilleatone (1.48) to a common biosynthetic 
precursor, diamine 2.2.  Over the course of our synthetic investigations it became 
necessary to revise and refine this biosynthetic proposal as we gained further insights 
into the chemical feasibility of our proposed pathways.  This iterative process of 
formulating, synthetically testing, and refining biosynthetic hypotheses highlights the 
fundamental basis of biomimetic synthesis.  Following the successful completion of 
all three total syntheses, we present here (Scheme 5.4) our proposed biosynthetic 
network linking seven phenylethanoid natural products from members of the 
Incarvillea and millingtonia genera, as informed by our biomimetic investigations. 
We proposed that all seven natural products could be formed through a series of 
divergent/re-convergent biosynthetic pathways (numbered 1-6, see Scheme 5.4), from 
diamine 2.2 as a common biosynthetic precursor.  At the initial point of divergence, 
diamine 2.2 can either undergo an oxidative dearomatisation (pathway 1) or oxidative 
deamination (pathway 2).  Following pathway 1, oxidative dearomatisation of diamine 
2.2, with subsequent hydrolysis gives the natural product cornoside (1.37).  
Deglycosylation of cornoside (1.37), followed by oxa-Michael cyclisation gives (±)-
rengyolone (1.39).43,47  Homochiral dimerisation of (±)-rengyolone (1.39), through a 
domino oxa-Michael/Michael sequence forms (±)-incarviditone (1.35b), while similar 














The second divergent arm, pathway 2, starts through a pyridoxal phosphate (PLP) 
dependant oxidative deamination of diamine 2.2.  Partially interrupted deamination 
could result in the formation of the pyridoxamine enamine 4.2, while completion of 
the deamination process followed by intramolecular condensation would form the N-
aryl enamine 2.4 and iminium ion 2.5.  Dimerisation of this N-aryl enamine 2.4 and 
iminium ion 2.5 through a non-enzymatic enamine-Mannich/SEAr sequence would 
account for the formation of incargranine B (2.1b) as well dia-incargranine B (2.63) 
which we propose as an, as yet, unidentified natural product. 
The two main divergent biosynthetic routes, pathways 1 and 2, could then re-converge 
along pathway 3 to give a range of pseudo-dimeric natural products.  Cross-
dimerisation of the pyridoxamine enamine (4.2) with cornoside (1.37) through an 
overall enamine-Michael/aza-Mannich/oxa-Mannich sequence with elimination of 
pyridoxamine phosphate would give the kinetically favoured cis-syn-cis dimer, dia-
millingtonine (3.94).  We propose that dia-millingtonine (3.94) represents both an 
undiscovered natural product and a key biosynthetic intermediate en-route to 
millingtonine (3.1) and incargranine A (4.1).   
Divergence from dia-millingtonine (3.94) potentially leads down three alternative 
pathways (4, 5 and 6).  Isomerisation of dia-millingtonine (3.94) through a retro-oxa-
Mannich/iminium-epimerization/oxa-Mannich sequence would give the 
thermodynamic cis-anti-cis isomer, millingtonine (3.1) (pathway 4).  Alternatively, 
double deglycosylation of dia-millingtonine (3.94) could feed into pathways 5 and 6.  
Rearrangement of the dia-millingtonine (3.94) aglycone through a retro-oxa-
Mannich/oxa-Michael/Mannich sequence could give incargranine A (4.1) (pathway 
5).  Simple Oxa-Michael cyclisation of dia-millingtonine (3.94) aglycone would, 
instead, form the pentacycle 4.19, which we suggest is also likely to represent an 
undiscovered natural product (pathway 6). 
 
5.3 PERSPECTIVE: BIOSYNTHETIC CONSIDERATIONS IN 
STRUCTURAL REVISION 
The use of bioimimetic thinking in the planning and execution of natural product 




Tamelen considered that a biomimetic approach to a natural product would, to most 
people, be the most aesthetically pleasing.19  He also noted that syntheses designed 
along biomimetic lines were often neater, shorter, and more efficient.19  Other arguable 
benefits of biomimetic approaches include: driving innovation in synthesis, both in 
terms of strategy and novel reactions; exploring fundamental chemistry, sometimes 
leading to the overturning of long-held chemical rules; highlighting relationships 
between natural products, with the possibility of exploiting this in synthesis; and 
identifying potential natural products prior to their isolation from natural sources.110  
We hope that the body of work described in this thesis has illustrated many of these 
benefits.   
A less well publicised, but arguably equally important, feature of biomimetic 
chemistry is the potential of biosynthetic considerations to shed light on the process of 
assigning (and reassigning) natural product structures.  This can be considered a 
particular feature of treating biomimetic chemistry as a lens through which to view all 
aspects of natural product chemistry, rather than just a means to achieve a synthetic 
goal.  The following section aims to illustrate the benefits of taking this broader 
approach to biomimetic chemistry, and place this thesis in a broader context, by 
providing a selection (not necessarily exhaustive) of recent examples where 
biosynthetic considerations have played an important role in revising the structures of 
natural products.  
5.3.1 Incarviditone 
 
Figure 5.1: Original and revised structures of incarviditone, with differences highlighted42,44,51 
(±)-Incarviditone (1.35a) (Figure 5.1) was isolated in 2009 by Zhang and co-workers 




and 2D NMR data.42  As part of our interest in dimeric phenylethanoid natural 
products, we undertook a total synthesis of Zhang’s proposed structure (1.35a) 
(discussed in detail in chapter 1.3).  Successful completion of our biosynthetically-
inspired synthesis provided access to synthetic (±)-incarviditone which matched all the 
spectroscopic data reported by Zhang.  Rre-examination of the NOESY data for both 
natural and synthetic (±)-incarviditone; however, led us to question the original 
stereochemical assignment.  Subsequent derivatisation and single crystal X-ray 
analysis of our synthetic (±)-incarviditone confirmed that the structure of the natural 
product needed to be re-assigned to 1.35b.44  A similar biomimetic synthesis by Wu 
and Tang further supported this conclusion.   
This work illustrates a unique feature of biomimetic synthesis.  By following the 
proposed biosynthetic pathway, we were able to successfully access the true structure 
of (±)-incarviditone (1.35b); despite targeting the original, incorrect structure 1.35a. 
5.3.2 Incargranine B 
 
Figure 5.2: Original and revised structures for incargranine B, with differences highlighted52,53 
Incargranine B was isolated from Incarvillea mairei var. grandiflora in 2010 by Zhang 
and co-workers.52  Analysis of HRMS, 1D and 2D NMR data led Zhang to propose a 
highly unusual decahydro-indolo-[1,7]-napthyridine structure for this compound.  As 
discussed in detail in chapter 2, attempts to determine plausible biosynthetic 
hypothesis for incargranine B (2.1a) caused us to question this structural assignment.53   
Biosynthetic speculation led us to propose a dipyrrolo-quinoline structure 2.1b as a 
possible alternative.  To test this speculative structural revision, we conducted a 
biomimetic total synthesis of our proposed structure for incargranine B (2.1b).  




suggested that incargranine B (2.1b) was likely to comprise of a 1:1 mixture of pseudo-
enantiomeric diastereomers (Figure 5.2).   
5.3.3 Cytosporolides A-C 
 
Figure 5.3: Orginal and revised structures of cytosporolide A, with differences highlighted111,112 
The cytosporolides (e.g., cytosporolide A 5.1a, see Figure 5.3) are caryophyllene 
derived meroterpenoids isolated in 2010, by Che and colleagues, from the fungus 
Cytospora sp.111  The carbon framework and oxygenation pattern of the caryophyllene 
moiety was assigned using 1D and 2D NMR spectroscopy, assisted by comparison to 
the known, co-isolated natural product fuscoatrol A (5.2) and the related natural 
product 6-hydroxpunctaporonin B (5.3) (Figure 5.4).  On the basis of the downfield 
chemical shift of C(8) in cytosporolide A (5.1a) (87.5 ppm), compared to the 
analogous hydroxylated C(8) position of 6-hydroxpunctaporonin B (5.3) (74.2 ppm), 
Che and coworkers proposed that the cytosporolides contained an unusual 9-
membered peroxylactone ring.111   
 
Figure 5.4: Cytosporolide A and related natural products111 
The presence of this unusual, highly strained, structural feature led George and Spence 




Comparison of the key C(8) chemical shift in cytosporolide A (5.1a) to the C(8) 
positions of the caryophyllene (5.4) derived natural products guajadial (5.6) (84.3 
ppm) and psidial A (5.7) (88.0 ppm) suggested that a similar 6-membered aryl ether 
ring could account for the observed cytosporolide 13C NMR data.   
 
Scheme 5.5: George's biosynthetically inspired structural revision of cytosporolide A (5.1b) 
George and Spence speculated that a biosynthetic pathway analogous to that proposed 
for guajadial (5.6) and psidial A (5.7)106 could produce a possible alternative structure 
for cytosporolide A (5.1b), which might adequately account for the reported 
characterization data (Scheme 5.5).  Thus, fuscoatrol A (5.2) could undergo a [4+2] 
cycloaddition with an ortho-quinone methide (5.8), derived from the known (although 




Spence suggested this alternative structure could also account for all the spectral 
features of cytosporolide A (5.1) (Scheme 5.5). 
To test this biosynthetic hypothesis and structural revision, George and Spence 
conducted a biomimetic model study to produce the core framework of their proposed 
cytosporolide structure.  The ortho-quinone methide 5.9 was produced in-situ, then β-
caryophyllene 5.4 added and heated to 100°C to give Diels-Alder adduct 5.10 in 53% 
yield as a single diastereomer.  The expected structure of adduct 5.10 was confirmed 
by single crystal X-ray analysis and despite having opposite stereochemical 
configurations at C(8), C(9) and C(16), the NMR and IR spectra of adduct 5.10 were 
found to be very similar to those reported for cytosporolides A-C.  In particular, the 
key C(8) resonance in the model compound 5.10 occurred at 88.6 ppm, closely 
matching the cytosporolide A C(8) signal (5.1b) (88.0 ppm).112  The proposed 
structural revision of cytosporolide A (5.1b) was subsequently confirmed by Takao 
and co-workers, who successfully completed a biomimetic total synthesis of 
cytosporolide A (5.1b) inspired by George’s biosynthetic hypothesis.113  This 
synthesis, combined with George and Spence’s biomimetic studies and reanalysis of 
NMR data, provides excellent validation of the proposed structural reassignment of 




Figure 5.5: Butylcycloheptylprodigiosin and streptorubin B, with differences highlighted114–117 
In 1975 Gerber and co-workers isolated a cyclic prodigiosin natural product from the 




butylcycloheptylprodigiosin (5.11) (Figure 5.5), based on analysis of MS, UV-Vis 
spectroscopic data and comparisons to the known prodigiosin natural products 
undecylprodigiosin (5.13) and metacycloprodigiosin (5.14) (Scheme 5.6). This initial 
assignment was supported with limited NMR data and analysis of degradation 
products using gas chromatography.  In 1978; however, as the result of extensive NMR 
studies on isotopically enriched prodigiosins, Gerber concluded this initial 
identification of butylcycloheptylprodigiosin (5.11) was incorrect, identifying that the 
isolated material was the known natural product streptorubin B (5.12).116 
Despite this, in 1985 Floss and co-workers assigned the structure of 
butylcycloheptylprodigiosin (5.11) to a pigment isolated from Streptomyces coelicolor 
A3.115  The existence of butylcycloheptylprodigiosin (5.11) as a separate natural 
product was subsequently supported by the synthetic work of Fürstner and then Reeves 
who both synthesised the proposed structure and concluded it was distinct from 
streptorubin B (5.12); however, the identification of butylcycloheptylprodigiosin 
(5.11) as a true natural product still rested on comparison to the very limited NMR 
data provided by the isolation teams.118,119  
 
Scheme 5.6: Prodigiosin biosynthesis and ion binding model117 
The question of whether butylcycloheptylprodigiosin (5.11) and streptorubin B (5.12) 




and biosynthesis of cyclic prodigiosins led Thomson and co-workers to re-examine the 
proposed structure of butylcycloheptylprodigiosin (5.11).117  Thomson noted that the 
cyclic prodigiosins are all derived biosynthetically from a common precursor, 
undecylprodigiosin (5.13), via radical cyclisation processes, (Scheme 5.6) exclusively 
to C(4) of the C-ring pyrrole, or to C(5) of the A-ring pyrrole.  This highly conserved 
cyclisation pattern within the cyclic prodigiosin family led Thomson to speculate that 
cyclisation to the C-ring C(4) or A-ring C(5) positions must provide an evolutionarily 
important function.117  They suggested that these cyclisation patterns provide a 
conformational bias between the A, B and C pyrrole rings, which allows effective 
anion or cation binding (see Scheme 5.6).  The unusual C(2)-C(3) cyclisation in 
butylcycloheptylprodigiosin (5.11); however, would not provide the same 
conformational bias, removing this presumed evolutionary function, leading Thomson 
to question this structural assignment.117 
To investigate the structure of butylcycloheptylprodigiosin (5.11), Thomson and co-
workers, re-synthesised the proposed structure, using a short biomimetic approach and 
compared this synthetic compound to the previously reported data for both natural and 
synthetic butylcycloheptylprodigiosin (5.11) as well as streptorubin B (5.12).  
Although the NMR data for their synthetic butylcyclohelptylprodigiosin (5.11) 
matched well with previously reported synthetic material, they found discrepancies in 
the comparison to the naturally occurring compound which they were not able to 
resolve using NMR spectroscopy.  As a result, they turned to a comparison of the EI 
mass spectra for their synthetic compound, natural butylcycloheptylprodigiosin (5.11) 
and streptorubin B (5.12).  From this they found that synthetic 
butylcycloheptylprodigiosin (5.11) and streptorubin B (5.12) showed characteristic 
differences in their EI mass spectra, with the data attributed to natural 
butylcycloheptylprodigiosin matching the mass spectrum of streptorubin B (5.12) 
extremely well.  On this basis, they were able to conclude that 
butylcycloheptylprodigiosin (5.11) was unlikely to represent a genuine natural 
product.117  This elimination of butylcycloheptylprodigiosin (5.11) as a natural 
product, resolving a long standing structural question, provides a good example of how 
consideration of both the biosynthesis and biological function of a compound can 




5.3.5 Caraphenol B and C 
 
Figure 5.6: Orginal and revised structures of caraphenols B and C, with differences highlighted120,121 
Caraphenol B (5.16a) and C (5.17a) are resveratrol (5.18) dimers, originally isolated 
from the roots of Caragana sinica by Hu and co-workers in 2001.120,122  On the basis 
of HRMS, UV-Vis, 1D and 2D NMR spectroscopic analysis Hu proposed substituted 
indane structures for caraphenol B (5.16a) and C (5.17a), differing in the 
hydroxylation pattern of the B and C-rings. Hu proposed relative stereochemistry 
featuring an all cis arrangement of the B, C and D-rings based on NOESY experiments 
(Figure 5.6).   
 
Figure 5.7: Resveratrol (5.18) and related indane natural products 
This all cis arrangement, which is highly unusual within the wider family of 
resveratrol-derived indane natural products, prompted Brill and Snyder to further 
investigate the structures of caraphenol B and C.  They noted that in a series of 
structurally and biosynthetically similar natural products, such as ampelopsin D (5.19), 




trans-trans relationship between the A, B and C-rings (Figure 5.7).  Brill and Snyder 
speculated that alternative structures with analogous trans-trans stereochemistry 
(5.16b and 5.17b) would adequately account for all the spectral data reported for 
caraphenol B and C.121   
To test this hypothesis, Snyder and Brill set about preparing samples of both Hu’s 
(5.16a, 5.17a) and their own (5.16b, 5.17b) proposed structures of caraphenols B and 
C.  Hu’s proposed structure for caraphenol B (5.16a) was prepared in five steps from 
permethylated ampelopsin D (5.23) (Scheme 5.7).  X-ray analysis of a derivative of 
synthetic 5.16a confirmed the anticipated all cis stereochemistry.  Analysis of the 
NMR data for synthetic 5.16a showed significant discrepancies, strongly suggesting 
this did not represent the structure of the natural product. 
 





Having shown that the original structure of caraphenol B was incorrect, Snyder and 
Brill undertook to test their proposed structural revision by synthesising their proposed 
trans-trans structure (5.16b).  Snyder’s proposed structure was accessed in seven steps 
from permethylated paucifloral F (5.24), via the formation of the trans-cis compound 
5.26, which was epimerised to the desired trans-trans diastereomer prior to global 
deprotection to give caraphenol B (5.16b).  Similar synthetic sequences allowed access 
to the originally proposed and revised structures of caraphenol C (5.17b).  In both 
cases the synthetic, revised structures (5.16b, 5.17b) matched the reported data for the 
natural products in all respects, allowing Snyder and Brill to confirm their proposed 
structural revisions.   
This successful structural revision highlights one of many ways in which consideration 
of biosynthetic origins can be relevant in structural assignment.  In this case, 
comparison of the conserved structural features of a family of biosynthetically related 
natural products identified a potentially anomalous structure, leading to further 




Figure 5.8: Original and revised structures of yuremaine, with differences highlighted123,124 
Yuremamine was isolated from the bark of Mimosa tenuiflora, a plant used in Brazil 
to prepare a psychoactive beverage, in 2005 by Callaway and co-workers who 
proposed the pyrroloindole structure 5.27a (Figure 5.8).123  This proposed structure 




tenuiflora as it was proposed that an internal hydrogen bond could prevent degradation 
by monoamine oxidase, making yuremamine (5.27a) an effective inhibitor and 
contributing to the oral bioavailability of the plant’s psychoactive components, which 
would otherwise be removed by monoamine oxidase.  The interest in the structure and 
proposed bioactivity of yuremamine prompted Calvert and Sperry to attempt a 
biomimetic total synthesis.124   
Calvert and Sperry proposed a biosynthetic hypothesis featuring an initial 
diastereoselective coupling of the known natural product, leucorobinetinidin (5.28) 
with N,N-dimethyltryptamine (5.29) to give the flavonoid indole 5.27b.  
Photochemically induced cleavage of the chromene C−O bond could then give the 
para-quinone methide 5.30 which could be trapped via [1,6]-addition of the indole 
nitrogen to give yuremamine (5.27a) (Scheme 5.8).  
 
Scheme 5.8: Sperry's biomimetic structural revision of yuremamine (5.27b)124 
Based on this biosynthetic hypothesis, Calvert and Sperry undertook a short 




subsequently rearrange to give the proposed structure of yuremamine (5.27a).  They 
successfully accessed the key protected leucorobinetinidin analogue 5.33 in three steps 
from aldehyde 5.31 and acetophenone 5.32 in 31% yield.  They were then able to 
diastereoselectively couple the leucorobinetinidin analogue 5.33 with N,N-
dimethyltryptamine 5.29 in the presence of TMSOTf, followed by a global 
deprotection to give the postulated key biosynthetic intermediate 5.27b in a 56% yield 
over two steps (Scheme 5.8).124   
Intriguingly, the NMR data for the proposed intermediate 5.27b was found to be very 
similar to that reported for the natural product.  On conversion of 5.27b to the TFA 
salt to match the characterised form of natural yuremamine, the spectroscopic data for 
the postulated intermediate 5.27b was found to match perfectly with the natural 
product.124   
The possibility that the material had spontaneously rearranged to give 5.27a was ruled 
out by the observation of an indole NH in the 1H-15N HSQC spectrum and following 
detailed re-analysis of the 2D NMR data and co-spiking of the natural and synthetic 
materials.  Thus, Calvert and Sperry were able to conclusively reassign the natural 
product structure to that of their proposed biosynthetic intermediate 5.27b.124  This 
serendipitous discovery provides a striking example of the benefits of taking a 
biomimetic approach and how the deep consideration of potential biosynthetic 
intermediates can give insights which would be impossible to achieve through 




5.3.7 Tridachiahydropyrones A-C 
 
Figure 5.9:Original and revised structures of tridachiahydropyrones A-C, with differences 
highlighted105,125,126 
The tridachiahydropyrones are polyketide-derived pyrone natural products isolated 
from sacoglossan molluscs.  Tridachiahydropyrone (5.34a) was isolated by Cimino 
and co-workers in 1996 from Tridachia crispata and assigned structure 5.34a on the 
basis of HRMS, 1D and 2D NMR data.125  Tridachiahydropyrones B (3.35a) and C 
(5.36a) were isolated from another sacoglossan mollusc, Placobranchus ocellatus, by 
Schmitz and co-workers in 2000 as an inseparable 4:5 mixture (Figure 5.9).126  Using 
HRMS, 1D and 2D NMR, IR and UV-Vis spectroscopy Schmitz and co-workers were 
able to assign the connectivity of tridachiahydropyrones B (5.35a) and C (5.36a).  
Schmitz noted the close structural similarity to tridachiahydropyrone (5.34a) and 
suggested that the inseparable mixture of tridachiahydropyrones B (5.35a) and C 
(5.36a) was due to differing geometry around the C(10)-C(11) alkene; however, 
remaining relative stereochemistry was left unassigned.126 
The sacoglossan molluscs have been a source of great interest to chemists, providing 
a range of intriguing pyrone natural products.  Previous biosynthetic and biomimetic 
studies by Ireland and co-workers had demonstrated that many γ-pyrone natural 




biosynthetic pathway featuring a series of photochemically mediated 
rearrangements.127  Ireland further suggested that these strongly UV absorbing γ-
pyrone natural products may serve an important biological function by acting as a 
sunscreen, protecting the molluscs from excessive UV exposure.127   
 
Scheme 5.9: Moses' biosynthetic hypothesis for tridachiahydropyrones A- C105 
Building on this biosynthetic speculation, Moses and co-workers proposed that all the 
members of this family of γ-pyrone natural products could be derived from a common 
polyene biosynthetic intermediate 5.37 via a series of isomerisations and 
electrocyclisations (Scheme 5.9).  Moses proposed that tridachiahydropyrone 
(5.34a/5.34b) could be derived biosynthetically from polyene 5.37 through a 6π 
electrocyclisation.  Depending on whether this electrocyclisation occurred in nature 
under thermal or photochemical conditions, a tridachiahydropyrone structure with a 
trans (thermal disrotatory cyclisation, structure 5.34a) or a cis (photochemical 
conrotatory cyclisation, structure 5.34b) relationship between the C(9) and C(4) 
substituents would result.  A previous total synthesis of the proposed structure of 
tridachiahydropyrone (5.34a) by Perkins had indicated that this trans structure was 
incorrect.128,129  In light of the postulated biological function of these compounds, 
Moses proposed the cis structure (5.34b) originating from a photochemical 6π 
electrocyclisation was likely to represent the true structure of tridachiahydropyrone.  
Moses also suggested that the closely related natural products tridachiahydropyrones 
B (5.35a) and C (5.36a) were likely to be derived from tridachiahydropyrone (5.34b) 
via a [4+2] cycloaddition of singlet oxygen.105 
To test this biosynthetic hypothesis and proposed structural revision, Moses and co-




5.35a, 5.36a), via their proposed polyene intermediate (5.37).  The key polyene 5.37 
was prepared in 75% yield by a Suzuki coupling of the pyrone bromide (5.38) and 
diene boronic ester (5.39).  This polyene (5.37) was then subjected to both thermal and 
photochemical conditions to test their biosynthetic hypothesis.  Heating the polyene 
(5.37) to 150 °C produced no reaction; however, on exposure to sunlight for three days 
the desired tridachiahydropyrone (5.34b) was formed in 20% yield, with all data 
matching that reported for the natural product (Scheme 5.10).  NOESY and single 
crystal X-ray analysis of the synthetic tridachiahydropyrone (5.34b) confirmed the 
anticipated cis stereochemistry, allowing Moses to confidently revise the structure of 
tridachiahydropyrone (5.34b) as well as lending support to his biosynthetic 
hypothesis.105 
 
Scheme 5.10: Moses' biomimetic synthesis of tridachiahydropyrones105 
With a sample of synthetic tridachiahydropyrone (5.34b) in hand, Moses and co-
workers were then also able to test their biosynthetic hypothesis for 
tridachiahydropyrones B (5.35a) and C (5.36a).  Exposure of tridachiahydropyrone 
(5.34b) to singlet O2 gave quantitative conversion to a 4:5 mixture of two products, 
which matched the reported data for tridachiahydropyrones B (5.35a) and C (5.36a).  
However, extensive nOe experiments on this mixture, supported by computational 




O2 was formed, with retention of the (E)-geometry at the C(10)−C(11) alkene (5.35b).  
The two products observed were, in fact, rotamers resulting from restricted rotation 
around the C(9) −C(10) bond.  This observation was further confirmed through the use 
of variable temperature NMR experiments, allowing the reassignment of 
tridachiahydropyrones B and C as a single natural product 5.35b.105   
The success of this synthesis provides an excellent example of the broad range of 
benefits biosynthetic considerations can provide.  Taking into account the possible 
biological function of these compounds allowed Moses to propose a biosynthetic 
hypothesis which linked three natural products together as well as suggesting a 
possible structural revision of tridachiahydropyrone (5.34b).  Then, by investigating 
this hypothesis synthetically, it was possible to simultaneously access several natural 
products in a single synthetic sequence and serendipitously reassign the structures of 
tridachiahydropyrones B and C; while lending further support to the postulated 
biosynthesis and biological function of these compounds. 
 
5.3.8 Conclusion 
The examples described above provide a diverse illustration of the wide range of ways 
in which the use of biosynthetic considerations can illuminate not only the design of 
synthetic strategies, but also in the analysis, assignment and revision of natural product 
structures.  Considerations of the potential biological function of compounds can help 
to identify inconsistencies in proposed structures and point the way to plausible 
alternatives, as highlighted in the cases of butylcycloheptylprodigiosin (5.11) and 
tridachiahydropyrone (5.34a).  Consideration of the structures of biosynthetically 
related compounds can also serve to highlight possible errors in structural assignments, 
as was a contributing factor in the reassignments of caraphenols B and C (5.16a and 
5.17a) and butylcycloheptylprodigiosin (5.11).  Attempts to develop a reasonable 
biosynthetic hypothesis and the consideration of the biosynthesis of structurally- or 
biosynthetically-related natural products can also play a part in driving reassignments, 
as occurred in the case of the cytosporolides (5.1a).  And finally, there are cases where 




a biomimetic strategy to synthesise the target, for example yuremamine (5.27b) or 
tridachiahydropyrones B and C (5.35b).   
In our own work, consideration of the likely biosynthesis of target compounds has 
proved invaluable, both in the design of synthetic strategies and the identification of 
potentially miss-assigned structures.  Taking a biomimetic approach allowed us to 
fortuitously synthesise the correct structure of (±)-incarviditone (1.35b), despite being 
unaware of the error in the original structural assignment.  Conversely, analysis of 
incargranine B (2.1b) helped us to identify a miss-assigned structure based purely on 
biosynthetic considerations.  Further biosynthetic analysis led to our proposal and 
synthetic validation of the correct structure of this natural product, completing this 
example of a purely biosynthetically inspired total synthesis. 
The work detailed in this thesis has hopefully provided a demonstration of the power 
of biosynthetic considerations in natural product synthesis.  Our investigations into 
Incarvillea and Millingtonia natural products have provided examples of the many 
benefits of biomimetic chemistry.  Consideration of the likely biosynthetic origins of 
(±)-incarviditone (1.35b), (±)-incarvilleatone (1.48), incargranine B (2.1b), 
millingtonine (3.1) and incargranine A (4.1) allowed us to achieve three concise total 
syntheses of challenging natural products.  Along the way, we have gained insight into 
the biosynthesis of this family of compounds and uncovered potentially undiscovered 
natural products and biosynthetic intermediates.  Hopefully these insights can be used 
to direct future biosynthetic and isolation studies, contributing to the bi-directional 







6 EXPERIMENTAL SECTION 
NMR spectra 
1H NMR spectra were recorded at 600 MHz, 500MHz, and 400 MHz using a, Bruker 
AVANCE 600, Bruker AVANCE 500, Bruker PRO 500, Bruker AVANCE 400 
Varian INOVA 500 or Varian 400-MR spectrometer. Residual solvent peaks were 
used as an internal reference for 1H NMR spectra (CDCl3 δ 7.26 ppm, CD2Cl2 δ 
5.32ppm, CD3OD δ 3.31 ppm). Coupling constants (J) are quoted to the nearest 0.1 
Hz. Assignment of proton signals was assisted by 1H-1H COSY, HSQC and HMBC 
experiments. 13C NMR spectra were recorded at 150 MHz or 125 MHz, using a Bruker 
AVANCE 600, or Bruker AVANCE 500, Varian INOVA 500 or Varian 400-MR 
spectrometer. Solvent peaks were used as an internal reference for 13C NMR spectra 
(CDCl3 δ 77.16 ppm, CD2Cl2 δ 54.00 ppm CD3OD δ 49.00 ppm). Assignment of 
carbon signals was assisted by 1H-1H COSY, HSQC, HMBC and NOESY 
experiments.   
IR spectra 
IR spectra of solids and liquids were recorded either as neat samples on a Shimadzu 
IRAffinity-1 FTIR spectrometer fitted with an ATR attachment or on a Perkin–Elmer 
1600 FTIR spectrometer as potassium bromide discs or as liquid films on sodium 
chloride discs. 
Melting Point 
Melting points were measured on a Gallenkamp Melting Point System or a Stanford 
Research Systems OptiMelt MPA100. 
Mass spectrometry 
Low resolution mass spectra were recorded on a Finnigan Polaris Q ion trap mass 
spectrometer using electron impact (EI+) ionization mode at 40 or 70 eV or on a 
Micromass ZMD spectrometer using electrospray (ESI+) ionization mode. High 




Electrospray Ionisation (ESI+), a VG Autospec mass spectrometer using electron 
impact (EI+) ionization, operating at 70 eV or on a Waters LCT Premier XE 
spectromer using electrospray ionization (ESI+ or ESI−). 
Analytical TLC 
Analytical TLC was performed with Merck silica gel plates, precoated with silica gel 
60 F254 (0.2 mm). Visualisation was effected by quenching of UV fluorescence (λmax= 
254 nm) and by staining with p-anisaldehyde or KMnO4 standard TLC stain solutions, 
followed by heating. 
Flash chromatography 
Flash chromatography employed Merck Kiesegel 60 (230–400 mesh) silica gel, or 
Merck aluminium oxide 90, active, neutral (70-230 mesh, activity I). 
Analytical HPLC 
Analytical HPLC was conducted using either a Waters 600 E pump and controller with 
a Rheondyne 7725 injection valve and monitored by a Waters 2996 photodiode array 
detector or a Hewlett Packard 1100 series system using a G1311A pump, G1313A 
autosampler, G1316A ColCom and G1365B photodiode array detector. 
Preparative HPLC 
Preparative HPLC was conducted using either a Waters 600 E pump and controller 
with a Rheondyne 7725 injection valve and monitored by a Waters 2996 photodiode 
array detector or an Agilent 1100 series system using 2 G1361A prep-pumps, a 
G2260A autosampler and a G1315B photodiode array detector. 
Analytical chiral HPLC 
Analytical chiral HPLC was conducted using an Agilent 1200 series system using a 
G1310A pump, G1329A autosampler and a G1365D photodiode array detector or a 
Shimadzu Prominence system using an LC-20AD pump, SPD-20A UV detector, 
CBM-20A controller and Rheondyne 7725i injection valve. 




Reactions were conducted under a positive pressure of dry nitrogen in oven-dried 
glassware. Anhydrous solvents were either obtained from commercial sources or dried 
according to the procedure outlined by Grubbs and co-workers.130 Commercially 
available chemicals were used as purchased.  The yields reported in this paper are 
shown as a range of isolated yields obtained on various scales, we herein provide 
experimental details for the largest scale procedures conducted (note: the stated scale 
corresponds to the quantity of product isolated).  Unless otherwise stated, reactions 





6.1 SPECIFIC EXPERIMENTAL CONDITIONS FOR CHAPTER 2 
6.1.1 Experimental Procedure for Compound 2.11 
 
2-(4-aminophenyl)ethanol 2.15 (1.00 g, 7.32 mmol) was dissolved in γ-butyrolactone 
2.45 (4 mL) at room temperature.  The solution was heated to 200 °C under microwave 
irradiation (200 W, 20 psi, 5 minute ramp time) without stirring for 3 hours.  At this 
point 1H-NMR indicated complete conversion of starting material. The crude reaction 
mixture was distilled at reduced pressure (0.1 mbar, b.p. 38-42 °C) to give a viscous, 
dark yellow oil, which solidified to a yellow solid on cooling. The crude solid was 
recrystallized from boiling EtOAc, washing with cold Et2O giving pure 1-(4-(2-
hydroxyethyl)phenyl)pyrrolidin-2-one 2.11 as square, cream-coloured crystals (1.05 
g, 5.12 mmol, 70% yield);  
Rf  0.20 (EtOAc);  
 1H NMR (400 MHz, CDCl3) δ 7.54 (d, J = 8.6 Hz, 2H), 7.22 (d, J = 8.6 Hz, 2H), 3.89 
– 3.77 (m, 4H), 2.84 (t, J = 6.6 Hz, 2H), 2.60 (t, J = 8.1 Hz, 2H), 2.15 (dt, J = 15.3, 7.5 
Hz, 2H), 1.57 (s, 1H) ppm;  
13C NMR (101 MHz, CDCl3); δ 174.3, 137.9, 135.0, 129.5, 120.4, 63.7, 49.0, 38.7, 
32.8, 18.2 ppm;  
IR (KBr disc, cm-1); 3412(br), 2922, 2851, 1682, 1516, 1397, 1304, 1223, 1044, 1021;  
HRMS (EI+) 205.1103 (calculated [M]+: 205.1103); 





6.1.2 Experimental Procedure for Compound 2.12 
 
2-(4-aminophenyl)ethanol 2.15 (0.500 g, 3.64 mmol) dissolved in anhydrous MeCN 
(15 mL) at room temperature.  iPr2NEt (2.54 mL, 14.6 mmol) and 1,4-
dibromobutane (0.57 mL, 4.7 mmol) were added and the mixture heated to reflux.  
After 4 days, the reaction mixture was cooled to room temperature, EtOAc (25 mL) 
added and washed with 1M HCl (20 mL) followed by saturated aqueous NaHCO3 (20 
mL).  The aqueous layers were combined and extracted with EtOAc (3 × 10 mL).  
These organic layers were combined and concentrated under reduced pressure to give 
a pale yellow solid.  The crude solid was dissolved in EtOAc and filtered through a 
short silica plug.  The filtrated was concentrated under reduced pressure to give 2-(4-
(pyrrolidin-1-yl)phenyl)ethanol 2.12 (0.55 g, 2.9 mmol, 79 % yield) as a white solid. 
Rf 0.65 (EtOAc); 
1H NMR (500 MHz, CDCl3) δ 7.09 (d, J = 8.5 Hz, 2H), 6.55 (d, J = 8.6 Hz, 2H), 3.80 
(q, J = 6.3 Hz, 2H), 3.30 – 3.24 (m, 4H), 2.78 (t, J = 6.6 Hz, 2H), 2.04 – 1.96 (m, 4H), 
1.49 – 1.45 (m, 1H) ppm; 
13C NMR (126 MHz, CDCl3) δ 146.9, 129.9, 124.8, 112.0, 64.2, 47.8, 38.4, 25.6 
ppm; 
IR (cm−1) 3292(br), 2965, 2930, 2847, 2837, 1614, 1520, 1460, 1368, 1186, 1042, 
1015; 
HRMS (EI+) 191.1311 (calculated [M]+ 191.1310); 





6.1.3 Experimental Procedure for Compound 2.48 
 
2-(3-Bromopropyl)-1,3-dioxolane 2.48 was prepared based on the procedure described 
by Bates and Sridhar.64  
a) Ethyl 4-bromobutyrate 2.46 (4.0 g, 20.5 mmol) was dissolved in anhydrous CH2Cl2 
(300 mL) at room temperature under a N2 atmosphere.  The solution was cooled in a 
dry-ice/acetone bath to an internal temperature of −70 °C and DIBAL-H (1M in 
hexanes, 24.6 mL, 24.6 mmol) was added over 5 minutes, ensuring the internal 
temperature did not exceed −68 °C.  The resulting solution was stirred at −70 °C for 
2.5 hours, then 1M aqueous HCl (200 mL) was added at −70°C and the solution 
warmed to room temperature.  The organic layer was separated and the aqueous layer 
extracted with CH2Cl2 (3 × 50 mL).  The combined organic layers were dried with 
Na2SO4 and concentrated under reduced pressure at < 25 °C to give 4-bromobutanal 
2.47 as a pale yellow, mobile oil with a pungent odour (3.1 g).  The crude aldehyde 
was used directly without further purification. 
b) Freshly prepared 4-bromobutanal 2.47 (3.1 g, 20.5 mmol) was dissolved directly in 
anhydrous benzene (35 mL) at room temperature under a N2 atmosphere.  Ethylene 
glycol (1.37 mL, 24.5 mmol) and p-TsOH.H2O (0.380 g, 2.05 mmol) were added, a 
Dean-Stark trap fitted and the mixture was heated to reflux.  After 5.5 hours the 
mixture was cooled to room temperature, washed with saturated aqueous NaHCO3 (30 
mL), brine (30 mL), dried with K2CO3 and concentrated under reduced pressure to 
give a pale yellow oil.  Distillation under reduced pressure (0.1 mbar, bp 44-47 °C) 
gave 2-(3-bromopropyl)-1,3-dioxolane 2.48 as a colourless oil (2.84 g, 14.6 mmol, 




1H NMR (400 MHz, CDCl3); δ 4.89 (t, J = 4.5 Hz, 1H), 3.98 – 3.94 (m, 2H), 3.86 – 
3.82 (m, 2H), 3.45 (t, J = 6.8 Hz, 2H), 2.04 – 1.96 (m, 2H), 1.85 – 1.77 (m, 2H) ppm;  
13C NMR (101 MHz, CDCl3); δ 103.8, 65.1, 33.7, 32.4, 27.3 ppm;  





6.1.4 Experimental Procedure for Compounds 2.10a and 2.10b  
 
2-(4-aminophenyl)ethanol 2.15 (1.58 g, 11.5 mmol), bromo-acetal 2.48 (0.90 g, 4.61 
mmol), NaI (1.036 g, 6.92 mmol) and diisopropylethylamine (3.22 mL, 18.4 mmol) 
were dissolved in anhydrous MeCN (18 mL) at room temperature with stirring.  The 
mixture was heated to reflux and stirred vigorously for 20 hours, then cooled to room 
temperature, water (60 mL) added and the resulting suspension extracted with CH2Cl2 
(3 × 40 mL).  The organic layers were combined, washed with brine, dried with 
Na2SO4 and concentrated under reduced pressure to give a viscous yellow oil.  The 
crude oil was dissolved in minimum hot EtOAc/CH2Cl2, allowed to cool to room 
temperature and placed in the freezer overnight.  The solution was then filtered and 
the solid washed with cold CH2Cl2.  The filtrate was concentrated under reduced 
pressure and subjected to flash chromatography (silica gel 230-400 mesh, CHCl3 + 2% 
MeOH) to give 2-(4-((3-(1,3-dioxolan-2-yl)propyl)amino)phenyl)ethanol 2.10a as a 
pale yellow oil which solidified to a waxy solid on standing in the freezer (0.960g, 
3.80 mmol, 83% yield) and 2-(4-(bis(3-(1,3-dioxolan-2-
yl)propyl)amino)phenyl)ethanol 2.10b as a yellow oil (0.112 g, 0.31 mmol, 13% 
yield). 
2-(4-((3-(1,3-dioxolan-2-yl)propyl)amino)phenyl)ethanol 2.10a: 
Rf  0.18 (CHCl3 + 2% MeOH);  
1H NMR (400 MHz, CDCl3); δ 7.02 (d, J = 8.5 Hz, 2H), 6.56 (d, J = 8.5 Hz, 2H), 4.90 
(t, J = 4.3 Hz, 1H), 4.02 – 3.93 (m, 2H), 3.90 – 3.81 (m, 2H), 3.79 – 3.75 (m, 2H), 3.67 





13C NMR (101 MHz, CDCl3); δ 147.1, 129.9, 126.8, 113.1, 104.3, 65.0, 64.1, 44.0, 
38.4, 31.4, 23.9 ppm;  
IR (KBr disc, cm-1); 3391(br), 2947, 2875, 1616, 1521, 1477, 1410, 1322, 1144, 1044;  
HRMS (EI+); m/z 251.1522 (calculated [M]+: 251.1521). 
2-(4-(bis(3-(1,3-dioxolan-2-yl)propyl)amino)phenyl)ethanol 2.10b: 
Rf  0.21 (CHCl3 + 2% MeOH);  
1H NMR (400 MHz, CDCl3); δ 7.04 (d, J = 8.6 Hz, 2H), 6.61 (d, J = 8.7 Hz, 2H), 4.87 
(t, J = 4.0 Hz, 2H), 4.00 – 3.91 (m, 4H), 3.90 – 3.81 (m, 4H), 3.77 (t, J = 6.6 Hz, 2H), 
3.29 (t, J = 7.1 Hz, 4H), 2.73 (t, J = 6.6 Hz, 3H), 1.73 – 1.63 (m, 8H) ppm; 
13C NMR (101 MHz, CDCl3); δ 146.8, 129.9, 125.0, 112.4, 104.4, 65.0, 64.0, 50.9, 
38.2, 31.3, 21.7 ppm; 
IR (NaCl disc, cm-1); 3451(br), 2950, 2880, 1615, 1520, 1399, 1372, 1141, 1045;  





6.1.5 Experimental Procedure for Compounds 2.7a and 2.7b 
 
 
To amino-acetal 2.10a (0.922 g, 3.67 mmol) was added 2M aqueous HCl (3.0 mL) and 
the resulting mixture stirred vigorously at room temperature.  After 3.5 hours saturated 
aqueous NaHCO3 (11 mL) was added and the resulting suspension extracted with 
CHCl3 (10 × 10 mL), the organic layers combined, washed with brine, dried with 
Na2SO4 and concentrated under reduced pressure to give the crude product as a pale 
orange foam (0.512 g).  A 0.270 g portion of the crude diastereomeric mixture was 
purified directly by preparative HPLC (reverse phase, Waters XBridge C 18 5 150mm 
x 19mm column, 25:75:0.05 MeCN:H2O:CF3CO2H, 17 mL/min), to give the desired 
aglycone 2.7a as a pale yellow solid (0.0647 g, 0.324 mmol, 18% extrapolated yield) 
and the un-desired diastereomer 2.7b as a pale yellow solid (0.117 g, 0.309 mmol, 32% 
extrapolated yield).  The desired aglycone 2.7a was recrystallised from CD3OD to give 
crystals (yellow blocks) suitable for single crystal x-ray analysis (CCDC 958614).  The 
undesired aglycone 2.7b was recrystallised from CH3CN to give crystals (yellow 
blocks) suitable for single crystal x-ray analysis (CCDC 958613) (see section 6.10). 
Incargranine B aglycone 2.7a: 
Rf 0.24 (CHCl3 + 2% MeOH);  
m.p. 136.8-138.9 °C;  
tR = 3.8 min (Waters XBridge C18 5 150mm x 19mm column, 25:75:0.05 




1H NMR (500 MHz, CD3OD) δ 7.05 (d, J = 8.6 Hz, 2H), 6.99 (d, J = 8.0 Hz, 1H), 
6.82 (s, 1H), 6.64 (dd, J = 10.6, 8.2 Hz, 3H), 4.30 (d, J = 9.1 Hz, 1H), 3.70 (t, J = 7.3 
Hz, 2H), 3.66 – 3.58 (m, 1H), 3.56 (t, J = 7.3 Hz, 2H), 3.42 (td, J = 8.9, 3.1 Hz, 1H), 
2.82 (q, J = 9.1 Hz, 1H), 2.73 (t, J = 7.3 Hz, 2H), 2.70 – 2.65 (m, 1H), 2.60 (t, J = 7.4 
Hz, 2H), 2.42 – 2.36 (m, 1H), 2.30 – 2.19 (m, 2H), 2.14 – 2.06 (m, 1H), 2.03 – 1.95 
(m, 1H), 1.77 – 1.68 (m, 2H), 2.44 – 2.35 (m, 1H) ppm; 
13C NMR (101 MHz, CD3OD) δ 149.5, 147.0, 130.6, 130.5, 129.8, 129.0, 128.8, 
128.6, 114.7, 113.5, 66.5, 64.9, 64.8, 61.6, 50.9, 49.2, 48.8, 40.0, 39.6, 32.8, 31.6, 23.5 
ppm; 
IR (KBr disc, cm-1); 3319(br), 2913, 2897, 2853, 2825; 
HRMS (EI+); m/z 378.2304 (calculated [M]+: 378.2307). 
Dipyrrolo-quinoline aglycone 2.7b: 
Rf 0.24 (CHCl3 + 2% MeOH);  
m.p. ~118 °C (decomposes);  
tR = 8.3 min (Waters XBridge C18 5 150mm x 19mm column, 25:75:0.05 
MeCN:H2O:CF3CO2H, 17 mL/min);  
1H NMR (400 MHz, CD3OD) δ 7.11 – 7.03 (m, 3H), 6.87 (dd, J = 8.2, 2.1 Hz, 1H), 
6.74 (d, J = 8.6 Hz, 2H), 6.33 (d, J = 8.2 Hz, 1H), 5.03 (d, J = 6.9 Hz, 1H), 3.71 (t, J 
= 7.3 Hz, 2H), 3.65 – 3.57 (m, 1H), 3.52 (t, J = 7.4 Hz, 2H), 3.35 (d, J = 8.7 Hz, 2H), 
3.23 – 3.15 (m, 2H), 2.73 (t, J = 7.3 Hz, 2H), 2.51 (t, J = 7.5 Hz, 2H), 2.48 – 2.44 (m, 
1H), 2.14 – 2.04 (m, 1H), 2.04 – 1.89 (m, 3H), 1.83 – 1.65 (m, 2H) ppm; 
13C NMR (101 MHz, CD3OD); δ 149.1, 143.4, 130.7, 130.1, 129.3, 126.9, 126.8, 
124.8, 112.7, 111.7, 64.8, 64.7, 59.1, 58.1, 48.8, 47.9, 41.6, 39.6, 39.4, 31.1, 24.21, 
24.14 ppm;  
IR (KBr disc, cm-1); 3418(br), 3031, 2962, 2928, 2852, 1613, 1514, 1480, 1364, 1045, 
101;  




6.1.6 Experimental Procedure for Compound 2.50 
 
i) BnNH2 (1.54 mL, 14.1 mmol) was added to a stirred solution of α-D-glucose 
pentaacetate (5.00 g, 12.8 mmol) in THF (55 mL) and the mixture heated to 55 °C.  
After 16 hours the solution was cooled to room temperature and concentrated under 
reduced pressure to give a yellow oily residue.  The residue was re-dissolved in CH2Cl2 
(80 mL) and washed with 1M aqueous HCl (2 × 100 mL), then brine and dried with 
Na2SO4.  Flash chromatography (silica gel, 1:1 → 1:2 petroleum ether/EtOAc) gave 
the anomerically deprotected tetraacetyl-D-glucopyranose as a mixture of α and β 
anomers (3.55 g, 10.2 mmol, 80 % yield).  The product mixture was used directly, 
without further purification. 
ii) The mixed tetraacetyl-D-glucopyranose (3.55 g, 10.2 mmol) was directly dissolved 
in anhydrous CH2Cl2 (150 mL) under an N2 atmosphere.  The solution was cooled to 
0 °C and Cl3CCN (10.0 mL, 100 mmol) and K2CO3 (6.90 g, 50.0 mmol) were added 
with stirring.  The resulting mixture was allowed to warm and stir at room temperature 
until TLC analysis indicated complete consumption of starting material (18 hours).  
The reaction mixture was then filtered through celite and concentrated under reduced 
pressure to give a viscous pale yellow oil.  Flash chromatography (silica gel, 1:1 
petroleum ether/EtOAc) gave 2,3,4,6-tetra-O-acetyl-α-D-glucopyranosyl 
trichloroacetimidate 2.50 as a  sticky yellow amorphous solid (3.06 g, 6.21 mmol, 49 





Rf 0.40 (1:1 petroleum ether/EtOAc);  
1H NMR (400 MHz, CDCl3); δ 8.69 (s, 1H), 6.55 (d, J = 3.7 Hz, 1H), 5.55 (t, J = 9.8 
Hz, 1H), 5.17 (t, J = 9.9 Hz, 1H), 5.12 (dd, J = 10.2, 3.7 Hz, 1H), 4.26 (dd, J = 12.3, 
4.3 Hz, 1H), 4.23 – 4.18 (m, 1H), 4.12 (dd, J = 12.3, 2.1 Hz, 1H), 2.06 (s, 3H), 2.04 
(s, 3H), 2.02 (s, 3H), 2.00 (s, 3H) ppm;  
13C NMR (101 MHz, CDCl3); δ 170.7, 170.1, 170.0, 169.6, 160.9, 93.0, 90.8, 70.1, 
70.0, 69.9, 67.9, 61.5, 20.8, 20.7, 20.6 ppm;  
IR (NaCl disc, cm-1); 3321, 29691, 1752, 1677, 1368, 1221, 1076, 1038;  




6.1.7 Experimental Procedure for Compound 2.51 
 
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosylbromide 2.51 was prepared according to 
the procedure described by Floyd.71 
1,2,3,4,6-Penta-O-acetyl-D-glucopyranose (5.00 g, 12.8 mmol) was dissolved in 
anhydrous CH2Cl2 (40 mL) at room temperature.  HBr (33 %w/w in AcOH, 26.5 mL, 
154 mmol) was added with stirring at room temperature under an N2 atmosphere.  The 
resulting solution was stirred at room temperature for 19 hours, until TLC analysis 
showed complete consumption of starting material.  The reaction mixture was then 
partitioned between water (100 mL) and CH2Cl2 (50 mL).  The organic layer was 
separated and the aqueous layer extracted with CH2Cl2 (3 × 50 mL).  The organic 
layers were combined, washed with saturated aqueous NaHCO3 (2 × 100 mL), then 
brine, dried over MgSO4 and concentrated under reduced pressure to give a pale yellow 
solid.  The crude material was recrystallised from EtOAc/petroleum spirit to give 
2,3,4,6-tetra-O-acetyl-α-D-glucopyranosylbromide 2.51 (4.32 g, 10.5 mmol, 82 % 
yield) as a white solid.  All data matched literature values.71 
1H NMR (400 MHz, CDCl3) δ 6.60 (d, J = 4.1 Hz, 1H), 5.55 (t, J = 9.7 Hz, 1H), 
5.19 – 5.10 (m, 1H), 4.83 (dd, J = 10.0, 4.0 Hz, 1H), 4.37 – 4.25 (m, 2H), 4.17 – 4.08 
(m, 1H), 2.10 (s, 3H), 2.09 (s, 3H), 2.05 (s, 3H), 2.03 (s, 3H) ppm;  
13C NMR (101 MHz, CDCl3) δ 170.6, 170.0, 169.9, 169.6, 86.7, 72.2, 70.8, 70.7, 




6.1.8 Experimental Procedure for Compound 2.52 
 
Glycosyl donor 2.50 (0.537 g, 1.09 mmol) and 2-(4-bromophenyl)ethanol 2.13 (0.100 
g, 0.497 mmol) were dissolved in anhydrous CH2Cl2 (2 mL) at room temperature under 
an N2 atmosphere.  Freshly activated, ground 4Å molecular sieves (0.5 g) were added 
and the mixture stirred for 1 hour, then [Pd(CH3CN)4](BF4)2 (0.026 g, 0.050 mmol) 
was added.  The resulting mixture was stirred at room temperature for 17 hours, until 
TLC analysis showed complete consumption of starting material.  The reaction 
mixture was then filtered through celite and concentrated under reduced pressure.  
Flash chromatography (silica gel, 9:1 → 2:1 petroleum spirit/EtOAc) gave glycoside 
2.52 (0.148 g, 0.278 mmol, 56 % yield) as a white solid, along with the 4-
bromophenethyl acetate 2.53 (0.048 g, 0.20 mmol, 40 % yield) as a colourless oil. 
Glycoside 2.52 
1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 
5.14 (t, J = 9.5 Hz, 1H), 5.05 (t, J = 9.6 Hz, 1H), 4.95 (dd, J = 9.6, 8.0 Hz, 1H), 4.44 
(d, J = 7.9 Hz, 1H), 4.24 (dd, J = 12.3, 4.7 Hz, 1H), 4.14 – 4.06 (m, 2H), 3.69 – 3.57 
(m, 2H), 2.88 – 2.74 (m, 2H), 2.06 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H), 1.86 (s, 3H) 
ppm; 
13C NMR (101 MHz, CDCl3) δ 170.7, 170.3, 169.5, 169.3, 137.6, 131.4, 130.9, 120.2, 
100.8, 72.8, 71.9, 71.2, 70.3, 68.5, 62.0, 35.4, 20.8, 20.7 (2 × C), 20.6 ppm; 




HRMS (ESI+); 553.0683, 555.0689 (calculated [M+Na]+: 553.0680, 555.0663); 
M.p. 86-88 °C. 
4-bromophenethyl acetate 2.53 
1H NMR (400 MHz, Chloroform-d) δ 7.44 – 7.38 (m, 2H), 7.12 – 7.05 (m, 2H), 4.25 
(t, J = 6.9 Hz, 2H), 2.88 (t, J = 6.9 Hz, 2H), 2.02 (s, 3H) ppm; 




6.1.9 Alternative Experimental Procedure for Compound 2.52 
 
To a solution of 2-(4-bromophenyl)ethanol 2.13 (0.100 g, 0.497 mmol) in anhydrous 
CH2Cl2 (2 mL) was added freshly prepared Ag2CO3 (0.164 g, 0.596 mmol) and 
activated 4Å molecular sieves (0.25 g) and the resulting suspension stirred at room 
temperature for 1 hour.  A solution of glycosyl bromide 2.51 (0.248 g, 0.596 mmol) in 
anhydrous CH2Cl2 (1 mL) was then added slowly at room temperature.  The resulting 
suspension was stirred in the dark for 19 hours until TLC analysis showed complete 
consumption of starting material.  The reaction mixture was then filtered through 
celite, the filtrate washed with saturated aqueous NaHCO3 (10 mL), then brine, dried 
over Na2SO4 and concentrated under reduced pressure to give a colourless oil.  Flash 
chromatography (silica gel, 4:1 → 2:1 petroleum spirit/EtOAc) gave the glycoside 
2.52 (0.160 g, 0.301 mmol, 61 % yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.37 (d, J = 8.4 Hz, 2H), 7.05 (d, J = 8.4 Hz, 2H), 
5.14 (t, J = 9.5 Hz, 1H), 5.05 (t, J = 9.6 Hz, 1H), 4.95 (dd, J = 9.6, 8.0 Hz, 1H), 4.44 
(d, J = 7.9 Hz, 1H), 4.24 (dd, J = 12.3, 4.7 Hz, 1H), 4.14 – 4.06 (m, 2H), 3.69 – 3.57 
(m, 2H), 2.88 – 2.74 (m, 2H), 2.06 (s, 3H), 2.00 (s, 3H), 1.97 (s, 3H), 1.86 (s, 3H) 
ppm; 
13C NMR (101 MHz, CDCl3) δ 170.7, 170.3, 169.5, 169.3, 137.6, 131.4, 130.9, 120.2, 
100.8, 72.8, 71.9, 71.2, 70.3, 68.5, 62.0, 35.4, 20.8, 20.7 (2 × C), 20.6 ppm; 
IR (cm-1) 2955, 2889, 1738, 1485, 1381, 1366, 1173, 1032; 
HRMS (ESI+); 553.0683, 555.0689 (calculated [M+Na]+: 553.0680, 555.0663); 




6.1.10 Experimental Procedure for Compound 2.54 
 
Lactam 2.11 (0.100 g, 0.487 mmol) was dissolved in anhydrous CH2Cl2 (2 mL).  
Ag2CO3 (0.175 g, 0.633 mmol) was added and the resulting suspension stirred over 
4Å molecular sieves (0.3 g) for 30 minutes.  A solution of glycosyl bromide 2.51 
(0.240 g, 0.585 mmol) in CH2Cl2 (1 mL) was added dropwise with stirring at room 
temperature.  The reaction mixture was stirred in the dark at room temperature for 19 
hours, then additional glycosyl bromide 2.51 (0.044 g, 0.11 mmol) and  Ag2CO3 (0.027 
g, 0.10 mmol) was added.  After 24 hours, when TLC analysis showed complete 
consumption of starting material, the reaction mixture was filtered through celite.  The 
filtrate was washed with saturated aqueous NaHCO3 (10 mL), then brine, dried over 
Na2SO4 and concentrated under reduced pressure.  Flash chromatography (silica gel, 
3:1 petroleum spirit/EtOAc → EtOAc) gave the orthoester 2.54 (89 mg, 0.13 mmol, 
52 % yield) as a colourless oil. 
1H NMR (601 MHz, CD2Cl2 δ 7.55 – 7.52 (m, 2H), 7.22 – 7.18 (m, 2H), 5.45 (d, J = 
5.2 Hz, 1H), 5.08 (t, J = 2.6 Hz, 1H), 4.82 (ddd, J = 9.4, 2.4, 1.0 Hz, 1H), 4.14 – 4.11 
(m, 2H), 4.08 (ddd, J = 5.2, 2.9, 1.1 Hz, 1H), 3.87 (dddd, J = 9.3, 5.4, 3.1, 0.6 Hz, 
1H), 3.82 (t, J = 7.1 Hz, 2H), 3.68 (td, J = 6.8, 3.1 Hz, 2H), 2.81 (t, J = 6.7 Hz, 2H), 
2.53 (dd, J = 8.5, 7.6 Hz, 2H), 2.16 – 2.09 (m, 2H), 2.07 (s, 3H), 2.05 (s, 3H), 2.05 
(s, 3H), 1.66 (s, 3H) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 173.89, 170.40, 169.53, 168.97, 138.10, 134.73, 
129.12, 121.18, 119.56, 96.78, 72.82, 69.66, 68.12, 66.92, 64.18, 63.18, 48.64, 35.49, 
32.65, 20.60, 20.53, 20.49, 20.42, 17.93 ppm; 









6.1.11 Experimental Procedure for Compound 2.56 
 
a) 1,2,3,4,6-Penta-O-pivaloyl-D-glucopyranose 2.55 was prepared based on the 
procedure of Kunz.131  To a stirred solution of pivaloyl chloride (213.4 mL, 1.74mol) 
in anhydrous CH2Cl2 (350 mL)  was added pyridine (201.5 mL, 2.5 mol) and D-
glucose (50.0 g, 0.278 mol) at room temperature.  The resulting mixture was stirred at 
room temperature for 19 hours, the extra pivaloyl chloride (34.2 mL, 0.278 mol) was 
added.  After 43 hours when TLC analysis showed complete consumption of starting 
material, 1M HCl (200 mL) was added, the organic layer separated, washed with 1M 
HCl (2 × 100 mL), then saturated aqueous NaHCO3 (2 × 100 mL), then brine, dried 
with Na2SO4 and concentrated under reduced pressure to give a sticky white solid.  
This was recystallised twice from MeOH to give 1,2,3,4,6-penta-O-pivaloyl-D-
glucopyranose 2.55 as a white solid (87.94 g, 0.146 mol, 53% yield).  All data matched 
literature values.2 
b) 2,3,4,6-Tetra-O-pivaloyl-D-glucopyranose was prepared according to the procedure 
of Schmidt.3 1,2,3,4,6-penta-O-pivaloyl-D-glucopyranose (40.0 g, 66.6 mmol) was 
dissolved in anhydrous DMF (180 mL) at 50 °C under an N2 atmosphere.  Hydrazine 
acetate (7.75 g, 83.2 mmol) was added and the solution stirred at 50 °C for 18 hours, 
then additional hydrazine acetate (3.09 g, 33.6 mmol) was added.  After 24 hours the 
mixture was cooled to room temperature, EtOAc (400 mL) added and washed with 
brine (3 × 200 mL), dried with Na2SO4 and concentrated under reduced pressure.  Flash 




O-pivaloyl-D-glucopyranose as a 3:1 mixture of of / anomers (14.7 g, 28.5 mmol, 
43 % yield). All data matched literature values.81 
c) 2,3,4,6-Tetra-O-pivaloyl-α-D-glucopyranosyltrichloroacetimidate 2.56 was 
prepared according to the procedure of Schmidt.3 To a solution of 2,3,4,6-tetra-O-
pivaloyl-D-glucopyranose (14.7 g, 28.5 mmol) in anhydrous CH2Cl2 (100 mL) was 
added Cl3CCN (11.4 mL, 114 mmol) at room temperature under an N2 atmosphere.  
NaH (3.42 g, 85.5 mmol) was added to the resulting solution at room temperature with 
vigorous stirring.  The mixture was stirred for 2.5 hours, then extra Cl3CCN (12.0 mL, 
120 mmol) was added.  After 20 hours, when TLC analysis showed complete 
consumption of the starting material, the reaction mixture was filtered through celite 
and concentrated under reduced pressure to give a dark yellow foam.  Flash 
chromatography (silica gel, 9:1 petroleum spirit 40-60:EtOAc) gave the desired 
2,3,4,6-tetra-O-pivaloyl-α-D-glucopyranosyltrichloroacetimidate  2.56 as a pale 
yellow solid (10.2 g, 15.4 mmol, 54% yield).  All data matched literature values.81 
2,3,4,6-tetra-O-pivaloyl-α-D-glucopyranosyltrichloroacetimidate 2.56: 
1H NMR (400 MHz, CDCl3) δ 8.67 (s, 1H), 6.57 (d, J = 3.8, 1H), 5.66 (t, J = 9.8, 1H), 
5.26 – 5.19 (m, 1H), 5.16 (dd, J = 10.1, 3.8, 1H), 4.22 (dd, J = 11.2, 4.4, 1H), 4.17 
(dd, J = 12.4, 1.9, 1H), 4.08 (dd, J = 12.4, 5.2, 1H), 1.20 (s, 9H), 1.18 (s, 9H), 1.13 (s, 
18H) ppm; 
13C NMR (101 MHz, CDCl3) 178.1, 177.4, 177.1, 176.6, 160.8, 92.9, 90.9, 70.6, 70.0, 





6.1.12 Experimental Procedure for Compound 2.57 
 
1,2,3,4,6-Penta-O-pivaloyl-D-glucopyranose 2.55 (2.00 g, 3.33 mmol) was dissolved 
in anhydrous CH2Cl2 (4 mL) at room temperature.  The solution was cooled to 0 ºC, a 
drying tube fitted and HBr (33 %w/w in AcOH, 3.50 mL, 20.0 mmol) was added with 
stirring.  The resulting solution was warmed to room temperature and stirred for 22 
hours, until TLC analysis showed complete consumption of starting material.  The 
reaction mixture was then partitioned between water (25 mL) and CH2Cl2 (40 mL).  
The organic layer was washed with saturated aqueous NaHCO3 (2 × 40 mL).  The 
aqueous layers were back-extracted with CH2Cl2 (2 × 40 mL).  The organic layers 
were combined, washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure.  Flash chromatography (silica gel, 9:1 petroleum spirit/Et2O) gave 2,3,4,6-
tetra-O-pivaloyl-α-D-glucopyranosylbromide 2.57 (1.08 g, 1.86 mmol, 56 % yield) as 
a white solid.  All data matched literature values.78 
Rf 0.30 (9:1 petroleum spirit:Et2O); 
1H NMR (400 MHz, CDCl3) δ 6.62 (d, J = 4.1 Hz, 1H), 5.63 (t, J = 9.7 Hz, 1H), 
5.21 (dd, J = 10.3, 9.6 Hz, 1H), 4.81 (ddd, J = 9.9, 4.1, 0.4 Hz, 1H), 4.31 (ddd, J = 
10.4, 4.2, 2.5 Hz, 1H), 4.19 – 4.14 (m, 2H), 1.22 (s, 9H), 1.19 (s, 9H), 1.17 (s, 9H), 
1.13 (s, 9H) ppm; 
13C NMR (101 MHz, CDCl3) δ 178.1, 177.5, 176.9, 176.6, 87.0, 72.7, 71.0, 69.7, 66.7, 




6.1.13 Experimental Procedure for Compound 2.58 
 
Lactam 2.11 (50 mg, 0.24 mmol) was dissolved in anhydrous CH3CN (1 mL).  Ag2CO3 
(100 mg, 0.34 mmol) was added and the resulting suspension stirred over 4Å 
molecular sieves (0.2 g) for 20 minutes.  A solution of glycosyl bromide 2.57 in 
CH2Cl2 (1.2 mL, 0.24 M, 0.29 mmol) was added dropwise with stirring at room 
temperature.  The reaction mixture was stirred in the dark at room temperature for 24 
hours, then additional Ag2CO3 (50 mg, 0.17 mmol) was added.  After 69 hours, when 
TLC analysis showed complete consumption of starting material, the reaction mixture 
was filtered through celite and concentrated under reduced pressure.  Flash 
chromatography (silica gel, 3:1 petroleum spirit/EtOAc → EtOAc) gave the orthoester 
2.58 (89 mg, 0.13 mmol, 52 % yield) as a white solid. 
1H NMR (400 MHz, CDCl3) δ 7.52 (d, J = 8.6 Hz, 2H), 7.20 (d, J = 8.6 Hz, 2H), 
5.67 (d, J = 5.7 Hz, 1H), 5.21 (dd, J = 6.3, 3.8 Hz, 1H), 4.94 (dd, J = 9.2, 6.3 Hz, 
1H), 4.22 – 4.16 (m, 2H), 4.16 – 4.05 (m, 2H), 3.84 (t, J = 7.2 Hz, 2H), 3.69 (qt, J = 
8.8, 7.1 Hz, 2H), 2.82 (t, J = 7.0 Hz, 2H), 2.60 (t, J = 8.1 Hz, 2H), 2.21 – 2.11 (m, 
2H), 1.21 (s, 9H), 1.19 (s, 9H), 1.17 (s, 9H), 1.08 (s, 9H) ppm; 
13C NMR (101 MHz, CDCl3) δ 178.1, 176.9, 176.8, 174.2, 137.9, 134.9, 129.5, 125.2, 
120.1, 97.5, 76.3, 72.3, 68.9, 67.1, 65.5, 62.7, 49.0, 39.5, 39.0, 38.9, 38.8, 36.0, 32.8, 




IR (cm-1) 2968, 2934, 2872, 1730, 1699, 1516, 1479, 1391, 1304, 1279, 1146, 1113, 
1090; 
M.p. 168-170 °C; 





6.1.14 Experimental Procedure for Compound 2.59 
 
Lactam 2.11 (50 mg, 0.24 mmol), and glycoside trichloroacetimidate 2.56 were 
dissolved in anhydrous CH3CN (1 mL) and CH2Cl2 (1 mL) and the resulting solution 
stirred over 4Å molecular sieves (0.2 g) for 20 minutes.  TMSOTf (0.062 mL, 0.34 
mmol) was added dropwise with stirring at room temperature.  After 66 hours, when 
TLC analysis showed complete consumption of starting material, solid NaHCO3 (0.15 
g) added, stirred for 5 minutes then filtered through celite and concentrated under 
reduced pressure to give a yellow oil.  Flash chromatography (silica gel, 3:2 petroleum 
spirit/EtOAc) gave the glycoside 2.59 (0.167 g, 0.237 mmol, 99 % yield) as a yellow 
oil. 
Rf 0.30 (3:2 petroleum spirit:EtOAc); 
1H NMR (400 MHz, CDCl3) δ 7.50 (d, J = 8.6 Hz, 2H), 7.17 (d, J = 8.5 Hz, 2H), 
5.30 (t, J = 9.5 Hz, 1H), 5.14 – 5.07 (m, 1H), 5.02 (dd, J = 9.7, 8.0 Hz, 1H), 4.53 (d, 
J = 8.0 Hz, 1H), 4.21 (dd, J = 12.2, 2.0 Hz, 1H), 4.09 – 3.96 (m, 2H), 3.86 – 3.80 (m, 
2H), 3.72 (ddd, J = 10.1, 5.9, 2.0 Hz, 1H), 3.65 (dt, J = 9.6, 7.5 Hz, 1H), 2.90 – 2.83 
(m, 2H), 2.60 (t, J = 8.1 Hz, 2H), 2.20 – 2.09 (m, 2H), 1.21 (s, 9H), 1.15 (s, 9H), 1.11 
(s, 9H), 1.10 (s, 9H) ppm; 
13C NMR (101 MHz, CDCl3) δ 178.2, 177.3, 176.6, 176.6, 174.2, 137.9, 134.4, 
129.4, 120.2, 101.2, 72.5, 72.4, 71.2, 70.7, 68.2, 62.2, 48.9, 39.0, 38.9, 38.8, 38.8, 
35.8, 32.8, 27.3, 27.3, 27.2, 27.2, 18.2 ppm; 





6.1.15 Experimental Procedure for Compound 2.60 
 
Algycone 2.7a (0.019 g, 0.050mmol) and glycosyl donor 2.56 (0.086 g, 0.135 mmol) 
were dissolved in anhydrous CH2Cl2 (1.0 mL) and anhydrous CH3CN (1.0 mL) at 
room temperature under an N2 atmosphere.  Freshly activated powdered 4Å molecular 
sieves (0.15 g) were added and the mixture stirred at room temperature for 30 minutes.  
TMSOTf (0.50 M in CH2Cl2, 0.27 mL) was added, the mixture stirred for 20 minutes 
then a second portion of glycosyl donor 2.56 (0.040 g, 0.061 mmol) and TMSOTf 
(0.50 M CH2Cl2, 0.13 mL) was added and stirred for a further 20 minutes, until TLC 
analysis showed complete consumption of starting material.  Solid NaHCO3 (0.060 g) 
was added, the reaction mix stirred for 5 minutes then filtered through celite and 
concentrated under reduced pressure to give a brown solid.  The crude material was 
directly purified by preparative HPLC (reverse phase, Waters Xbridge C18 5μ 150 × 
19 mm column, 99:1 MeOH: NH3, 17 mL/min) to give 2.60 as a yellow solid (0.0198 
g, 28% yield).   
tR = 6.98 min (Waters XBridge C 18 5 150mm x 19mm column, 99:1 MeOH:NH3, 17 
mL/min);  
1H NMR (400 MHz, CD2Cl2) δ 7.02 (d, J = 8.2, 2H), 6.98 (d, J = 8.1, 1H), 6.85 (s, 
1H), 6.62 – 6.54 (m, 3H), 5.31 – 5.23 (m, 2H), 5.12 – 5.02 (m, 2H), 5.01 – 4.89 (m, 
2H), 4.57 (d, J = 8.0, 1H), 4.48 (dd, J = 15.1, 8.0, 1H), 4.29 (d, J = 9.1, 1H), 4.15 – 




3.54 (m, 4H), 3.40 (t, J = 7.4, 1H), 3.26 (dd, J = 16.0, 9.6, 1H), 2.85 – 2.74 (m, 3H), 
2.73 – 2.63 (m, 3H), 2.43 – 2.33 (m, 1H), 2.28 – 2.13 (m, 2H), 2.13 – 2.02 (m, 1H), 
2.01 – 1.88 (m, 1H), 1.77 – 1.66 (m, 2H), 1.20 (s, 9H), 1.18 (s, 9H), 1.13 (d, J = 1.9, 
27H), 1.09 (s, 9H), 1.08 (s, 9H), 1.06 (d, J = 6.3, 9H) ppm;  
13C NMR (101 MHz,CD2Cl2) δ 178.2, 177.3, 176.8, 176.8, 176.7, 148.7, 146.3, 146.3, 
129.8, 129.0, 128.5, 128.4, 128.0, 127.9, 127.8, 127.7, 126.2, 126.1, 113.3, 113.2, 
112.4, 101.8, 101.7, 101.5, 72.6, 72.6, 72.1, 72.0, 71.9, 71.7, 71.5, 71.5, 71.4, 68.4, 
65.1, 62.3, 60.5, 50.0, 48.6, 47.8, 39.1, 39.1, 39.0, 39.0, 36.1, 35.6, 32.3, 30.9, 30.1, 
27.3, 27.2, 22.8 ppm; 
IR (KBr disc, cm-1); 2969, 2873, 1744, 1614, 1518, 1480, 1280, 1193, 1057;  





6.1.16 Experimental Procedure for Incargranine B 2.1b 
 
 
Octa-O-pivaloyl-incargranine B 2.60 (0.010 g, 7.27 mol) was dissolved in THF (0.2 
mL) and MeOH (0.8 mL) at room temperature.  LiOH (1 M in H2O, 0.145 mL) was 
added and the resulting suspension stirred at room temperature for 21.5 hours, then 
concentrated under reduced pressure.  The crude material was purified directly by 
preparative HPLC (reverse phase, Waters Xbridge C18 5μ 150 × 19 mm column, 
40:60:1 H2O:MeOH:NH3, 17 mL/min) to give incargranine B (2.1b) as a pale yellow 
oil (4.9 mg, 6.97 mol, 96% yield).  Data matched that reported for natural 
incargranine B,52 see discussion and comparison of spectra 6.3.18). 
tR = 10.86 min (Waters XBridge C 18 5 150mm x 19mm column, 40:60:1 
H2O:MeOH:NH3, 17 mL/min);  
1H NMR; (600 MHz, CD3OD) δ 7.10 (d, J = 8.5, 2H), 7.04 (d, J = 8.0, 1H), 6.87 (s, 
1H), 6.66 (d, J = 8.1, 1H), 6.61 (dd, J = 8.5, 1.7, 2H), 4.31 (overlapping d, J = 7.9, 
1H), 4.30 (overlapping d, J = 9.9, 1H), 4.21 (dd, J = 7.8, 3.6, 1H), 4.10 – 4.04 (m, 1H), 
3.95 – 3.89 (m, 1H), 3.87 (m, 1H), 3.81 (td, J = 11.9, 2.2, 1H), 3.74 (dd, J = 16.4, 8.2, 
1H), 3.69 – 3.57 (m, 4H), 3.46 – 3.41 (m, 1H), 3.38 – 3.32 (m, 2H), 3.30 – 3.24 (m, 
4H), 3.23 – 3.17 (m, 2H), 3.13 (t, J = 8.5, 1H), 2.90 – 2.79 (m, 3H), 2.78 – 2.68 (m, 
3H), 2.39 (dd, J = 16.6, 7.5, 1H), 2.28 (m, 1H), 2.22 (m, 1H), 2.11 (m, 1H), 2.04 – 




13C NMR (151 MHz, CD3OD) δ 149.57, 149.55, 147.07, 147.05, 130.67, 130.33, 
130.28, 129.90, 129.89, 129.03, 128.99, 128.90, 128.86, 128.37, 128.35, 114.65, 
114.62, 113.52, 113.50, 104.59, 104.55, 104.54, 104.52, 78.24, 78.17, 78.10, 78.09, 
78.06, 78.02, 75.31, 75.29, 75.23, 75.20, 72.42, 72.40, 71.83, 71.72, 71.68, 66.56, 
66.54, 62.95, 62.87, 62.84, 61.56, 61.54, 50.89, 50.85, 50.00, 49.72, 37.00, 36.93, 
36.50, 32.79, 31.58, 23.46 ppm; 
IR (NaCl disc, cm-1); 3377(br), 2924, 1517, 1384, 1194, 1057;  
HRMS (ESI-); m/z 701.3289 (calculated [M-H]-: 701.3286); 
[𝜶]𝑫
𝟐𝟎 (c 0.275, MeOH) –16.7; 
Analytical Chiral HPLC (reverse phase, Merck LiChroCART 250-4 ChiraDex 5μ 
column, 80:20 H2O:MeOH MeOH, 20min, 1.0 mL/min) indicated the presence of 













6.1.18 Comparison of the NMR Spectra for Synthetic and Natural Incargranine 
B 
Prof. Zhang very kindly provided pdf files of the processed NMR data. There are several important 
issues regarding the spectra: 
a) The pdf files of the processed spectra provided by Prof. Zhang appear to be from a 500 MHz 
machine whereas the tabulated data in the isolation paper appear to be from a 600 MHz 
machine.52 
b) The natural sample of incargranine B contained impurities. 
c) The 13C NMR spectrum provided by Prof. Zhang appears to be referenced to ~ 49.30 ppm (not 
49.15 ppm), which accounts for very slight discrepancies between the reported data and our 
data. 
d) The tabulated values for the 13C NMR signals for C-3, C-4 and C-4a, from the isolation paper,52 
donʹt match with the values from the spectrum provided by Prof. Zhang. This appears to be a 
simple mistake wherein the values reported in the table actually correspond to impurity peaks. 
e) Analysis of the COSY and HSQC spectra reveals there were six incorrectly assigned 1H NMR 
signals; H-2, H-4, H-3```, H-3````, H-5``` and H-5```` (highlighted in red). This resulted in 
misinterpretation of COSY data; The COSY spectrum DOES NOT have a H-4/H-4a cross-
peak and DOES have H-4/H-8a cross-peak. 
f) On several occasions we were unable to distinguish between peaks that were very close 
(highlighted in blue). 
 
 




m, J (Hz) δ  13C 
(150MHz) 
δ  1H 
(600MHz) 





1H m, overlap 49.72 
3.64-3.65 
2.79-2.81 
1H, m, Ha 
1H m, Hb 49.3 








1H m, overlap 32.79 
2.21-2.25 
1.70-1.75 
1H, overlap, m, Ha 
1H, overlap, m Hb 33.3 (32.9) 




1H, overlap, m 31.58 
2.21-2.25 
1.70-1.75 
1H, overlap, m, Ha 
1H, overlap, m, Hb 31.7 
6 3.57-3.69 
3.24-3.29 
1H, overlap, m 1H, 
overlap, m 50.89, 50.85 
3.55-3.58 
3.25-3.26 
1H, overlap, m, Ha 
1H, m, Hb 51 
8 4.30 1H, overlap, d (9.9) 61.56, 61.54 4.27 1H, d (8.0) 61.7 




128.35 -- -- 128.5 
2ʹ 
7.10 2H, d (8.5) 
130.67 
 7.09 1H, d (8.4) 130.8 
3ʹ 
6.61 2H, dd (8.6, 1.7) 
114.65, 




149.55  -- -- 149.7 
5ʹ 
6.61 2H, dd (8.6, 1.7) 
114.65, 
114.62 6.59 1H, d (8.4) 114.8 
6ʹ 7.10 2H, d (8.5) 130.67 7.09 1H, d (8.4) 130.8 





1H, dd (16.4, 8.2) 
72.42, 72.40 




1H, m, Ha 






130.33 -- -- 130.3 
2ʹʹ 
















6.66 1H, d, (8.1) 
113.52, 
113.50 6.65 1H, d (7.9) 113.7 
6ʹʹ 




128.89 7.03 1H, d (7.9) 129 
7ʹʹ 2.68-2.78 2H, overlap, m 37.00, 36.93 2.71-2.75 2H, overlap, m 37.0 
8ʹʹ 3.57-3.69  
3.89-3.95 
1H, m 





1H, m, Ha 





4.31 or 4.21 
1H, overlap, d (7.9) 
or dd (7.8, 3.6) 
104.59, 
104.55 or  
104.54, 
104.52 4.31 1H, d (7.8) 104.6 
2ʹʹʹ 3.13 or 3.17-
3.23 
1H, t (8.5) or 
overlap, m 75.31, 75.29 3.13 1H, t (7.8) 75.3 
3ʹʹʹ 3.32-3.38 2H, overlap, m 78.24 3.19-3.22 1H, m 78.2 
4ʹʹʹ 3.24-3.30 2H, overlap, m 71.72 3.27-3.29 1H, overlap, m 71.8 
5ʹʹʹ 3.17-3.21 or 
3.24-3.30 
1H, overlap, m or 1H 





2H, overlap, m 
and/or 1H td (11.9, 
2.2) and/or 1H, m 62.95 
3.90, 
3.62 
1H, dd (13.2, 9.6), 
Ha 
1H, dd (13.2, 2.4), 
Hb 63.0 
1ʹʹʹʹ 
4.31 or 4.21 
1H, overlapping, d 




104.52 4.21 1H, d (7.8) 104.6 
2ʹʹʹʹ 3.13 or 3.17-
3.23 
1H, t (8.5), or 1H, 
overlap, m 75.23, 75.20 3.23 1H, t (8.5) 75.3 
3ʹʹʹʹ 3.32-3.38 2H, overlap, m 78.17 3.27-3.29 1H, overlap, m 78.2 
4ʹʹʹʹ 3.24-3.30 2H, overlap, m 71.68 3.27-3.29 1H, overlap, m 71.8 
5ʹʹʹʹ 3.17-3.21 or 
3.24-3.30 
1H, overlap, m or 





2H, overlap, m 
and/or 1H td (11.9, 
2.2) and/or 1H, m 62.87, 62.84 
3.72, 
3.62 
1H, dd (13.2, 9.6), 
Ha 












6.2 SPECIFIC EXPERIMENTAL CONDITIONS FOR CHAPTER 3 
6.2.1 Experimental Procedure for Compound 3.23a 
 
2-(4-aminophenyl)ethanol 2.15 (2.00 g, 14.6 mmol), bromide 3.24 (1.56 g, 5.84 
mmol), iPr2Net (4.04 mL, 23.2 mmol) and NaI (1.30 g, 8.67 mmol) were dissolved in 
anhydrous CH3CN (20 mL) at room temperature.  The solution was heated to reflux 
for 21 hours, until TLC analysis showed complete consumption of starting material.  
The reaction mixture was then cooled to room temperature, water (25 mL) added and 
extracted with CH2Cl2 (3 × 50 mL).  The organic fractions were combined, washed 
with brine, dried over Na2SO4 and concentrated under reduced pressure.  Flash 
chromatography (silica gel, 3:2 petroleum ether/EtOAc) gave compound 3.23a (1.30 
g, 4.02 mmol, 69 % yield) as a pale yellow oil. 
Rf 0.30 (4:1 petroleum ether:EtOAc); 
1H NMR (400 MHz, CDCl3) δ 7.03 (d, J = 8.4 Hz, 2H), 6.57 (d, J = 8.4 Hz, 2H), 3.79 
(t, J = 6.5 Hz, 2H), 3.66 (t, J = 5.9 Hz, 2H), 3.12 (t, J = 6.7 Hz, 2H), 2.75 (t, J = 6.5 
Hz, 2H), 1.73 – 1.57 (m, 4H), 0.90 (s, 9H), 0.06 (s, 6H) ppm; 
13C NMR (101 MHz, CDCl3) δ 147.2, 129.9, 126.7, 113.1, 64.1, 63.0, 44.2, 38.4, 
30.5, 26.1, 26.1, 18.5, −5.2 ppm; 
IR (cm−1) 3368, 2949, 2928, 2857, 1616, 1520, 1254, 1096; 




6.2.2 Experimental Procedure for Compound 3.23 
 
Compound 3.23a (0.205 g, 0.618 mmol) was dissolved in anhydrous THF (10 mL) at 
room temperature.  TBAF (1.0 M in THF, 1.24 mL, 1.24 mmol) was added slowly at 
room temperature.  The resulting solution was stirred at room temperature for 50 
minutes, until TLC analysis showed complete consumption of starting material.  
Saturated aqueous NH4Cl (10 mL), was then added and the resulting mixture was 
extracted with EtOAc (4 × 20 mL).  The organic layers were combined, washed with 
brine, dried over Na2SO4 and concentrated under reduced pressure.  Flash 
chromatography (silica gel, EtOAc), gave 4-((4-(2-
hydroxyethyl)phenyl)amino)butan-1-ol 3.23 (0.111 g, 0.530 mmol, 87 % yield) as a 
white solid. 
Rf 0.20 (EtOAc); 
1H NMR (500 MHz, Chloroform-d) δ 7.04 (d, J = 8.4 Hz, 2H), 6.59 (d, J = 8.5 Hz, 
2H), 3.79 (t, J = 6.5 Hz, 2H), 3.69 (t, J = 6.1 Hz, 2H), 3.15 (t, J = 6.6 Hz, 2H), 2.76 
(t, J = 6.5 Hz, 2H), 1.76 – 1.64 (m, 4H) ppm; 
13C NMR (126 MHz, CDCl3) δ 147.1, 130.0, 127.2, 113.4, 64.1, 62.8, 44.3, 38.4, 
30.5, 26.3 ppm;  
IR (cm−1) 3362, 3264, 2940, 2924, 2859, 2849, 1612, 1514, 1474, 1246, 1184, 1069, 
1038; 
HRMS (ESI+) 210.1503 (calculated [M+H]+: 210.1489); 




6.2.3 Experimental Procedure for Compound 3.27a 
 
Aniline 3.26 (0.85 mL, 9.4 mmol), bromide 3.24 (1.00 g, 3.74 mmol) and iPr2Net (2.61 
mL, 15.0 mmol) were dissolved in anhydrous CH3CN (12 mL) at room temperature.  
NaI (0.841 g, 5.61 mmol) was added and the mixture was heated to reflux.  After 4 
hours, when TLC analysis showed complete consumption of starting material, the 
reaction mixture was cooled to room temperature, water (25 mL) added and extracted 
with EtOAc (4 × 20 mL).  The organic layers were combined, washed with 1M HCl 
(2 × 20 mL), then saturated aqueous NaHCO3 (2 × 20 mL), water (20 mL), brine, dried 
over Na2SO4 and concentrated under reduced pressure to give a brown oil.  Flash 
chromatography (silica gel, 19:1 petroleum ether/Et2O) gave compound 3.27a (0.515 
g, 1.84 mmol, 49 % yield) as a yellow oil. 
Rf 0.30 (19:1 petroleum ether/Et2O); 
1H NMR (400 MHz, CDCl3) δ 7.18 (t, J = 7.7 Hz, 2H), 6.70 (t, J = 7.3 Hz, 1H), 6.63 
(d, J = 8.1 Hz, 2H), 3.66 (t, J = 5.9 Hz, 2H), 3.15 (t, J = 6.7 Hz, 2H), 1.76 – 1.58 (m, 
4H), 0.91 (s, 9H), 0.06 (s, 6H) ppm; 
13C NMR (101 MHz, CDCl3) δ 148.3, 129.4, 117.5, 113.1, 63.0, 44.2, 30.5, 26.1, 26.1, 
18.5, −5.1 ppm; 
IR (cm−1) 2951, 2928, 2855, 1603, 1506, 1254, 1096; 




6.2.4 Experimental Procedure for Compound 3.27 
 
Compound 3.27a (0.250 g, 0.894 mmol) was dissolved in anhydrous THF (10 mL) at 
room temperature.  TBAF (1.0 M in THF, 1.79 mL, 1.79 mmol) was added slowly at 
room temperature.  The resulting solution was stirred at room temperature for 1.5 
hours, until TLC analysis showed complete consumption of starting material.  
Saturated aqueous NH4Cl (10 mL), was then added and the resulting mixture was 
extracted with EtOAc (4 × 20 mL), dried over Na2SO4 and concentrated under reduced 
pressure to give a brown oil.  Flash chromatography (silica gel, Et2O) gave compound 
3.27 (0.120 g, 0.726 mmol, 81 % yield) as a pale yellow oil. 
Rf 0.35 (Et2O); 
1H NMR (500 MHz, CDCl3) δ 7.20 – 7.15 (m, 2H), 6.70 (tt, J = 7.3, 1.1 Hz, 1H), 6.64 
– 6.60 (m, 2H), 3.74 – 3.66 (m, 2H), 3.16 (t, J = 6.6 Hz, 2H), 1.77 – 1.65 (m, 4H) ppm; 
13C NMR (126 MHz, CDCl3) δ 148.5, 129.4, 117.6, 113.1, 62.8, 44.0, 30.5, 26.3 ppm; 
IR (cm−1) 3341, 2934, 2862, 1601, 1504, 1321, 1256, 1055; 




6.2.5 Experimental Procedure for Compound 3.28 
 
2-(4-aminophenyl)ethanol 2.15 (1.77 g, 12.8 mmol), ethyl 4-bromobutanoate 2.46 
(0.774 mL, 5.15 mmol), iPr2Net (3.59 mL, 20.6 mmol) were dissolved in anhydrous 
CH3CN (20 mL) at room temperature.  NaI (1.16 g, 7.73 mmol) was added and the 
solution heated to reflux for 4 hours, until TLC analysis showed complete consumption 
of starting material.  The reaction mixture was then cooled to room temperature, water 
(40 mL) added and extracted with EtOAc (4 × 20 mL).  The organic fractions were 
combined, washed with brine, dried over Na2SO4 and concentrated under reduced 
pressure.  Flash chromatography (silica gel, 2:1 petroleum ether/EtOAc) gave 
compound 3.28 (0.807 g, 3.21 mmol, 63 % yield) as a pale yellow solid. 
1H NMR (500 MHz, Chloroform-d) δ 7.03 (d, J = 8.5 Hz, 2H), 6.57 (d, J = 8.4 Hz, 
2H), 4.13 (q, J = 7.1 Hz, 2H), 3.78 (t, J = 6.6 Hz, 2H), 3.16 (t, J = 6.9 Hz, 2H), 2.75 
(t, J = 6.6 Hz, 2H), 2.41 (t, J = 7.2 Hz, 2H), 1.94 (p, J = 7.1 Hz, 2H), 1.25 (t, J = 7.2 
Hz, 3H) ppm; 
13C NMR (126 MHz, CDCl3) δ 173.5, 146.9, 130.0, 127.0, 113.1, 64.1, 60.6, 43.6, 
38.4, 32.1, 24.8, 14.3 ppm; 
IR (cm−1) 3379, 3298, 2982, 2934, 2868, 2820, 1722, 1612, 1522, 1479, 1281, 1177, 
1016; 
HRMS (EI+) 251.1519 (calculated [M]+: 251.1521); 




6.2.6 Experimental Procedure for Compound 3.32 
 
2-(4-aminophenyl)ethanol 2.15 (0.200 g, 1.46 mmol), ), iPr2NEt (0.64 mL, 3.2 mmol), 
NaI (0.55 g, 3.6 mmol) were dissolved in anhydrous CH3CN (10 mL) at room 
temperature.  1,4-dibromobutan-2-ol 3.33 (0.44 mL, 3.2 mmol) was added and the 
solution heated to reflux.  After 19 hours, when TLC analysis showed complete 
consumption of starting material, the reaction mixture was cooled to room 
temperature, water (25 mL) added and extracted with EtOAc (3 × 25 mL).  The organic 
fractions were combined, dried over Na2SO4 and concentrated under reduced pressure 
to give a dark brown oil.  Flash chromatography (alumina, CH2Cl2 + 3% MeOH) gave 
1-(4-(2-hydroxyethyl)phenyl)pyrrolidin-3-ol 3.32 (0.250 g, 1.21 mmol, 83% yield) as 
a brown solid. 
1H NMR (601 MHz, CDCl3) δ 7.09 (d, J = 8.5 Hz, 2H), 6.54 (d, J = 8.5 Hz, 2H), 
4.57 (tt, J = 5.0, 2.5 Hz, 1H), 3.79 (t, J = 6.6 Hz, 2H), 3.51 – 3.45 (m, 2H), 3.32 (td, J 
= 8.8, 3.6 Hz, 1H), 3.27 – 3.22 (m, 1H), 2.77 (t, J = 6.6 Hz, 2H), 2.16 (dtd, J = 13.5, 
8.6, 5.0 Hz, 1H), 2.08 – 2.01 (m, 1H), 1.90 (s, 1H), 1.58 – 1.47 (m, 1H) ppm; 
13C NMR (151 MHz, CDCl3) δ 146.7, 129.9, 125.6, 112.3, 71.5, 64.2, 56.6, 45.9, 
38.3, 34.4 ppm; 
IR (cm−1) 3292, 2938, 2920, 2851, 1612, 1518, 1371, 1175, 1101, 1043; 
HRMS (ESI+) 208.1338 (calculated [M+H]+ 208.1332); 




6.2.7 Experimental Procedure for Compounds 3.21 and 3.22 
 
Pyrroline 3.21 and trimer 3.22 were prepared according to the procedure described by 
Nomura.89 
Pyrrolidine 3.41 (5.87 mL, 70.3 mmol), AgNO3 (0.059 g, 0.35 mmol) and NaOH (5.62 
g, 141 mmol) were added to water (75 mL) at room temperature.  The resulting mixture 
was cooled to 0 °C and solution of Na2S2O8 (16.74 g, 70.3 mmol) in H2O (50 mL) was 
added dropwise with vigorous stirring.  After 3.5 hours, saturated aqueous Na2S2O3 
(50 mL) was added and the mixture extracted with CH2Cl2 (3 × 100 mL).  The organic 
fractions were combined, washed with brine, dried over Na2SO4 and concentrated 
under reduced pressure to give dark yellow oil.  Flash chromatography (neutral 
alumina, Et2O), gave the pyrroline 3.21 and trimer 3.22 as an inseparable mixture 
(0.995 g, 14.4 mmol, 20% yield).  All data matched literature values.84,89 
1H NMR (400 MHz, D2O) δ 7.68 (s, 1H, monomer), 3.76 (ddq, J = 9.8, 7.1, 2.3 Hz, 
2H, monomer), 3.19 (t, J = 6.4 Hz, 1H, trimer), 2.93 (td, J = 8.8, 5.0 Hz, 1H, trimer), 
2.58 (tt, J = 8.8, 1.9 Hz, 2H, monomer), 2.44 (td, J = 9.1, 6.4 Hz, 1H, trimer), 2.02 – 
1.91 (m, 2H, trimer), 1.82 (dt, J = 15.4, 8.1 Hz, 2H, monomer), 1.77 – 1.65 (m, 2H, 
trimer) ppm; 
1H NMR (601 MHz, CDCl3) δ 7.59 (tt, J = 2.4, 1.1 Hz, 1H, monomer), 3.88 – 3.79 
(m, 2H, monomer), 3.04 – 2.95 (m, 6H, trimer), 2.52 (ddtd, J = 8.4, 7.3, 2.2, 1.1 Hz, 
2H, monomer), 2.31 (td, J = 8.6, 6.3 Hz, 3H, trimer), 1.91 – 1.82 (m, 6H, monomer + 
trimer), 1.81 – 1.66 (m, 8H, trimer) ppm; 
13C NMR (151 MHz, CDCl3) δ 167.0 (monomer), 82.2 (trimer), 61.4 (monomer), 46.0 




6.2.8 Experimental Procedure for Compound 3.43 
 
P-quinol 1.43 (0.100 g, 0.373 mmol), was dissolved in CHCl3 (2.0 mL).  A mixture of 
pyrroline 3.21 and trimer 3.22 (0.031 g, 0.37 mmol) was added and the mixture heated 
to reflux.  After 4 days, the reaction mixture was cooled to room temperature and 
concentrated under reduced pressure.  Flash chromatography (silica gel, 1:2 petroleum 
ether/EtOAc) gave compound 3.43 (0.044 g,  mmol, 35% yield) as a white solid. 
Rf 0.20 (1:2 petroleum ether:EtOAc); 
1H NMR (500 MHz, CDCl3) δ 6.52 (dd, J = 10.3, 1.7 Hz, 1H), 6.07 (dd, J = 10.3, 
0.8 Hz, 1H), 4.76 (dd, J = 4.3, 2.3 Hz, 1H), 3.83 (ddd, J = 10.5, 6.2, 5.3 Hz, 1H), 
3.76 (ddd, J = 10.6, 7.2, 5.1 Hz, 1H), 3.23 (td, J = 3.2, 1.7 Hz, 1H), 2.95 (ddd, J = 
11.0, 8.1, 6.1 Hz, 1H), 2.71 – 2.68 (m, 1H), 2.68 – 2.64 (m, 2H), 2.07 – 1.92 (m, 2H), 
1.88 – 1.76 (m, 3H), 1.70 – 1.62 (m, 1H), 0.87 (s, 9H), 0.04 (d, J = 1.2 Hz, 6H) ppm; 
13C NMR (126 MHz, CDCl3) δ 198.1, 149.1, 130.7, 96.1, 81.0, 69.1, 58.5, 55.3, 40.8, 
39.7, 32.2, 26.0, 23.7, 18.3, −5.3 ppm; 
IR (cm−1) 2951, 2928, 2878, 2855, 1680, 1472, 1360, 1252, 1093; 
HRMS (ESI+) 338.2166 (calculated [M+H]+: 338.2146); 
M.p. 50-52 °C.  
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6.2.9 Experimental Procedure for Compound 3.46 
 
Aniline 3.26 (1.00 mL, 10.7 mmol), iPr2NEt (5.60 mL, 32.1 mmol), NaI (4.15 g, 26.8 
mmol) were dissolved in anhydrous MeCN (40 mL) at room temperature under an N2 
atmosphere.  Allyl bromide (1.95 mL, 22.5 mmol) was then added and the solution 
heated to 60 °C.  The reaction mixture was stirred at 60 °C for 2 hours, until TLC 
analysis showed complete consumption of starting material, then cooled to room 
temperature.  Water (100 mL) was added, and the resulting mixture extracted with 
EtOAc (3 × 100 mL).  The organic fractions were combined, washed with brine, dried 
with Na2SO4 and concentrated under reduced pressure to give a brown oil.  Flash 
chromatography (silica gel, 9:1 petroleum ether/Et2O) gave N,N-diallylaniline 3.46 as 
a colourless oil (1.28 g, 7.39 mmol, 69 % yield).  All data matched literature values.132 
1H NMR (500 MHz, CD2Cl2) δ 7.20 – 7.13 (m, 2H), 6.73 – 6.68 (m, 2H), 6.65 (tt, J = 
7.2, 1.1 Hz, 1H), 5.89 (ddt, J = 17.2, 10.1, 4.9 Hz, 2H), 5.21 – 5.14 (m, 4H), 3.93 (dt, 
J = 4.9, 1.8 Hz, 4H) ppm; 





6.2.10 Experimental Procedure for Compound 3.44 
 
Diallyl aniline 3.46 (0.200 g, 1.15 mmol) was dissolved in anhydrous CH2Cl2 (4 mL) 
at room temperature under an N2 atmosphere.  Grubbs’ 1
st generation catalyst (0.048 
g, 0.058 mmol, 5 mol%) was added and the resulting solution stirred at room 
temperature.  After 60 minutes additional Grubbs’ catalyst (0.010 g, 0.012 mmol) was 
added.  After 75 minutes, when TLC analysis showed complete consumption of 
starting material, petroleum spirit (10 mL) was added and the resulting suspension 
filtered through celite.  The filtrate was concentrated under reduced pressure to give 
1-phenyl-2,5-dihydro-1H-pyrrole 3.44 (0.085 g, 0.59 mmol, 51% yield) which was 
used without further purification. 
1H NMR (600 MHz, CD2Cl2); δ 7.24 – 7.20 (m, 2H), 6.65 (tt, J = 7.3, 1.1 Hz, 1H), 
6.53 (dd, J = 8.8, 1.1 Hz, 2H), 5.97 (s, 2H), 4.09 (s, 4H) ppm; 
13C NMR (151 MHz, CD2Cl2); δ 147.8, 129.7, 126.9, 116.0, 111.7, 55.0 ppm; 
IR (cm−1) 3059, 3042, 2851, 2822, 1628, 1598, 1568, 1504, 1466, 1360, 1184; 
HRMS (ESI+) 146.0965 (calculated [M+H]+ 146.0964); 





6.2.11 Alternative Experimental Procedure for Model Compound 3.44 
 
Aniline 3.26 (1.96 mL, 21.5 mmol), iPr2NEt (7.79 mL, 44.8 mmol), NaI (1.34 g, 8.95 
mmol) and a trace amount (~1-2 mg) BHT were dissolved in anhydrous MeCN (40 
mL) at room temperature under an N2 atmosphere.  The solution was heated to reflux 
with stirring then cis-1,4-dichlorobutene 3.51 (1.19 mL, 19.9 mmol) was added 
dropwise over approximately 10 minutes.  The reaction mixture was stirred at reflux 
for 45 minutes, until TLC analysis showed complete consumption of the 1,4-
dichlorobutene, then cooled to room temperature.  Water (150 mL) was added, and the 
resulting mixture extracted with EtOAc (5 × 100 mL).  The organic fractions were 
combined, washed with brine, dried with Na2SO4 and concentrated under reduced 
pressure to give a brown solid.  Flash chromatography (silica gel, neutralised with 
Et3N, 4:1 petroleum ether/CH2Cl2 with a trace amount of BHT) gave 1-phenyl-2,5-
dihydro-1H-pyrrole 3.44 as a pale brown solid (1.42 g, 9.78 mmol, 55% yield); 
1H NMR (600 MHz, CD2Cl2); δ 7.24 – 7.20 (m, 2H), 6.65 (tt, J = 7.3, 1.1 Hz, 1H), 
6.53 (dd, J = 8.8, 1.1 Hz, 2H), 5.97 (s, 2H), 4.09 (s, 4H) ppm; 
13C NMR (151 MHz, CD2Cl2); δ 147.8, 129.7, 126.9, 116.0, 111.7, 55.0 ppm; 
IR (cm−1) 3059, 3042, 2851, 2822, 1628, 1598, 1568, 1504, 1466, 1360, 1184; 
HRMS (ESI+) 146.0965 (calculated [M+H]+ 146.0964); 




6.2.12 Experimental Procedure for 1-Phenylpyrrolidine 3.48 
 
Aniline 3.26 (0.98 g, 10.7 mmol) dissolved in anhydrous MeCN (40 mL) at room 
temperature.  iPr2NEt (5.59 mL, 32.1 mmol), NaI (4.81 g, 32.1 mmol) and 1,4-
dibromobutane (1.92 mL, 16.5 mmol) were added and the mixture heated to reflux.  
After 2 days, the reaction mixture was cooled to room temperature, water (100 mL) 
added and extracted with EtOAc (3 × 60 mL).  The organic layers were combined, 
washed with brine, dried over Na2SO4 and concentrated under reduced pressure.  Flash 
chromatography (silica gel, 19:1 petroleum ether/Et2O) gave 1-phenylpyrrolidine 3.48 
(1.29 g, 8.77 mmol, 82% yield) as a yellow oil.  All data matched literature values.133 
1H NMR (500 MHz, CDCl3) δ 7.24 (dd, J = 8.8, 7.2 Hz, 2H), 6.68 (t, J = 7.3 Hz, 
1H), 6.59 (d, J = 8.1 Hz, 2H), 3.33 – 3.27 (m, 4H), 2.04 – 1.99 (m, 4H) ppm; 




6.2.13 Experimental Procedure for Compound 3.50 
 
2-(4-aminophenyl)ethanol 2.15 (5.00 g, 36.4 mmol), iPr2NEt (19.0 mL, 109 mmol), 
NaI (13.6 g, 91 mmol) were dissolved in anhydrous MeCN (150 mL) at room 
temperature under an N2 atmosphere.  Allyl bromide (6.62 mL, 76.5 mmol) was then 
added and the solution heated to 60 °C.  The reaction mixture was stirred at 60 °C for 
4.5 hours, until TLC analysis showed complete consumption of starting material, then 
cooled to room temperature.  Water (150 mL) was added, and the resulting mixture 
extracted with EtOAc (3 × 100 mL).  The organic fractions were combined, washed 
with brine, dried with Na2SO4 and concentrated under reduced pressure to give a dark 
yellow oil.  Flash chromatography (silica gel, 2:1 petroleum spirit/ETOAc) gave 2-(4-
(diallylamino)phenyl)ethanol 3.50 as a yellow oil (7.85 g, 36.1 mmol, 99% yield); 
1H NMR (500 MHz, CDCl3) δ 7.06 (d, J = 8.8 Hz, 2H), 6.67 (d, J = 8.7 Hz, 2H), 
5.86 (ddt, J = 17.2, 10.1, 4.9 Hz, 2H), 5.23 – 5.11 (m, 4H), 3.91 (dt, J = 4.9, 1.7 Hz, 
4H), 3.80 (tt, J = 6.4, 2.6 Hz, 2H), 2.76 (t, J = 6.5 Hz, 2H) ppm; 
13C NMR (126 MHz, CDCl3) δ 147.6, 134.2, 129.8, 125.8, 116.1, 112.8, 64.1, 53.0, 
38.3 ppm; 
IR (cm−1) 3354, 3076, 2928, 2860, 1614, 1519, 1387, 1233, 1179, 1043; 




6.2.14 Experimental Procedure for Compound 3.49 
 
Diallyl aniline 3.50 (0.300 g, 1.38 mmol) was dissolved in anhydrous CH2Cl2 (4 mL) 
at room temperature under an N2 atmosphere.  Grubbs 1
st generation catalyst (0.057 g, 
0.069 mmol, 5 mol%) was added and the resulting solution stirred at room temperature.  
After 1.25 hours, additional Grubbs catalyst (0.012 g, 0.015 mmol) was added.  After 
1.75 hours, when TLC analysis showed complete consumption of starting material, the 
reaction mixture was concentrated under reduce pressure and directly purified.  Flash 
chromatography (silica gel, 2:1 petroleum spirit/EtOAc + trace BHT) gave 2-(4-(2,5-
dihydro-1H-pyrrol-1-yl)phenyl)ethan-1-ol 3.49 (0.166 g, 0.877 mmol, 64% yield). 
Rf 0.20 (CH2Cl2); 
1H NMR (500 MHz, CDCl3); δ 7.12 (d, J =8.6 Hz, 2H), 6.51 (d, J = 8.6 Hz, 2H), 
5.95 (s, 2H), 4.10 (s, 4H), 3.81 (q, J =6.5 Hz, 2H), 2.78 (t, J = 6.5 Hz, 2H), 1.39 (t, J 
= 6.0 Hz, 1H) ppm; 
13C NMR (126 MHz, CDCl3); δ 146.1, 130.1, 126.6, 125.0, 111.5, 64.2, 54.7, 38.4 
ppm; 
IR (cm−1) 3302(br), 2922, 2849, 2824, 1626, 1612, 1522, 1474, 1362, 1188, 1043, 
1015, 1003; 
HRMS (ESI+) 190.1240 (calculated [M+H]+ 190.1226); 





6.2.15 Experimental Procedure for Isomerisation of Compound 3.49 
 
2-(4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl)ethan-1-ol 3.49 (0.026 g, 0.138 mmol) and 
Rh(H)(CO)(PPh3)3 (5 mol%, 0.006 g, 0.007 mmol) were placed in an NMR tube fitted 
with a J Young tap.    The tube was evacuated and flushed with N2 three times then, 
degassed, anhydrous CD2Cl2 (0.5 mL) was added, the tube sealed and heated to 40 °C.  
After 3 hours, when 1H NMR analysis showed complete consumption of starting 
material, the reaction mixture was concentrated under reduced pressure.  Flash 
chromatography (silica gel, 97:3 CHCl3/MeOH) gave compounds 2.7a and 2.7b as a 
1:1 mixture (0.009 g, 0.02 mmol, 17% yield).  Data matched that previously reported 





6.2.16 Experimental Procedure for Compound 3.53 
 
 
2-(4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl)ethan-1-ol 3.49 (0.200 g, 1.06 mmol) and 
imidazole (0.080 g, 1.16 mmol) were dissolved in anhydrous THF (3 mL) at room 
temperature under an N2 atmosphere.  TBSCl (0.175 g, 1.16 mmol) was added with 
stirring at room temperature.  After 1.5 hours, additional imidazole (0.014 g) and 
TBSCl (0.032 g) were added.  After 2.5 hours, when TLC analysis showed complete 
consumption of starting material, Et2O (10 mL) and saturated aqueous NH4Cl (5 mL) 
were added, the organic fraction separated and the aqueous fraction extracted with 
Et2O (2 × 10 mL).  The organic fractions were combined, dried over Na2SO4 and 
concentrated under reduced pressure to give a pale yellow solid.  Flash 
chromatography (silica gel, 19:1 petroleum ether/Et2O) gave OTBS 2-(4-(2,5-dihydro-
1H-pyrrol-1-yl)phenyl)ethanol 3.53 as a white solid (0.270 g, 0.890 mmol, 84% yield). 
1H NMR (500 MHz, CD2Cl2) δ 7.07 (d, J = 8.5 Hz, 2H), 6.46 (d, J = 8.5 Hz, 2H), 
5.96 (s, 2H), 4.07 (s, 4H), 3.73 (t, J = 7.2 Hz, 2H), 2.70 (t, J = 7.2 Hz, 2H), 0.89 (s, 
9H), 0.02 (s, 6H) ppm; 
13C NMR (126 MHz, CD2Cl2) δ 146.4, 130.4, 127.0, 126.5, 111.6, 65.6, 55.1, 39.3, 
26.3, 18.8, −5.1 ppm; 
IR (cm−1) 2953, 2928, 2855, 2822, 1626, 1614, 1524, 1472, 1373, 1361, 1254, 1188, 
1088; 
HRMS (ESI+) 304.2127 (calculated [M+H]+ 304.2091); 




6.2.17 Experimental Procedure for Model Compound 3.54 
 
Compound 3.53 (0.020 g, 0.066 mmol) and Rh(H)(CO)(PPh3)3 (5 mol%, 0.0030 g, 
0.0033 mmol) were placed in an NMR tube fitted with a J Young tap.  The tube was 
evacuated and flushed with N2 three times then, degassed, anhydrous CD2Cl2 was 
added, the tube sealed and the reaction monitored by 1H NMR at room temperature.  
After 4 hours 1H NMR analysis indicated complete conversion to the desired 1-(4-(2-
(OTBS)ethyl)phenyl)-2,3-dihydro-1H-pyrrole 3.54  All attempts to isolate the product 
led to decomposition, so Compound 3.54 was characterised in-situ using 1D and 2D 
NMR spectrometry; 
1H NMR (601 MHz, CD2Cl2) δ 7.07 (d, J = 8.6 Hz, 2H), 6.69 (dt, J = 4.2, 2.1 Hz, 1H), 
6.65 (d, J = 8.6 Hz, 2H), 4.96 (dt, J = 4.2, 2.6 Hz, 1H), 3.75 (t, J = 7.1 Hz, 2H), 3.65 
(dd, J = 10.0, 9.1 Hz, 2H), 2.73 – 2.68 (m, 4H), 0.89 (s, 9H), 0.02 (s, 6H) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 143.4, 132.3, 130.5, 128.8, 112.6, 103.3, 65.4, 





6.2.18 Experimental Procedure for Model p-quinol 3.55 
 
p-quinol 3.55 was prepared according to the procedure described by Novak.96 
p-cresol (2.04 g, 18.5 mmol) was dissolved in MeCN (68 mL) and H2O (60 mL) at 
room temperature.  The solution was cooled to 0 °C and PhI(OAc)2 (6.56 g, 20.3 
mmol) was added portion-wise with vigorous stirring at room temperature.  After 1 
hour, when TLC analysis showed complete consumption of starting material, 
saturated aqueous Na2SO3 (40 mL) was added and the resulting mixture extracted 
with EtOAc (3 × 100 mL).  The organic layers were combined, washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure to give a brown oil.  
Flash chromatography (silica gel 230-400 mesh, 2:1 → 1:1 petroleum ether/EtOAc) 
gave 4-hydroxy-4-methylcyclohexa-2,5-dien-1-one 3.55 (1.54 g, 12.4 mmol, 67% 
yield) as an orange solid.  All data matched literature values.96 
1H NMR (601 MHz, CDCl3) δ 6.87 (d, J = 10.1 Hz, 2H), 6.11 (d, J = 10.1 Hz, 2H), 
2.45 (s, 1H), 1.47 (s, 3H) ppm; 




6.2.19 Experimental Procedure for Compound 3.62 
 
[Ru(bpy)3](PF6)2 was prepared according to the procedure described by Yoon.
99 
Ru(bpy)3Cl2.6H2O (0.100 g, 0.134 mmol) was dissolved in EtOH (5 mL) at room 
temperature.  KPF6 (0.098 g, 0.53 mmol) was added and the resulting mixture stirred 
at room temperature.  After 1 hour, the reaction mixture was filtered, the solid collect, 
washed with water and dried to give [Ru(bpy)3](PF6)2 (0.044 g, 0.052 mmol, 39% 
yield.  All data matched literature values.134 
1H NMR (500 MHz, DMSO-d6) δ 8.83 (d, J = 8.0 Hz, 6H), 8.17 (td, J = 8.0, 1.4 Hz, 
6H), 7.73 (dd, J = 5.6, 0.7 Hz, 6H), 7.53 (ddd, J = 7.1, 5.7, 1.3 Hz, 6H) ppm; 




6.2.20 Experimental Procedure for Compound 3.64 
 
Methyl viologen bis(hexafluorophosphate) 3.64 was prepared according to the 
procedure described by Yoon.99 
Methyl viologen chloride 3.64a (1.00 g, 3.89 mmol) was dissolved in water (8 mL) at 
room temperature.  KPF6 (1.93 g, 10.5 mmol) and the resulting solution stirred at room 
temperature.  After 2 hours the reaction mixture was filtered, the solid collected, 
washed with water (2 × 50 mL) and dried to give MV(PF6)2 3,64 (1.72 g, 3.61 mmol, 
93 % yield) as a white solid.  All data matched literature values.99 
1H NMR (500 MHz, DMSO-d6) δ 9.27 (d, J = 6.8 Hz, 4H), 8.74 (d, J = 6.7 Hz, 4H), 
4.43 (s, 6H) ppm; 




6.2.21 Experimental Procedure for Compound S1 
 
Bipyrazine S1 was prepared according to the procedure described by Yoon.100 
2-chloropyrazine S2 (5.00 g, 43.7 mmol) was dissolved in DMF (42 mL) at room 
temperature.  Pd(PPh3)4 (1.50 g, 1.30 mmol), Bu4NBr (14.0 g, 43.4 mmol) and K2CO3 
(20.5 g, 148.3 mmol) were added, the mixture heated to 140 °C and stirred open to air 
for 18 hours.  The reaction mixture was then cooled to room temperature and filtered 
through celite, washing with CH2Cl2.  The filtrate was washed with water (300 mL, 
then 100 mL).  The aqueous fractions were extracted with CH2Cl2 (3 × 100 mL).  The 
organic fractions were combined, washed with brine, dried over MgSO4 and 
concentrated under reduced pressure to give a brown oil.  Flash chromatography (silica 
gel, 1:1 petroleum ether/EtOAc) gave a yellow solid which was washed with MeOH 
to give bipyrazine S1 (0.791 g, 5.00 mmol, 11 % yield) as a white crystalline solid.  
All data matched literature values.135 
1H NMR (500 MHz, CDCl3) δ 9.60 (d, J = 1.1 Hz, 2H), 8.66 (d, J = 1.2 Hz, 4H) 
ppm; 




6.2.22 Experimental Procedure for Compound 3.61a 
 
Ru(bpz)2Cl2 3.61a was prepared according to the procedure described by Rillema.
136 
RuCl3.3H2O (0.261 g, 1.00 mmol) was dissolved in ethylene glycol (20 mL) at room 
temperature.  Bipyrazine S1 (0.554 g, 3.50 mmol) was added and the mixture heated 
to reflux for 1.5 hours.  The reaction mixture was then cooled to room temperature, 
acetone (200 mL) added, then placed in the freezer for 1 hour, until precipitate formed.  
The suspension was filtered, the solid collect, washed with acetone and dried.  The 
filtrated was concentrated under reduced pressure, iPrOH (70 mL) added and placed 
in the freezer over night to give a second batch of crystals which were collected, 
washed with acetone and dried.  Both batches of crystals were combined to give 
Ru(bpz)2Cl2 3.61a (0.431 g, 0.667 mmol, 67 % yield) as a dark brown solid.  All data 
matched literature values. 
1H NMR (500 MHz, DMSO) δ 10.15 (s, 1H), 8.71 (d, J = 3.2 Hz, 1H), 8.00 (d, J = 
3.2 Hz, 1H) ppm; 




6.2.23 Experimental Procedure for Compound S3 
 
NaBArF24 S3 was prepared according to the procedure described by Bergman.
137 
1-bromo-3,5-bis(trifluoromethyl)benzene S4 (25.0 mL, 145 mmol) was dissolved in 
dry THF under an N2 atmosphere.  The resulting solution was cooled to −20 °C and 
iPrMgCl (80.0 mL, 2.0 M in THF 160 mmol) was added dropwise at −20 °C over ~1.5 
hours with stirring.  The reaction mixture was allowed to warm to 5 °C over 1 hour, 
then NaBF4 (2.68 g, 24.0 mmol) was added quickly and the resulting mixture allowed 
to warm to room temperature.  After 46 hours the reaction mixture was poured into a 
stirred solution of Na2CO3 (44 g) and NaHCO3 (20 g) in water (600 mL) and the 
resulting yellow suspension stirred for 1 hour at room temperature then extracted with 
Et2O (4 × 200 mL).  The organic fractions were combined, washed with brine (100 
mL), dried over Na2SO4, concentrated under reduced pressure and dried at 100 °C at 
0.1 mbar for 4 hours.  The crude material was washed with CH2Cl2 at −78 °C to give 
NaBArF24 S3 (2.25 g, 2.54 mmol, 11 % yield) as a fine white powder.  All data 
matched literature values.137 
1H NMR (400 MHz, Acetone-d6) δ 7.79 (p, J = 2.2 Hz, 8H), 7.67 (s, 4H) ppm; 
13C NMR (126 MHz, Acetone-d6) δ 162.6 (q, J = 49.9 Hz), 135.6, 130.1 (qdd, J = 
31.9, 5.9, 2.9 Hz), 125.4 (q, J = 271.8 Hz) 118.5 (p, J = 4.1 Hz) ppm; 




6.2.24 Experimental Procedure for Compound 3.61b 
 
Ru(bpz)3(BArF24)2 3.61b was prepared according to the procedure described by 
Yoon.100 
Ru(bpz)3Cl2 3.61a (0.199 g, 0.309 mmol) was dissolved in H2O (15 mL) at room 
temperature. A solution of NaBArF24 S3 (0.602 g, 0.681 mmol) in MeOH (5 mL) was 
added, followed by H2O (5 mL).  The resulting mixture was stirred at room 
temperature for 45 minutes, then filtered to give a dark brown solid.  The crude 
material was dissolved in CH3CN, filtered through a short plug of basic alumina and 
recrystallised from CH2Cl2/benzene to give Ru(bpz)3(BArF24)2 3.61b (0.340 g, 0.148 
mmol, 48% yield) as an orange solid.  All data matched literature values.100 
1H NMR (601 MHz, CD3CN) δ 9.78 (d, J = 1.2 Hz, 6H), 8.65 (d, J = 3.2 Hz, 6H), 
7.82 (dd, J = 3.2, 1.2 Hz, 6H), 7.69 (p, J = 2.0 Hz, 16H), 7.67 (s, 8H) ppm; 
13C NMR (151 MHz, CD3CN) δ 162.6 (q, J = 49.8 Hz), 151.3, 149.8, 148.1, 146.4, 




6.2.25 Experimental Procedure for Compound 3.72 
 
1-phenyl-2,5-dihydro-1H-pyrrole 3.44 (20 mg, 0.138 mmol) was placed in an NMR 
tube fitted with a J Young valve.  The tube was evacuated and flushed with N2 three 
times, then a solution of durene in degassed, anhydrous CD2Cl2 (0.275 M, 0.5 mL, 
0.138 mmol) was added followed by anhydrous, degassed pyrrolidine (12 μL, 0.145 
mmol).  An initial 1H NMR spectrum was recorded, then Rh(H)(CO)(PPh3)3 (63 mg, 
7 μmol, 5 mol%) was added, the tube sealed and heated to 40 ºC for 65 minutes until 
1H NMR analysis showed complete conversion to the desired 1ʹ-phenyl-1,2ʹ-
bipyrrolidine 3.72 (see 6.6.3, for spectra).  All attempts to isolate the product led to 
decomposition, so 1ʹ-phenyl-1,2ʹ-bipyrrolidine 3.72 was characterised in-situ using 1D 
and 2D NMR (see 6.6.4, 6.6.5); 
1H NMR (500 MHz,CD2Cl2) δ 7.24 – 7.19 (m, 2H), 6.88 – 6.84 (m, 2H), 6.70 (tt, J = 
7.3, 1.2 Hz, 1H), 4.69 (dd, J = 7.2, 1.2 Hz, 1H), 3.57 (ddd, J = 8.3, 7.2, 2.2 Hz, 1H), 
3.16 – 3.09 (m, 1H), 2.68 (td, J = 8.2, 4.7 Hz, 2H), 2.60 (pd, J = 5.2, 4.4, 2.4 Hz, 2H), 
2.17 – 1.98 (m, 3H), 1.84 – 1.69 (m, 5H) ppm; 
13C NMR (126 MHz, CD2Cl2) δ 148.9, 131.5, 116.7, 113.4, 75.9, 49.1, 47.7, 26.3, 




6.2.26 Experimental Procedure for Model Compound 3.73 
 
Dihydropyrrole 3.44 (0.020 g, 0.138 mmol) placed in an NMR tube fitted with a J 
Young valve.  The tube was evacuated and flushed with N2 three times, then a 
solution of durene in anhydrous, degassed CD2Cl2 (0.275 M, 0.5 mL, 0.138 mmol) 
was added followed by anhydrous MeOH (6.0 μL, 0.14 mmol).  Initial 1H NMR 
spectrum recorded, then Rh(H)(CO)(PPh3)3 (6 mg, 7 μmol, 5 mol%) was added, the 
tube sealed and heated to 40 ºC.  After 1.5 hours, when 1H NMR analysis showed 
quantitative conversion to the desired product, 2-methoxy-1-phenylpyrrolidine 3.73, 
the reaction mixture was cooled to room temperature and was characterised in-situ 
by 1D and 2D NMR spectroscopy.  
1H NMR (601 MHz, CD2Cl2) δ 7.32 – 7.20 (m, 2H), 6.78 (tt, J = 7.5, 1.2 Hz, 1H), 
6.75 (dd, J = 8.8, 1.1 Hz, 2H), 4.94 (d, J = 5.3 Hz, 1H), 3.53 – 3.48 (m, 1H), 3.32 (s, 
3H), 3.28 – 3.21 (m, 1H), 2.18 – 2.11 (m, 2H), 2.05 – 1.99 (m, 1H), 1.94 – 1.86 (m, 
1H); 





6.2.27 Experimental Procedure for Model Cross-dimerisation  
 
Dihydropyrrole 3.44 (0.101 g, 0.689 mmol) was placed in a single neck Schlenk flask.  
The flask was evacuated and flushed with N2 three times.  Degassed, anhydrous 
CD2Cl2 (2.5 mL) and degassed anhydrous pyrrolidine (0.064 mL, 0.76 mmol) were 
added, followed by Rh(H)(CO)(PPh3)3 (5 mol%, 0.032 g, 0.035 mmol), the flask 
sealed and heated to 40 ºC with stirring.  After 2 hours, when 1H-NMR analysis showed 
complete conversion of starting material to aminal 3.72, the solution was cooled to 
room temperature, water (25 μL) added followed by p-quinol 3.55 (0.257 g, 2.07 
mmol), the tube re-sealed and stirred at room temperature.  After 18 hours at room 
temperature, when 1H-NMR analysis indicated consumption of aminal 3.72, the 
solvent was removed under reduced pressure to give a brown oil.  The crude was 
triturated with Et2O to give the quinol dimer 3.74 as a brown solid (0.116 g, 0.465 
mmol, 23% yield).  The Et2O soluble fraction was purified by flash chromatography 
(silica gel 19:1 → 1:1 petroleum ether/EtOAc) to give the cross-dimer 3.56b (0.069 g, 
0.26 mmol, 37% yield) as a yellow oil, along with a mixture of  homo-dimers 2.26 and 
2.27 1:1.3 ratio (0.021 g, 0.072 mmol, 21% combined yield). 
Quinol dimer 3.74 
Rf 0.21 (2:1 Petroleum Ether/EtOAc);  
1H NMR (500 MHz, CDCl3) δ 6.74 (d, J = 10.2 Hz, 1H), 6.20 (d, J = 10.1 Hz, 1H), 
3.97 (dt, J = 5.2, 0.9 Hz, 1H), 3.38 (dd, J = 5.2, 4.2 Hz, 1H), 3.11 (s, 1H), 2.92 – 2.81 
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(m, 1H), 2.72 – 2.67 (m, 1H), 2.65 – 2.59 (m, 1H), 2.49 (ddd, J = 20.0, 3.2, 1.2 Hz, 
1H), 2.29 (dd, J = 20.0, 3.0 Hz, 1H), 1.49 (s, 3H), 1.17 (s, 3H) ppm;  
13C NMR (126 MHz, CDCl3) δ 210.0, 196.7, 147.0, 130.1, 83.4, 77.4, 72.3, 56.2, 45.4, 
45.4, 44.4, 43.8, 28.0, 26.6 ppm; 
IR (cm-1) 3431 (br), 2928, 1713, 1669, 1516, 1443, 1379, 1277; 
HRMS (EI+) 248.10379 (calculated [M]+ 248.10431); 
Homo-dimers 2.26 and 2.27 
Data for the mixture of 2.26 and 2.27 matched literature values.59 
Rf 0.65 (4:1 Petroleum Ether/EtOAc); 
1H NMR (500 MHz, CDCl3) δ 7.34 (dt, J = 7.7, 1.3 Hz, 1H), 7.32 – 7.27 (m, 3H), 
7.27 – 7.23 (m, 2H), 7.21 (tt, J = 7.8, 1.3 Hz, 1H), 7.14 (dt, J = 7.5, 1.4 Hz, 1H), 7.13 
– 7.09 (m, 1H), 6.87 – 6.82 (m, 3H), 6.80 (dd, J = 7.5, 1.1 Hz, 1H), 6.76 (tt, J = 7.3, 
1.1 Hz, 1H), 6.72 (tt, J = 8.7, 1.2 Hz, 4H), 6.54 (td, J = 7.5, 1.2 Hz, 1H), 6.42 (dd, J 
= 8.1, 1.2 Hz, 1H), 5.14 (d, J = 6.9 Hz, 1H), 4.48 (d, J = 9.1 Hz, 1H), 3.75 (ddd, J = 
10.8, 5.2, 3.2 Hz, 1H), 3.68 (ddd, J = 9.2, 7.8, 1.4 Hz, 1H), 3.47 (dtd, J = 10.5, 9.0, 
2.1 Hz, 3H), 3.42 – 3.25 (m, 5H), 2.89 (td, J = 9.2, 8.0 Hz, 1H), 2.79 (ddt, J = 11.3, 
9.1, 7.0 Hz, 1H), 2.57 – 2.46 (m, 2H), 2.32 – 2.20 (m, 2H), 2.20 – 2.09 (m, 2H), 2.09 
– 1.93 (m, 5H), 1.93 – 1.67 (m, 5H) ppm; 
13C NMR (126 MHz, CDCl3) δ 149.3, 149.0, 147.3, 143.3, 129.4, 129.2, 128.9, 128.4, 
128.1, 127.3, 127.2, 123.1, 119.0, 116.6, 115.9, 115.5, 112.9, 112.2, 111.4, 110.4, 64.7, 
59.6, 57.6, 56.6, 49.3, 48.3, 47.5, 47.4, 46.7, 40.2, 32.1, 30.7, 30.3, 23.4, 23.3, 22.5 
ppm; 
Cross-dimer 3.56b 
1H NMR (500 MHz, CD2Cl2) δ 7.22 (dd, J = 8.8, 7.3 Hz, 2H, (H-2ʹ, H-6ʹ), 6.79 (dt, J 
= 7.7, 1.1 Hz, 2H, H-3ʹ, H-5ʹ), 6.76 (tt, J = 7.4, 1.1 Hz, 1H, H-1ʹ), 6.49 (dd, J = 10.3, 
1.7 Hz, 1H, H-6), 5.84 (d, J = 10.3 Hz, 1H, H-5), 5.74 (d, J = 6.3 Hz, 1H, H-1ʹʹ), 3.27 
(td, J = 9.1, 4.7 Hz, 1H, H-4ʹʹa), 3.23 – 3.17 (m, 1H, H-2ʹʹ), 3.14 (td, J = 8.6, 6.8 Hz, 
1H, H-4ʹʹb), 2.74 – 2.68 (m, 1H, H-2), 2.67 (d, J = 5.2 Hz, 2H, CH2-3), 1.98 (dddd, J 
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= 13.8, 10.4, 9.2, 6.7 Hz, 1H, H-3ʹʹa), 1.80 (ddt, J = 13.2, 8.1, 4.7 Hz, 1H, H-3ʹʹb), 
1.46 (s, 3H, CH3-7) ppm; 
13C NMR (126 MHz, CD2Cl2) δ 197.40 (C-4), 154.97 (C-6), 146.43 (C-4ʹ), 129.44 
(C-2ʹ, C-6ʹ), 126.83 (C-5), 118.21 (C-1ʹ), 113.99(C-3ʹ, C-5ʹ), 94.06 (C-1ʹʹ), 79.07 (C-
1), 48.46 (C-4ʹʹ), 47.80 (C-2ʹʹ), 46.61 (C-2), 36.29 (C-3), 26.43 (C-7), 24.46 (C-3ʹʹ) 
ppm; 
IR (cm-1) 2967, 2924, 2859, 1670, 1599, 1576, 1485, 1371, 1350, 995. 
HRMS (ESI+) 170.1431 (calculated [M+H]+ 170.1489); 




6.2.28 Experimental Procedure for Compound 3.74 
 
p-quinol 3.55 (0.100 g, 0.806 mmol) was dissolved in (CH2Cl)2 (4.0 mL) at room 
temperature.  Pyrrolidine (7 μL, 0.08 mmol) was added and the mixture heated to 70 
°C with stirring. After 20 hours, additional pyrrolidine (7 μL, 0.08 mmol) was added.  
After 48 hours, when TLC analysis showed complete consumption of the starting 
material the reaction mixture was concentrated under reduced pressure to give a brown 
solid. The crude solid was loaded onto a sintered funnel and washed with EtOAc (3 × 
20 mL). The solid was collected and purified by flash chromatography (silica gel 20:1 
CHCl3/MeOH) to yield compound 3.74 as a white solid (62.5 mg, 0.25 mmol, 63% 
yield). 
Rf 0.21 (2:1 Petroleum Ether 40-60/EtOAc);  
1H NMR (500 MHz, CDCl3) δ 6.74 (d, J = 10.2 Hz, 1H, H-3), 6.20 (d, J = 10.1 Hz, 
1H, H-4), 3.97 (dt, J = 5.2, 0.9 Hz, 1H, H-3ʹ), 3.38 (dd, J = 5.2, 4.2 Hz, 1H, H-2ʹ), 
3.11 (s, 1H, OH), 2.84 (dd, J = 9.8, 4.2 Hz, 1H, H-5ʹ), 2.72 – 2.67 (m, 1H, H-5ʹ), 2.65 
– 2.59 (m, 1H, H-6), 2.49 (ddd, J = 20.0, 3.2, 1.2 Hz, 1H, H-6ʹa), 2.29 (dd, J = 20.0, 
3.0 Hz, 1H, H-6ʹb), 1.49 (s, 3H, H-7), 1.17 (s, 3H, H-7ʹ) ppm;  
13C NMR (126 MHz, CDCl3) δ 210.0 (C-1ʹ), 196.7 (C-1), 147.0 (C-3), 130.1 (C-2), 
83.4 (C-3ʹ), 77.4 (C-4), 72.3 (C-4ʹ), 56.2 (C-2ʹ), 45.4 (C-6), 45.4 (C-5ʹ), 44.4 (C-6ʹ), 
43.8 (C-5), 28.0 (C-7), 26.6 (C-7ʹ) ppm; 
IR (cm-1) 3431 (br), 2928, 1713, 1669, 1516, 1443, 1379, 1277; 




6.2.29 Experimental Procedure for Compound 3.83 
 
Compound 28c was prepared following a two-step procedure described by Smith.102 
a)  4-hydroxyphenethyl alcohol 1.41 (1.00 g, 7.24 mmol, 1 mol. equiv.) was added in 
one portion to a stirred solution of TBSCl (2.76 g, 18.3 mmol, 2.5 mol. equiv.) and 
imidazole (1.24 g, 18.2 mmol, 2.5 mol. equiv.) in anhydrous DMF (10 mL) at room 
temperature under an N2 atmosphere. After 18 hours, when TLC analysis showed 
complete consumption of starting material, the reaction mixture was partitioned 
between H2O (30 mL) and hexane (50 mL) and the aqueous layer extracted with 
hexane (2 × 30 mL). The organic layers were combined, washed with H2O (20 mL), 
then brine (30 mL), dried over MgSO4, and concentrated under reduced pressure, 
yielding crude doubly-protected phenol 3.83a as a clear oil. The crude product was 
used directly for the next step without purification. 
b) To a solution of the crude TBS ether 3.83a in methanol (30 mL) was added I2 (279 
mg, 1.10 mmol) and the resulting solution stirred at room temperature. After 30 
minutes, when TLC analysis showed complete consumption of starting material, the 
reaction was quenched with aqueous 10% Na2S2O4 (15 mL). The resulting solution 
was concentrated under reduced pressure to remove the majority of the MeOH.  The 
residue was diluted with diethyl ether (200 mL), washed with H2O (50 mL), then brine 
(50 mL), dried over MgSO4 and concentrated under reduced pressure.  Flash 
chromatography (silica gel 3:7 EtOAc/petroleum ether), gave the alcohol 3.83 as a 
colourless oil (1.53 g, 6.04 mmol, 83% over two steps).  All data for 3.83 matched 
literature values.102 
1H NMR (400 MHz, CDCl3) δ 7.07 (d, J = 8.2 Hz, 2H), 6.78 (d, J = 8.2 Hz, 2H), 3.81 
(bs, 2H), 2.80 (t, J = 6.6 Hz, 2H), 1.42 (bs, 1H), 0.98 (s, 9H), 0.19 (s, 6H) ppm; 
13C NMR (100 MHz, CDCl3) δ 154.4 (Cq), 131.1 (Cq), 130.0 (CH), 120.3 (CH), 64.0 
(CH2), 38.5 (CH2), 25.8 (CH3), 18.3 (CH3), −4.3 (Cq) ppm; 
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IR (cm−1) 3368, 2859, 1509, 1252, 913, 836, 779; 




6.2.30 Experimental Procedure for Compound 3.13 
 
2-(4-((tert-butyldimethylsilyl)oxy)phenyl)ethanol 3.83 (0.425 g, 1.66 mmol) and 
glycosyl trichloroacetimidate 2.56 (1.00 g, 1.51 mmol) were dissolved in anhydrous 
CH2Cl2 (10 mL) under an N2 atmosphere and stirred over freshly ground and activated 
4Å molecular sieves (~1.5 g) for 1.5 hours. TMSOTf (0.27 mL, 1.51 mmol) was added 
dropwise at room temperature and the resulting solution stirred for 17 hours.  
Additional TMSOTf (0.27 mL, 1.51 mmol) was added.  After 19 hours, when TLC 
analysis showed complete consumption of starting material, 1M HCl (30 mL) was 
added.  The organic fraction was separated, washed with saturated aqueous NaHCO3 
(2 × 30 mL), then with brine, dried over Na2SO4 and concentrated under reduced 
pressure to give a brown oil.  Flash chromatography (silica gel  4:1 petroleum 
ether/EtOAc) gave 2-(4-hydroxyphenyl)ethanol 2,3,4,6-tetra O-pivaloyl 
glucopyranoside 3.13 as a pale yellow foaming amorphous solid (0.676 g, 1.06 mmol, 
70% yield). 
Rf 0.20 (4:1 petroleum ether:EtOAc); 
1H NMR (600 MHz, CDCl3); δ 7.03 (d, J = 8.5 Hz, 2H), 6.73 (d, J = 8.5 Hz, 2H), 
5.30 (t, J = 9.5 Hz, 1H), 5.10 (t, J = 9.7 Hz, 1H), 5.02 (dd, J = 9.7, 8.0 Hz, 1H), 4.92 
(s, 1H), 4.52 (d, J = 8.0 Hz, 1H), 4.21 (dd, J = 12.2, 1.9 Hz, 1H), 4.05 (dd, J = 12.2, 
5.8 Hz, 1H), 4.00 – 3.95 (m, 1H), 3.74 – 3.69 (m, 1H), 3.63 (dt, J = 9.5, 7.4 Hz, 1H), 
2.79 (td, J = 7.4, 7.0, 2.4 Hz, 2H), 1.21 (s, 9H), 1.15 (s, 9H), 1.11 (s, 9H), 1.10 (s, 
9H) ppm;  
13C NMR (151 MHz, CDCl3); δ 178.31, 177.43, 176.66, 176.64, 154.34, 130.36, 
130.17, 115.40, 101.19, 72.44, 72.41, 71.27, 70.95, 68.24, 62.18, 39.02, 38.91, 38.86, 
38.81, 35.45, 27.28, 27.25, 27.19, 27.12 ppm; 
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IR (cm−1); 3460, 2970, 2934, 2874, 1740, 1614, 1516, 1479, 1277, 1134, 1036; 









6.2.31 Experimental Procedure for Compound 3.12 
 
2-(4-hydroxyphenyl)ethanol 2,3,4,6-tetra O-pivaloyl glucopyranoside 3.13 (2.98 g, 
4.69 mmol) was dissolved in MeCN (70 mL) and water (20 mL) at room temperature.  
The solution was cooled to 0 °C and phenyliodide diacetate (1.66 g, 5.15 mmol) added 
portion-wise over ~10 minutes with vigorous stirring.  The reaction was stirred at 0 °C 
for 20 minutes until TLC analysis showed complete consumption of starting material, 
then saturated aqueous NaSO3 (20 mL) was added and the resulting mixture extracted 
with Et2O (5 × 75 mL). The organic fractions were combined, washed with brine, dried 
over Na2SO4 and concentrated under reduced pressure to give a foaming brown oil.  
Flash chromatography (silica gel  2:1 → 1:1 petroleum ether/EtOAc) gave 4-hydroxy-
O-pivaloyl cornoside 3.12 as a pale yellow foaming amorphous solid (1.99 g, 3.05 
mmol, 65% yield). 
Rf 0.40 (1:1 petroleum ether:EtOAc); 
1H NMR (500 MHz, CDCl3); δ 6.93 – 6.87 (m, 2H), 6.18 – 6.12 (m, 2H), 5.33 (t, J = 
9.5 Hz, 1H), 5.12 (dd, J = 10.1, 9.4 Hz, 1H), 5.03 (dd, J = 9.7, 8.0 Hz, 1H), 4.51 (d, J 
= 8.0 Hz, 1H), 4.26 (dd, J = 12.3, 2.0 Hz, 1H), 4.09 – 4.02 (m, 2H), 3.73 (ddd, J = 
10.1, 5.6, 2.0 Hz, 1H), 3.68 (dt, J = 10.0, 5.8 Hz, 1H), 2.79 (s, 1H), 2.05 – 1.93 (m, 
2H), 1.22 (s, 9H), 1.16 (s, 9H), 1.16 (s, 9H), 1.11 (s, 9H) ppm; 
13C NMR (126 MHz, CDCl3); δ 185.35, 178.16, 177.29, 176.88, 176.56, 150.60, 
127.93, 127.88, 101.05, 72.71, 72.00, 71.16, 68.73, 68.03, 65.55, 61.83, 39.82, 39.04, 
38.94, 38.93, 38.88, 27.28, 27.27, 27.22, 27.20 ppm; 
IR (cm−1); 2970, 2938, 2874, 1736, 1670, 1628, 1479, 1279, 1134, 1033; 




6.2.32 Experimental Procedure for Compound 3.85 
 
Dihydropyrrole 3.44 (0.010 g, 0.0689 mmol), durene (0.0094 g, 0.0700 mmol) and 
trace BHT were placed in an NMR tube fitted with a J Young valve.  The tube was 
evacuated and flushed with N2 three times, then anhydrous, degassed CD2Cl2 (0.5 
mL) was added, followed by Rh(H)(CO)(PPh3)3 (0.0032 g, 0.0034 mmol, 5 mol%).  
The tube was sealed and heated to 40 °C.  After 30 minutes, when 1H NMR analysis 
showed complete consumption of starting material, pyrrolidine (0.004 mL, 0.05 
mmol) was added.  The solution was heated at 40 °C for a further 2 hours, until 1H 
NMR analysis showed complete conversion to aminal 3.72 (60% yield from 3.44), 
then cooled to room temperature.  OPiv cornoside 3.12 (0.028 g, 0.042 mmol) was 
added, the tube sealed and left to stand at room temperature for 48 hours, until 1H 
NMR analysis indicated complete consumption of aminal 3.72, then the reaction 
mixture was concentrated under reduced pressure.  The crude product was purified 
by flash chromatography (silica gel 230-400 mesh 19:1 → 1:1 petroleum 
ether/EtOAc) to give the inseparable mixture of cross-dimer diastereomers 3.85 
(0.017 g, 0.021 mmol, 31% yield from 3.44, 50% from cornoside 3.12) as a 
colourless oil. 
†Observed signal corresponds to only one diastereomer in sample 
 ‡Observed signal corresponds to both diastereomers in sample 
1H NMR (601 MHz, CD2Cl2) δ 7.24 – 7.18 (m, H-2ʹ
‡, H-6ʹ‡), 6.79 – 6.76 (m, H-3ʹ‡, 
H-5ʹ‡), 6.75 (ddt, J = 7.3, 2.1, 1.1 Hz, H-1ʹ‡), 6.44 (ddd, J = 10.4, 5.7, 1.7 Hz, H-6‡), 
5.88 (ddd, J = 13.2, 10.4, 0.8 Hz, H-5‡), 5.69 (dd, J = 15.8, 6.2 Hz, H-1ʹʹ‡), 5.30 (ddd, 
J = 9.6, 7.3, 2.3 Hz, CH in Glc‡), 5.12 – 5.06 (m, CH in Glc‡), 4.96 (ddd, J = 9.7, 8.0, 
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2.8 Hz, CH in Glc‡), 4.52 (d, J = 8.0 Hz, H-1 in Glc‡), 4.23 – 4.00 (m, H-8a†, CH2 in 
Glc‡), 3.93 (dt, J = 10.0, 6.9 Hz, H-8a†), 3.78 – 3.70 (m, H-8b†, CH in Glc‡), 3.66 (dt, 
J = 9.8, 6.3 Hz, H-8b†), 3.28 (tdd, J = 9.0, 5.3, 1.7 Hz, H-4ʹʹa‡), 3.19 – 3.12 (m, H-
2ʹʹ‡, H-4ʹʹb‡), 3.00 – 2.96 (m, H-2†), 2.86 (ddt, J = 9.3, 7.3, 1.7 Hz, H-2†), 2.78 (dd, J 
= 18.3, 7.3 Hz, H-3a†), 2.66 – 2.58 (m, H-3a†, H-3b‡), 2.10 – 1.90 (m, H-3ʹʹa‡, CH2-
7‡), 1.83 – 1.76 (m, H-3ʹʹb‡), 1.22 – 1.07 (m, 36H, 4 × OPiv)‡ ppm; 
13C NMR (126 MHz, CD2Cl2) δ 197.61 (C-4)
†, 197.55 (C-4)†, 178.31 (OPiv)‡, 
177.52 (OPiv)†, 177.51 (OPiv)†, 177.08 (OPiv)†, 177.04 (OPiv)†, 176.93 (OPiv)†, 
176.91 (OPiv)†, 153.73 (C-6)†, 153.01 (C-6)†, 146.44 (C-4ʹ)‡, 129.48 (C-2ʹ, C-6ʹ)‡, 
128.11 (C-5)†, 127.60 (C-5)†, 118.30 (C-1ʹ)‡, 113.99 (C-3ʹ, C-5ʹ)†, 113.97 (C-3ʹ, C-
5ʹ)†, 101.95 (C-1 in Glc)†, 101.75 (C-1 in Glc)†, 94.32 (C-1ʹʹ)†, 94.15 (C-1ʹʹ)†, 80.18 
(C-1)†, 79.97 (C-1)†, 72.88, 72.65, 72.62, 71.75, 71.69, 68.53, 68.50 (4 × CH in Glc), 
66.43 (C-8)†, 66.00 (C-8)†, 62.42 (CH2 in Glc)
‡, 48.55 (C-4ʹʹ)†, 48.52 (C-4ʹʹ)†, 48.15 
(C-2ʹʹ)†, 47.89 (C-2ʹʹ)†, 44.47 (C-2)†, 43.75 (C-2)†, 40.14 (C-7)†, 39.31, 39.28, 39.21, 
39.16, 39.14 (4 × C in OPiv), 39.06 (C-7)†, 36.10 (C-3)†, 36.05 (C-3)†, 27.47, 27.43, 
27.36 (12 × CH3 in OPiv)
‡, 24.77 (C-3ʹʹ)‡ ppm;. 
IR (cm-1) 2968, 2932, 2872, 1742, 1678, 1601, 1504, 1479, 1460, 1279, 1136. 




6.2.33 Experimental Procedure for Compound 3.86 
 
2-(4-aminophenyl)ethanol 2.15 (5.01 g, 36.5 mmol) was dissolved in anhydrous 
CH2Cl2 (200 mL) at room temperature under an N2 atmosphere.  
iPr2NEt (12.7 mL, 
72.8 mmol) was added followed by Boc2O (9.54 g, 43.7 mmol) and the resulting 
mixture stirred at room temperature.  Additional Boc2O was added after 3 days (9.54 
g, 43.7 mmol) and after 4 days (9.54 g, 43.7 mmol).  After 6 days, when TLC analysis 
showed complete consumption of the starting material, the reaction mixture was 
transferred to a separating funnel and washed with 1M aqueous HCl (3 × 100 mL), 
then with saturated aqueous NaHCO3 (2 × 100 mL) before being washed with brine, 
dried over Na2SO4 and concentrated under reduced pressure to give a pale yellow solid.  
The crude product was recrystallised from hot EtOAc/petroleum ether, the solid 
collected, triturated twice with petroleum ether and dried to give pure tert-butyl (4-(2-
hydroxyethyl)phenyl)carbamate 3.68 (6.42 g, 27.0 mmol, 74% yield).  All data 
matched literature values.138 
1H NMR (500 MHz, CDCl3) δ 7.30 (d, J = 8.3 Hz, 2H), 7.15 (d, J = 8.4 Hz, 2H), 
6.43 (s, 1H), 3.82 (q, J = 6.4 Hz, 2H), 2.82 (t, J = 6.5 Hz, 2H), 1.52 (s, 9H), 1.36 (t, J 
= 6.0 Hz, 1H) ppm; 





6.2.34 Experimental Procedure for Compound 3.87 
 
Tert-butyl (4-(2-hydroxyethyl)phenyl)carbamate 3.86 (1.29 g, 5.45 mmol) and 
glycosyl trichloroacetimidate 2.56 (2.99 g, 4.54 mmol) were dissolved in anhydrous 
CH2Cl2 (36 mL) under an N2 atmosphere and stirred over freshly ground and activated 
4Å molecular sieves (~3.5 g) for 30 minutes. TMSOTf (1.64 mL, 9.06 mmol) was 
added dropwise at room temperature.  The solution was stirred for 18 hours at room 
temperature then extra alcohol 3.86 (0.269 g, 1.13 mmol) and TMSOTf (0.41 mL, 2.27 
mmol) were added.  After 21 hours, when TLC analysis showed complete consumption 
of starting material, saturated aqueous NaHCO3 (40 mL) was added.  The organic 
phase was then washed with saturated aqueous NaHCO3 (2 × 40 mL) followed by 
brine, dried with Na2SO4 and concentrated under reduced pressure to give a foaming 
yellow oil.  The crude material was dissolved in minimum warm CHCl3, allowed to 
cool to room temperature and placed in the freezer overnight.  The liquid portion was 
triturated away from the solid trichloroacetamide and purified by flash 
chromatography (silica gel  4:1 petroleum ether/EtOAc) gave 2-(4-
aminophenyl)ethanol 2,3,4,6-tetra O-pivaloyl glucopyranoside 3.87 as a yellow 
foaming amorphous solid (2.09 g, 3.29 mmol, 72% yield). 
Rf 0.20 (4:1 petroleum ether:EtOAc); 
1H NMR (600 MHz, CDCl3); δ 6.95 (d, J = 8.2 Hz, 2H), 6.60 (d, J = 8.3 Hz, 2H), 
5.30 (t, J = 9.5 Hz, 1H), 5.10 (dd, J = 10.1, 9.4 Hz, 1H), 5.02 (dd, J = 9.7, 8.0 Hz, 
1H), 4.52 (d, J = 8.0 Hz, 1H), 4.21 (dd, J = 12.2, 2.0 Hz, 1H), 4.06 (dd, J = 12.2, 5.9 
Hz, 1H), 3.96 (ddd, J = 9.6, 8.4, 6.3 Hz, 1H), 3.71 (ddd, J = 10.1, 5.9, 1.9 Hz, 1H), 
3.61 (ddd, J = 9.6, 8.3, 7.0 Hz, 1H), 3.56 (s, 2H), 2.76 (dt, J = 8.2, 6.3 Hz, 2H), 1.21 
(s, 9H), 1.15 (s, 9H), 1.11 (s, 9H), 1.11 (s, 9H) ppm; 
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13C NMR (151 MHz, CDCl3); δ 178.23, 177.37, 176.61, 176.59, 144.89, 129.84, 
128.07, 115.38, 101.22, 72.44, 72.42, 71.28, 71.22, 68.27, 62.21, 39.01, 38.90, 38.85, 
38.81, 35.48, 27.28, 27.26, 27.19, 27.14 ppm; 
IR (cm−1); 3377, 2970, 2936, 2872, 1736, 1626, 1518, 1479, 1277, 1134, 1036; 




6.2.35 Experimental Procedure for Compound 3.89 
 
2-(4-aminophenyl)ethanol 2,3,4,6-tetra O-pivaloyl glucopyranoside 3.87 (0.100 g, 
0.157 mmol), iPr2NEt (0.068 mL, 0.39 mmol), NaI (0.012 g, 0.079 mmol) were 
dissolved in anhydrous CH3CN (3.0 mL) at room temperature under a N2 atmosphere. 
Cis-1,4-dichlorobut-2-ene 3.51 (0.020 mL, 0.19 mmol) was added and the mixture 
heated to reflux with stirring.  After 17 hours, extra Cis-1,4-dichlorobut-2-ene 3.51 
(0.010 mL, 0.10 mmol) iPr2NEt (0.034 mL, 0.20 mmol) were added.  After 18 hours, 
when TLC analysis indicated complete consumption of starting material, the reaction 
mixture was cooled to room temperature, water (10 mL) added and extracted with 
EtOAc (4 × 10 mL).  The organic layers were combined, washed with brine, dried with 
Na2SO4 and concentrated under reduced pressure to give a brown foaming oil.  Flash 
chromatography (silica gel 3:1 petroleum ether/EtOAc) gave pyrrole 3.89 as yellow 
oil (0.041 g, 0.060 mmol, 45% yield). 
Rf 0.20 (9:1 petroleum ether:EtOAc); 
1H NMR (500 MHz, CDCl3) δ 7.29 (d, J = 8.5 Hz, 2H), 7.23 (d, J = 8.5 Hz, 2H), 
7.04 (t, J = 2.2 Hz, 2H), 6.35 – 6.31 (m, 2H), 5.31 (t, J = 9.5 Hz, 1H), 5.11 (dd, J = 
10.1, 9.3 Hz, 1H), 5.04 (dd, J = 9.7, 8.0 Hz, 1H), 4.55 (d, J = 7.9 Hz, 1H), 4.23 (dd, J 
= 12.2, 2.0 Hz, 1H), 4.09 – 4.02 (m, 2H), 3.77 – 3.65 (m, 2H), 2.89 (t, J = 7.0 Hz, 
2H), 1.21 (s, 9H), 1.15 (s, 9H), 1.11 (s, 9H), 1.08 (s, 9H) ppm; 
13C NMR (126 MHz, CDCl3) δ 178.17, 177.33, 176.59, 176.54, 139.38, 135.89, 
130.15, 120.71, 119.44, 110.35, 101.15, 72.49, 72.35, 71.22, 70.34, 68.20, 62.12, 
39.01, 38.90, 38.85, 38.78, 35.68, 27.28, 27.26, 27.19, 27.10 ppm; 
IR (cm−1) 2972, 2936, 2872, 1740, 1522, 1479, 1460, 1329, 1277, 1134; 
HRMS (ESI+); 708.3732 (calculated [M+H]+ 708.3718).  
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6.2.36 Experimental Procedure for Compound 3.88 
 
2-(4-aminophenyl)ethanol 2,3,4,6-tetra O-pivaloyl glucopyranoside 3.87 (1.30 g, 2.05 
mmol), iPr2NEt (0.74 mL, 4.26 mmol), NaI (0.128 g, 0.852 mmol) and a trace quantity 
of BHT were dissolved in anhydrous CH3CN (12.0 mL) at room temperature under a 
N2 atmosphere. Cis-1,4-dichlorobut-2-ene 3.51 (0.180 mL, 1.70 mmol) was added and 
the mixture heated to 60 °C with stirring.  After1 hour, when TLC analysis indicated 
complete consumption of starting material, the reaction mixture was cooled to room 
temperature, water (50 mL) added and extracted with EtOAc (4 × 30 mL).  The organic 
layers were combined, washed with brine, dried with Na2SO4 and concentrated under 
reduced pressure to give a brown foaming oil.  Flash chromatography (silica gel  
neutralised with Et3N 9:1 → 4:1 petroleum ether/EtOAc + trace BHT) gave 2-(4-(2,5-
dihydro-1H-pyrrol-1-yl)phenyl)ethan-1-ol 2,3,4,6-tetra O-pivaloyl glucopyranoside 
3.88 as white amorphous solid (0.588 g, 0.855 mmol, 50% yield, 59% yield BRSM). 
Rf 0.35 (9:1 petroleum ether:EtOAc); 
1H NMR (600 MHz, CD2Cl2); δ 7.04 (d, J = 8.6 Hz, 2H), 6.45 (d, J = 8.6 Hz, 2H), 
5.96 (s, 2H), 5.30 (t, J = 9.5 Hz, 1H), 5.09 (dd, J = 10.1, 9.4 Hz, 1H), 4.98 (dd, J = 
9.7, 8.0 Hz, 1H), 4.55 (d, J = 8.0 Hz, 1H), 4.15 (dd, J = 12.3, 2.0 Hz, 1H), 4.09 (dd, 
J = 12.3, 5.5 Hz, 1H), 4.07 (s, 4H), 3.94 (ddd, J = 9.6, 8.1, 6.8 Hz, 1H), 3.74 (ddd, J 
= 10.1, 5.5, 2.0 Hz, 1H), 3.64 (ddd, J = 9.7, 8.0, 7.0 Hz, 1H), 2.76 (ddd, J = 8.5, 7.0, 
2.1 Hz, 2H), 1.20 (s, 9H), 1.14 (s, 9H), 1.12 (s, 9H), 1.09 (s, 9H) ppm; 
13C NMR (151 MHz, CD2Cl2); δ 178.36, 177.52, 177.01, 176.90, 146.50, 130.20, 
126.96, 125.27, 111.73, 101.81, 72.85, 72.83, 72.14, 71.71, 68.63, 62.56, 55.09, 
39.31, 39.21, 39.17, 39.14, 35.79, 27.49, 27.46, 27.39, 27.37 ppm; 
IR (cm−1); 2970, 2938, 2868, 2822, 1740, 1618, 1528, 1479, 1279, 1142, 1087; 
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6.2.37 Experimental Procedure for Compound 3.91 
 
2,5-dihydropyrrole 3.88 (95 mg, 140 μmol) was placed in an NMR tube fitted with a 
J Young tap.  The tube was evacuated and flushed with N2 three times.  Degassed, 
anhydrous CD2Cl2 (0.5 mL) and degassed anhydrous pyrrolidine (13.0 μL, 150 μmol) 
were added, followed by Rh(H)(CO)(PPh3)3 (5 mol%, 6 mg, 70 μmol), the tube sealed 
and heated to 40 ºC.  After 1.5 hours, when 1H-NMR analysis showed complete 
conversion of starting material to aminal 3.90 (for 1H NMR specta showing in-situ 
formation of 3.90, see section 6.6), the solution was cooled to room temperature, water 
(5 μL) added followed by tetra-OPiv cornoside 3.12 (269 mg, 413 μmol), the tube re-
sealed and left to stand at room temperature.  After 20 hours at room temperature, 
when 1H-NMR analysis indicated consumption of starting material, the solvent was 
removed under reduced pressure to give a brown foaming oil.  Flash chromatography 
(silica gel neutralised with Et3N 9:1 → 1:1 petroleum ether/EtOAc + trace BHT) gave 
octa-OPiv dia-millingtonine 3.91 (93 mg, 69 μmol, 50% yield) as a yellow oil, along 
with an in separable mixture of octa-OPiv incargranine B 2.60 and octa-OPiv dia-
incargranine B 3.92 as mixture in a 1:1.2 ratio (determined by HPLC) (14 mg, 10 μmol, 
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14% combined yield) (a small amount of this mixture was separated by HPLC for 
characterisation). 
Aminal 3.90 
NB: aminal 3.90 was unable to be isolated, with all attempts resulting in 
decomposition; however, NMR monitoring of reaction mixtures allowed for the in-
situ characterisation of 3.90 by 1H, 13C and 2D NMR spectroscopy. 
1H NMR (601 MHz, CD2Cl2) δ 7.04 (d, J = 8.6 Hz, 2H), 6.79 (d, J = 7.7 Hz, 2H), 
5.35 (td, J = 9.5, 1.3 Hz, 1H), 5.16 (t, J = 9.7 Hz, 1H), 5.04 (dd, J = 9.7, 8.0 Hz, 
1H), 4.64 (dd, J = 6.9, 2.6 Hz, 1H), 4.59 (dd, J = 8.1, 2.7 Hz, 1H), 4.21 (dd, J = 
12.3, 2.0 Hz, 1H), 4.16 (dd, J = 12.3, 5.4 Hz, 1H), 4.03 – 3.97 (m, 1H), 3.77 (ddt, J 
= 9.1, 5.4, 1.7 Hz, 1H), 3.69 (dtd, J = 9.4, 7.4, 1.7 Hz, 1H), 3.55 (td, J = 8.3, 2.0 Hz, 
1H), 3.09 (td, J = 9.2, 7.3 Hz, 1H), 2.99 – 2.91 (m, 3H), 2.81 (t, J = 7.4 Hz, 2H), 
2.69 – 2.63 (m, 2H), 2.62 – 2.54 (m, 2H), 2.16 – 2.10 (m, 1H), 2.10 – 1.96 (m, 2H), 
1.83 – 1.69 (m, 5H), 1.26 (s, 8H), 1.21 – 1.11 (m, 27H) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 178.35, 177.52, 177.00, 176.98, 176.89, 147.55, 
147.53, 129.69, 129.67, 126.02, 126.01, 113.47, 101.86, 76.06, 76.02, 72.91, 72.88, 
72.20, 71.77, 68.66, 62.56, 49.24, 47.66, 47.65, 39.35, 39.24, 39.20, 39.20, 39.18, 
35.88, 27.55, 27.52, 27.47, 27.46, 27.44, 26.33, 26.30, 25.88, 24.68, 24.14, 24.07 
ppm; 
Octa-OPiv incargranine B 2.60 
tR = 5.5 min (ACE C18 PFP 5 250mm x 4.6mm column, MeOH, 1.5 mL/min); 
See 6.3.16 for data; 
Octa-OPiv dia-incargranine B 3.92  
tR = 6.2 min (ACE C18 PFP 5 250mm x 4.6mm column, MeOH, 1.5 mL/min); 
1H NMR (601 MHz,CD2Cl2) δ 7.08 – 7.04 (m, 2H), 7.02 (s, 1H), 6.87 (td, J = 7.9, 
2.1 Hz, 1H), 6.75 – 6.70 (m, 2H), 6.31 (dd, J = 8.3, 3.6 Hz, 1H), 5.30 (dd, J = 9.5, 
1.6 Hz, 1H), 5.26 (td, J = 9.6, 3.3 Hz, 1H), 5.11 (dd, J = 10.1, 9.4 Hz, 1H), 5.07 (ddd, 
J = 10.1, 9.4, 4.8 Hz, 1H), 5.00 (t, J = 6.9 Hz, 1H), 4.99 (dd, J = 9.7, 8.0 Hz, 1H), 
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4.92 (ddd, J = 9.9, 8.0, 2.0 Hz, 1H), 4.58 (dd, J = 8.0, 4.5 Hz, 1H), 4.47 (dd, J = 26.4, 
8.0 Hz, 1H), 4.16 (ddd, J = 12.3, 3.6, 2.0 Hz, 1H), 4.14 – 4.09 (m, 2H), 4.07 (ddd, J 
= 12.3, 5.1, 1.7 Hz, 1H), 4.01 – 3.95 (m, 1H), 3.84 (dt, J = 9.5, 7.2 Hz, 1H), 3.76 
(ddd, J = 10.1, 5.3, 2.0 Hz, 1H), 3.70 – 3.62 (m, 3H), 3.56 – 3.51 (m, 1H), 3.40 (td, J 
= 8.7, 3.8 Hz, 1H), 3.37 – 3.31 (m, 1H), 3.21 (tt, J = 10.1, 5.1 Hz, 2H), 2.79 (t, J = 
7.5 Hz, 2H), 2.60 (t, J = 7.5 Hz, 2H), 2.47 (dtd, J = 12.8, 6.5, 3.1 Hz, 1H), 2.10 – 
2.05 (m, 1H), 2.02 – 1.91 (m, 3H), 1.82 – 1.76 (m, 1H), 1.72 – 1.66 (m, 1H), 1.24 – 
1.02 (m, 72H, 8 × OPiv) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 178.35, 178.33, 177.52, 177.50, 177.02, 176.99, 
176.96, 176.92, 176.88, 176.86, 176.86, 148.61, 148.59, 142.62, 142.60, 130.24, 
130.20, 129.54, 129.43, 128.96, 128.86, 125.47, 125.41, 125.21, 125.12, 124.12, 
124.08, 111.87, 111.86, 111.06, 101.85, 101.80, 72.84, 72.84, 72.81, 72.80, 72.77, 
72.76, 72.20, 72.19, 72.00, 71.72, 71.68, 71.65, 68.58, 68.56, 68.52, 62.52, 62.47, 
58.64, 57.16, 48.62, 48.59, 47.29, 40.75, 39.32, 39.29, 39.20, 39.19, 39.17, 39.14, 
39.14, 39.12, 39.09, 35.96, 35.89, 35.77, 35.76, 30.67, 30.27, 27.48, 27.45, 27.41, 
27.37, 27.35, 23.86, 23.83, 23.76 ppm; 
IR (cm−1) 2970, 2936, 2872, 1744, 1614, 1516, 1481, 1366, 1281, 1140; 
HRMS (ESI+); 1375.8105 (calculated [M+H]+ 1375.8038); 
Octa-OPiv dia-millingtonine 3.91  
Rf 0.35 (2:1 petroleum ether:EtOAc); 
†Observed signal corresponds to only one diastereomer in sample 
 ‡Observed signal corresponds to both diastereomers in sample 
1H NMR (601 MHz, CD2Cl2) δ 7.03 (dd, J = 8.6, 2.2 Hz, H-4ʹ
‡, H-6ʹ‡), 6.70 (d, J = 
8.6 Hz, H-3ʹ‡, H-5ʹ‡), 6.42 (ddd, J = 10.4, 5.5, 1.7 Hz, H-6‡), 5.87 (dd, J = 13.3, 10.4 
Hz, H-5‡), 5.66 (dd, J = 15.6, 6.2 Hz, H-1ʹʹ‡), 5.32 – 5.27 (m, 2 × CH in Glc‡), 5.13 – 
5.06 (m, 2 × CH in Glc‡), 5.00 – 4.94 (m, 2 × CH in Glc‡), 4.55 (d, J = 8.0 Hz, H-1 
in Glc‡), 4.52 (dd, J = 8.0, 3.5 Hz, H-1 in Glc‡), 4.21 – 4.14 (m, CH2 in Glc
‡), 4.13 – 
4.07 (m, H-8a†, 1H from CH2 in Glc
‡, 1H from CH2 in Glc
†), 4.05 (dd, J = 12.3, 5.5 
Hz, 1H from CH2 in Glc
†), 3.99 – 3.90 (m, H-8aʹ‡, H-8b
†), 3.78 – 3.71 (m, H-8b†, 2 × 
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CH in Glc‡), 3.68 – 3.62 (m, H-8ʹb‡, H-8a
†), 3.24 (td, J = 8.9, 5.2 Hz, H-4ʹʹa‡), 3.17-
3.10 (m, H-4ʹʹb‡, H-2ʹʹ
‡), 2.97 (ddt, J = 8.1, 6.1, 2.2 Hz, H-2†), 2.85 (ddt, J = 9.1, 7.3, 
1.6 Hz, H-2†), 2.79 (d, J = 7.3 Hz, H-3a†), 2.77 (t, J = 7.5 Hz, CH2-7ʹ
‡), 2.69 – 2.59 
(m, H-3a†, H-3b‡), 2.09 – 1.88 (m, H-3ʹʹa‡, CH2-7
‡), 1.82 – 1.74 (m, H-3ʹʹb‡), 1.21 – 
1.09 (m, 8 × OPiv) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 197.58 (C-4)
†, 197.55 (C-4)†, 178.35 (C OPiv)‡, 
178.28 (C OPiv)†, 178.27 (C OPiv)† 177.52 (C OPiv)‡, 177.50 (C OPiv)†, 177.49 (C 
OPiv)†, 177.05 (C OPiv)†, 177.02 (C OPiv)†, 176.99 (C OPiv)‡, 176.89 (2 × C 
OPiv)‡, 153.77 (C-6)†, 153.06 (C-6)†, 145.01 (C-4ʹ) ‡, 129.95 (C-2ʹ, C-6ʹ)†, 129.94 
(C-2ʹ, C-6ʹ)†, 128.09 (C-5)†, 127.78, (C-1ʹ)† 127.73 (C-1ʹ)†, 127.58 (C-5)†, 114.06 (C-
3ʹ, C-5ʹ)†, 114.02 (C-3ʹ, C-5ʹ)†, 101.98 (C-1 in Glc)†, 101.85 (C-1 in Glc)†, 101.83 
(C-1 in Glc)†, 101.78 (C-1 in Glc)†, 94.42 (C-1ʹʹ)†, 94.26 (C-1ʹʹ)†, 80.17 (C-1)†, 79.95 
(C-1)†, 72.89 (Glc)‡, 72.86 (Glc)‡, 72.81 (Glc)‡, 72.65 (Glc)†, 72.64 (Glc)†, 71.99 (C-
8ʹ)†, 71.95 (C-8ʹ)†, 71.76 (Glc)†, 71.70 (Glc†, Glc‡), 68.60 (Glc)‡, 68.53 (Glc)†, 68.51 
(Glc)†, 66.45 (C-8)†, 66.02 (C-8)†, 62.54 (Glc)‡, 62.42 (Glc)†, 62.41 (Glc)†, 48.58 (C-
4ʹʹ)†, 48.54 (C-4ʹʹ)†, 48.16 (C-2ʹʹ)†, 47.86 (C-2ʹʹ)†, 44.38 (C-2)†, 43.68 (C-2)†, 40.06 
(C-7)†, 39.32, 39.31, 39.29, 39.21, 39.17, 39.14 (8 x C OPiv)‡, 39.01 (C-7)†, 36.10 
(C-3)†, 36.05 (C-3)†, 35.85 (C-7ʹ)†, 35.84 (C-7ʹ)†, 27.49, 27.47, 27.45, 27.41, 27.39, 
27.37 (24 × C OPiv)‡, 24.80 (C-3ʹʹ)†, 24.77 (C-3ʹʹ)† ppm; 
IR (cm−1); 2970, 2936, 2909, 2874, 1740, 1676, 1520, 1479, 1277, 1134, 1036; 
HRMS (ESI+); 1340.7611 (calculated [M+H]+ 1340.7514), 1362.7396, (calculated 
[M+Na]+ 1362.7333).  
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6.2.38 Experimental Procedure for Compound 3.93 
 
Octa-OPiv dia-millingtonine 3.91 (0.317 g, 0.236 mmol) was dissolved in CH2Cl2 (12 
mL) at room temperature.  TFA (9.0 μL, 0.12 mmol) was added and the resulting 
solution stirred at room temperature.  After 5 hours, when TLC analysis showed 
complete consumption of starting material, the reaction was quenched by addition of 
Et3N (75 μL), solvent removed under reduced pressure and residue purified directly.  
Flash chromatography (silica gel 230-400 3:1 → 2:1 petroleum ether/EtOAc) gave 
octa-OPiv millingtonine 3.93 (0.177 g, 0.132 mmol, 56% yield) as a yellow oil. 
Rf 0.20 (3:1 petroleum ether:EtOAc); 
 †Observed signal corresponds to only one diastereomer in sample 
 ‡Observed signal corresponds to both diastereomers in sample 
1H NMR (601 MHz, CD2Cl2) δ 7.02 (dd, J = 8.6, 1.7 Hz, H-2ʹ
‡, H-6ʹ‡), 6.70 (dd, J = 
8.6, 1.9 Hz, H-3ʹ‡, H-5ʹ‡) , 6.59 (ddd, J = 10.2, 3.8, 1.8 Hz, H-6‡) , 5.93 (ddd, J = 
14.5, 10.3, 0.9 Hz, H-5‡) , 5.56 (dd, J = 13.0, 6.3 Hz, H-1ʹʹ‡), 5.30 (t, J = 9.9 Hz, CH 
in Glc‡), 5.25 (dt, J = 16.5, 9.6 Hz, CH in Glc‡), 5.15 – 5.06 (m, 2 × CH in Glc‡), 
5.01 – 4.91 (m, 2 × CH in Glc‡), 4.56 (dd, J = 8.0, 2.0 Hz, CH-1 in Glc‡) , 4.45 (d, J 
= 8.0 Hz, CH-1 in Glc†), 4.39 (d, J = 8.0 Hz, CH-1 in Glc†), 4.15 (m, 1H from CH2 
in Glc‡, 1H from CH2 in Glc
†), 4.13 – 4.08 (m, CH2 in Glc
‡), 4.04 (dd, J = 12.3, 5.4 
Hz, 1H from CH2 in Glc
†), 3.99 – 3.92 (m, H-8ʹa‡, H-8†), 3.85 – 3.80 (m, H-8a†), 
3.75 (ddd, J = 10.1, 5.4, 2.0 Hz, CH in Glc‡), 3.72 – 3.68 (m, CH in Glc†), 3.68 – 
3.61 (m, H-8ʹb‡, H-8b†, CH in Glc†), 3.50 (ddd, J = 9.7, 6.1, 4.8 Hz, H-8b†), 3.47 – 
3.33 (m, H-4ʹʹ‡), 2.80 – 2.74 (m, CH2-7ʹ
‡, H-3a†), 2.74 – 2.69 (m, H-2ʹʹ‡), 2.65 – 2.54 
(m, H-3a†, H-3b‡, H-2†), 2.50 – 2.44 (m, H-2†), 2.07 – 2.00 (m, H-3ʹʹa‡), 2.00 – 1.95 
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(m, H-7a‡, H-7b†), 1.87 (td, J = 7.4, 4.8 Hz, H-7b†), 1.85 – 1.81 (m, H-3ʹʹb‡), 1.21 – 
1.18 (m, 18H, 2 × OPiv‡), 1.15-1.08 (m, 54H, 6 × OPiv‡) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 197.69 (C-4)
†, 197.68 (C-4)†, 178.34 (C OPiv)‡, 
178.31 (C OPiv)†, 178.28 (C OPiv)†, 177.52 (C OPiv)‡, 177.47 (C OPiv)‡, 177.03 (C 
OPiv)†, 176.99 (C OPiv)†, 176.97 (C OPiv)†, 176.89 (2 × C OPiv)‡, 176.77 (C 
OPiv)†, 152.52 (C-6)†, 151.74 (C-6)†, 144.66 (C-4ʹ)†, 144.62 (C-4ʹ)†, 130.01 (C-2ʹ, C-
6ʹ)†, 129.97 (C-2ʹ, C-6ʹ)†, 129.33 (C-5)†, 128.83 (C-5)†, 127.51 (C-1ʹ)†, 127.47 (C-
1ʹ)†, 113.98 (C-3ʹ, C-5ʹ)†, 113.94 (C-3ʹ, C-5ʹ)†, 102.27 (C-1 in Glc)†, 101.86 (C-1 in 
Glcʹʹʹ)†, 101.84 (C-1 in Glc)†, 101.82 (C-1 in Glc)†, 92.60 (C-1ʹ)†, 92.57 (C-1ʹ)†, 
81.94 (C-1)†, 81.87 (C-1)†, 72.86 (Glc)‡, 72.81 (Glc)‡, 72.79 (Glc)†, 72.67 (Glc)‡, 
72.56 (Glc)‡, 72.01 (C-8ʹ)†, 71.95 (C-8ʹ)†, 71.74†, 71.71 (2C)‡, 68.60 (Glc)‡, 68.45 
(Glc)†, 68.21 (Glc)†, 66.63 (C-8)†, 65.75 (C-8)†, 62.54 (Glc)‡, 62.39 (Glc)†, 62.28 
(Glc)†, 49.39 (C-2ʹʹ)†, 48.96 (C-2ʹʹ)†, 47.03 (C-2)†, 45.96 (C-4ʹʹ)†, 45.86 (C-4ʹʹ)†, 
45.66 (C-2)†, 39.34, 39.32, 39.30, 39.21, 39.19, 39.17, 39.14 (8C OPiv)‡, 38.40 (C-
7)†, 37.83 (C-3)†, 37.58 (C-3)†, 36.81 (C-7)†, 35.84 (C-7ʹ)†, 35.83 (C-7ʹ)†, 28.94 (C-
3ʹʹ)†, 28.88 (C-3ʹʹ)†, 27.49, 27.47, 27.44, 27.41, 27.37 (24C OPiv)‡ ppm;  
IR (cm−1); 2970, 2936, 2911, 2872, 1742, 1684, 1616, 1520, 1479, 1279, 1138, 1036; 




6.2.39 Experimental Procedure for Millingtonine 3.1 
 
Octa-OPiv millingtonine 3.93 (152 mg, 114 μmol) was dissolved in THF (5.0 mL) 
and MeOH (20 mL).  LiOH (2.27 mL, 1.0 M in H2O, 2.27 mmol) was added and the 
resulting suspension stirred at room temperature.  After 24 hours, when TLC analysis 
showed complete consumption of starting material, the solvent was removed under 
reduce pressure and the residue purified directly.  Flash chromatography (silica gel 
230-400 13:6:1 CHCl3/MeOH/H2O) gave millingtonine 1 (49 mg, 73 μmol, 64% 
yield) as a foaming, pale brown amorphous solid.  All data matched that previously 
reported for both isolated83 and synthetic72 millingtonine 3.1. 
 †Observed signal corresponds to only one diastereomer in sample 
 ‡Observed signal corresponds to both diastereomers in sample 
Rf 0.27 (13:6:1 CHCl3:MeOH:H2O); 
1H NMR (601 MHz, Pyr) δ 7.16 (dd, J = 8.4, 5.1 Hz, H-2ʹ‡, H-6ʹ‡), 6.89 (app. t, J = 
8.6 Hz, H-3ʹ‡, H-5ʹ‡), 6.76 (dd, J = 10.2, 1.6 Hz, H-6†), 6.68 (dd, J = 10.2, 1.9 Hz, H-
6†), 6.05 (dd, J = 10.2, 7.2 Hz, H-5‡), 5.57 (dd, J = 6.0, 2.1 Hz, H-1ʹʹ‡), 4.90 (dd, J = 
7.8, 2.1 Hz, H-1 in Glc‡), 4.71 (dd, J = 7.8, 1.5 Hz, H-1 in Glc‡), 4.58 – 4.55 (m, 1H 
of CH2 in Glc
‡), 4.45 (ddd, J = 20.5, 11.8, 2.6 Hz, 1H of CH2 in Glc
‡), 4.38 (dd, J = 
11.8, 5.3 Hz, CH in Glc‡), 4.35 – 4.29 (m, H-8ʹa‡, CH in Glc‡), 4.24 (dd, J = 7.6, 5.1 
Hz, 2 × CH in Glc‡), 4.23 – 4.19 (m, H-8a†), 4.20 – 4.15 (m, 2 × CH in Glc‡), 4.15 – 
4.09 (m, H-8b†), 4.08 – 4.03 (m, CH in Glc‡), 3.99 – 3.92 (m, 2 × CH in Glc‡), 3.90 – 
3.85 (m, H-8b†, H-8ʹb‡), 3.85 – 3.80 (m, CH in Glc‡), 3.80 – 3.74 (m, H-8a†), 3.46 – 
3.31 (m, H-4ʹʹa‡, H-4ʹʹb‡), 3.01 – 2.95 (m, CH2-7ʹ
‡), 2.95 – 2.89 (m, H-3a‡), 2.73 – 
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2.67 (m, H-2†), 2.66 – 2.55 (m, H-3b‡, H-2†, H-2ʹʹ‡), 2.15 – 2.01 (m, CH2-7
‡), 1.78 – 
1.68 (m, H-3ʹʹa‡), 1.68 – 1.64 (m, H-3ʹʹb†), 1.59 – 1.54 (m, H-3ʹʹb†) ppm; 
13C NMR (151 MHz, Pyr) δ 197.51 (C-4)†, 197.41 (C-4)†, 152.40 (C-6)†, 152.31 (C-
6)†, 144.60 (C-4ʹ)†, 144.58 (C-4ʹ)†, 129.96 (C-2ʹ, C-6ʹ)‡, 128.69 (C-5)†, 128.57 (C-
5)†, 127.80 (C-1ʹ)†, 127.78 (C-1ʹ)†, 114.08 (C-3ʹ, C-5ʹ)†, 114.05 (C-3ʹ, C-5ʹ)†, 104.77 
(C-1 in Glc)†, 104.77 (C-1 in Glc)†, 104.66 (C-1 in Glc)†, 104.36 (C-1 in Glc)†, 92.30 
(C-1ʹʹ)†, 92.24 (C-1ʹʹ)†, 82.06 (C-1)†, 82.02 (C-1)†, 78.58 (2 × C Glc)‡, 78.39 (2 × C 
Glc)‡, 75.20 (Glc)‡, 75.03 (Glc)‡, 71.68 (Glc)‡, 71.53 (Glc)‡, 71.28 (C-8ʹ)†, 71.25 (C-
8ʹ)†, 65.24 (C-8)†, 64.97 (C-8)†, 62.81 (Glc)‡, 62.64 (Glc)‡, 49.03 (C-2ʹʹ)†, 48.98 (C-
2ʹʹ)†, 46.12 (C-2)†, 45.99 (C-2)†, 45.64 (C-4ʹʹ)†, 45.57 (C-4ʹʹ)†, 37.69 (C-3)†, 37.63 
(C-3)†, 37.48 (C-7)†, 37.32 (C-7)†, 35.94 (C-7ʹ)†, 35.92 (C-7ʹ)†, 28.35 (C-3ʹʹ)†, 28.26 
(C-3ʹʹ)† ppm; 
1H NMR (601 MHz, CD3OD) δ 7.09 (d, J = 8.3 Hz, H-2ʹ
‡, H-6ʹ‡), 6.79 (dd, J = 10.3, 
1.9 Hz, H-6†), 6.78 – 6.73 (m, H-3ʹ‡, H-5ʹ‡, H-6†), 5.96 (ddd, J = 10.2, 4.9, 1.0 Hz, 
H-5‡), 5.61 (dd, J = 6.2, 1.2 Hz, H-1ʹʹ‡), 4.30 (dd, J = 7.8, 0.8 Hz, H-1 in Glc‡), 4.16 
(d, J = 7.8 Hz, H-1 in Glc‡), 4.04 (ddd, J = 9.6, 8.3, 6.7 Hz, H-8ʹa‡), 4.02 – 3.98 (m, 
H-8a†), 3.94 (ddd, J = 10.1, 6.7, 5.4 Hz, H-8a†), 3.89 – 3.77 (m, CH2 in Glc
‡), 3.71 
(dddd, J = 9.7, 8.2, 6.7, 1.4 Hz, H-8ʹb‡), 3.69 – 3.58 (m, H-8b‡, CH2 in Glc
‡), 3.49 – 
3.40 (m, H-4ʹʹa‡, H-4ʹʹb‡), 3.38 – 3.32 (m, CH in Glc‡, CH in Glc†), 3.29 – 3.23 (m, 3 
× CH in Glc‡, CH in Glc†), 3.21 – 3.16 (m, 2 × CH in Glc‡), 3.11 (ddd, J = 9.0, 7.8, 
2.6 Hz, CH in Glc‡), 2.90 – 2.85 (m, H-3a†), 2.85 – 2.81 (m, CH2-7ʹ
‡), 2.75 – 2.69 
(m, H-2ʹʹ‡), 2.69 – 2.65 (m, H-2†), 2.64 – 2.61 (m, H-2†), 2.61 – 2.55 (m, H-3b‡), 
2.10 – 1.97 (m, H-3ʹʹa‡, H-7a‡, H-7b‡), 1.91 – 1.87 (m, H-3ʹʹb‡) ppm; 
13C NMR (151 MHz, CD3OD) δ 200.40 (C-4)
†, 200.26 (C-4)†, 154.49 (C-6)†, 154.33 
(C-6)†, 145.40 (C-4ʹ)†, 145.38 (C-4ʹ)†, 130.46 (C-2ʹ, C-6ʹ)‡, 129.08 (C-5)†, 128.90 (C-
5)†, 128.77 (C-1ʹ)†, 128.74 (C-1ʹ)†, 114.73 (C-3ʹ, C-5ʹ)†, 114.67 (C-3ʹ, C-5ʹ)†, 104.48 
(C-1 in Glc)†, 104.36 (C-1 in Glc)‡, 104.20 (C-1 in Glc)†, 93.37 (C-1ʹʹ)†, 93.37 (C-
1ʹʹ)†, 83.04 (C-1)†, 82.88 (C-1)†, 78.15 (Glc)†, 78.13 (Glc)†, 78.09 (Glc)‡, 77.94 
(Glc)‡, 77.87 (Glc)†, 77.84 (Glc)†, 75.12 (Glc)‡, 75.06 (Glc)‡, 72.18 (C-8ʹ)†, 72.16 
(C-8ʹ)†, 71.65 (Glc)‡, 71.62 (Glc)†, 71.61 (Glc)†, 66.16 (C-8)†, 65.90 (C-8)†, 62.77 
(Glc‡, Glc†), 62.74 (Glc)†, 50.07 (C-2ʹʹ)†, 50.02 (C-2ʹʹ)†, 46.81 (C-2)†, 46.80 (C-2)†, 
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46.45 (C-4ʹʹ)‡, 38.11 (C-3)†, 38.07 (C-3)†, 37.72 (C-7ʹ)†, 37.63 (C-7ʹ)†, 36.35 (C-7ʹ)‡, 
29.11 (C-3ʹʹ)†, 28.89 (C-3ʹʹ)† ppm;  
IR (cm−1) 3348(br), 2926, 2873, 1667, 1638, 1612, 1566, 1520, 1373, 1076, 1026; 




6.2.39.1 Comparison of NMR Spectra of Isolated and Synthetic Millingtonine in 
Pyridine-d5 
 
A comparison of 1H and 13C NMR data reported for our synthetic 
millingtonine (3.1) (in pyridine-d5) synthetic material form the 
total synthesis reported by Wagner et al.72 and natural, isolated 
millingtonine (3.1) as reported by Hase et al.83 







m J (Hz) δ  13C 
(150MHz) 




δ  13C 
(125MHz) 




δ  13C 
(100MHz) 
1 -- -- 82.06, 
82.02 
-- -- 82.00, 
81.98 
NR   82.01, 
81.97 











NR  46.06, 
45.93 






NR  37.64, 
37.58 




NR   
4 -- -- 197.51, 
197.41 
-- -- 197.53, 
197.45 
-- -- 197.53, 
197.47 




6.05 d, 10.3 128.66, 
128.56 














d, 10.3 152.44, 
152.34 
7 2.15-2.01 m 37.48, 
37.32 
2.17-2.00# m 37.43, 
37.38 
NR  37.40, 
37.26 



















NR   
1ʹ -- -- 127.80, 
127.78 
-- -- 127.72, 
127.68 
-- -- 127.74, 
127.72 
2ʹ, 6ʹ 7.16 app dd 8.4, 
5.1 
129.96 7.14 d, 8.5 129.97 7.15, 
7.16 
d, 7.9 129.93 
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3ʹ, 5ʹ 6.89 app t 8.6 114.08, 
114.05 




d, 7.9 114.04, 
114.01 
4ʹ -- -- 144.60, 
144.58 
-- -- 144.55 -- -- 144.55, 
144.33 






NR  35.88, 
35.86 








NR  71.24, 
71.22 
8ʹb 3.90-3.85 m(overlap) 3.90-3.81 m 
(overlap) 
NR   




5.56 d, 5.4 92.21, 
92.14 
5.38 d, 5.5 92.27, 
92.19 






48.95 NR  48.97, 
48.93 
3ʹʹa 1.78-1.68 m 28.35, 
28.26 
1.76-1.62 m 28.28, 
28.20 
NR  28.31, 




1.58-1.50 m NR  
4ʹʹ 3.46-3.31 m 45.64, 
45.57 







app dd 7.8, 
2.1 





















NR – not reported (see ref 83 for details) 
#possible typographical error in peak assignment – multiplet at 2.17-2.00 assigned to 5H but only integrates for 2H (see SI of ref 72 
for details)  
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6.2.39.2 Comparison of NMR Spectra of Synthetic Millingtonine in CD3OD 
A comparison of 1H and 13C NMR data reported for our synthetic millingtonine (3.1) (in 
CD3OD) and synthetic material form the total synthesis reported by Wagner et al.
83 




m J (Hz) δ  13C (150MHz) δ  1H (500MHz) m, J (Hz) δ  13C (125Mhz) 





46.81, 46.80 NR  46.71 
3a 2.90-2.85 m 38.11, 38.07 2.76-2.61 m (overlap) 38.09, 38.05 
3b 2.61-2.55 m  m (overlap) 
4 -- -- 200.40, 200.26 -- -- 200.44, 200.30 
5 5.96 ddd, 10.2, 4.9, 1.0 129.08, 128.90 5.97 dd, 10.2, 1.7 128.90, 128.72, 
128.69 
6 6.79,  
6.78-6.73 
dd, 10.3, 1.9, 
 m (overlap) 
154.49, 154.33 6.79 dd, 10.9, 1.7 154.55, 154.38 




ddd 10.1, 6.7, 5.4 
66.16, 65.90 3.74-3.57 m (overlap) 66.16, 65.88 
8b 3.69-3.58 m (overlap) 3.37-3.08 m (overlap) 
1ʹ -- -- 128.77, 128.74 -- -- 128.90, 128.72, 
128.69 
2ʹ, 6ʹ 7.09 d, 8.3 130.46 7.09 d, 8.2 130.48, 129.08 
3ʹ, 5ʹ 6.78-6.73 m (overlap) 114.73, 114.67 6.76 d, 8.2 114.72, 114.66 
4ʹ -- -- 145.40, 145.38 -- -- 145.39, 145.37 
7ʹ  2.85-2.81 m 36.35 2.91-2.82 m (overlap) 36.35 
8ʹa  4.04 ddd 9.6, 8.3, 6.7 71.18, 71.16 4.07-3.98 m (overlap) 72.21, 72.19 
8ʹb 3.71 dddd 9.7, 8.2, 6.7, 
1.4 
3.88-3.79 m (overlap) 
1ʹʹ 5.61 dd, 6.2, 1.2 93.37 5.61 d, 6.1 93.32 
2ʹʹ 2.75-2.69 m  50.07, 50.02 2.76-2.61 m (overlap) 50.00, 48.42 
3ʹʹa 2.10-1.97 m (overlap) 29.11, 28.89 2.09-1.97 m (overlap) 29.10, 28.87 
3ʹʹb 1.91-1.87 m 1.93-1.88 m 
4ʹʹa 3.49-3.40 m 46.45 2.91-2.82# m (overlap) 46.39 
4ʹʹb  2.76-2.61# m (overlap)  
 




6.3 SPECIFIC EXPERIMENTAL CONDITIONS FOR CHAPTER 4 
6.3.1 Experimental Procedure for Compound 4.7 
 
Dihydropyrrole 3.53 (42 mg, 0.14 mmol), durene (18 mg, 0.14 mmol) and a trace 
quantity of BHT were placed into an NMR tube fitted with a J Young valve.  The tube 
was evacuated and flushed with N2 three times, then anhydrous, degassed CD2Cl2 (0.5 
mL) was added, followed by Rh(H)(CO)(PPh3)3 (6 mg, 7 μmol).  The tube was sealed 
and heated to 40 °C for 30 minutes, then cooled to room temperature, pyrrolidine (7 
μL, 93 μmol) was added.  After 16 hours, when 1H NMR analysis showed complete 
consumption of starting material (giving a 66 % yield of aminal 4.6), (±)-rengyolone 
1.39 (49 mg, 0.31 mmol) was added.  After 10 days at room temperature, when 1H 
NMR analysis showed complete consumption of aminal 4.6, the reaction mixture was 
concentrated under reduced pressure and purified.  Flash chromatography (silica gel, 
19:1 CH2Cl2/MeOH) gave the cross-dimer 4.7 (7 mg, 15 μmol, 12 % yield) as a yellow 
oil. 
1H NMR (601 MHz, CD2Cl2) δ 7.08 (d, J = 8.6 Hz, 2H, H-2ʹ, H-6ʹ), 6.74 (d, J = 8.6 
Hz, 2H, H-3ʹ, H-5ʹ), 5.58 (d, J = 6.4 Hz, 1H, H-1ʹʹ), 4.15 (dd, J = 9.3, 5.5 Hz, 1H, H-
6), 4.02 – 3.95 (m, 2H, CH2-7), 3.73 (td, J = 7.4, 1.6 Hz, 2H, CH2-8ʹ), 3.46 – 3.38 
(m, 2H, CH2-4ʹʹ), 3.27 – 3.21 (m, 1H, H-2ʹʹ), 2.71 (t, J = 7.2 Hz, 2H, CH2-7ʹ), 2.68 – 
2.63 (m, 2H, H-5a, H-2), 2.47 (dd, J = 16.1, 5.8 Hz, 1H, H-3a), 2.35 (dd, J = 16.1, 
9.7 Hz, 1H, H-3b), 2.31 – 2.24 (m, 2H, H-5b, H-8a), 2.08 – 1.98 (m, 2H, H-8b, H-





13C NMR (151 MHz, CD2Cl2) δ 209.39 (C-4), 144.92 (C-4ʹ), 130.20 (C-2ʹ, C-6ʹ), 
129.13 (C-1ʹ), 113.77 (C-3ʹ, C-5ʹ), 94.68 (C-1ʹʹ), 91.41 (C-1), 80.24 (C-6), 67.00 (C-
7), 65.45 (C-8ʹ), 49.46 (C-4ʹʹ), 46.97 (C-2ʹʹ), 44.31 (C-5), 42.94 (C-2), 39.48 (C-3), 
39.27 (C-7ʹ), 38.56 (C-8), 26.29 (3 × CH3 OTBS), 24.82 (C-3ʹʹ), 18.78 (C OTBS), 
−5.05 (2 × CH3 OTBS) ppm; 
IR (cm−1) 2951, 2928, 2884, 2855, 1717, 1614, 1518, 1462, 1377, 1254, 1188; 
HRMS (ESI+) 458.2785 (calculated [M+H]+ 458.2721).
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6.3.2 Experimental Procedure for Compound 1.43 
 
Compound 1.43 was prepared according to the previously reported procedure.44 
a) Phenol 1.41 (15.0 g, 108.9 mmol) was dissolved in anhydrous THF (60 mL) at room 
temperature under an N2 atmosphere.  The solution was cooled to 0 °C and a solution 
of tert-butyldimethylsilylchloride (14.8 g, 98.1 mmol) in anhydrous THF (60 mL) was 
added dropwise over 45 minutes with vigorous stirring.  The mixture was stirred at 0 
°C until TLC analysis indicated complete consumption of the starting material (50 
minutes).  The reaction mixture was then diluted with Et2O (150 mL) and saturated 
aqueous NH4Cl (100 mL) added.  The aqueous layer was separated and extracted with 
Et2O (3 × 100mL).  The organic layers were combined, dried with MgSO4, filtered and 
concentrated under reduced pressure to give a white crystalline solid.  Flash 
chromatography (silica gel, 3:1 Petroleum Ether 40-60/EtOAc) gave 4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)phenol 1.42 as a white crystalline solid (25.0 g, 99.1 
mmol, 91% yield);  All data matched that previously reported.44 
1H NMR (400 MHz, CDCl3) δ 7.11 - 7.04 (m, 2H), 6.78 - 6.72 (m, 2H), 3.76 (t, J = 
7.1 Hz, 2H), 2.75 (t, J = 7.1 Hz, 2H), 0.87 (s, 9H), −0.01 (s, 6H) ppm;  
13C NMR (101 MHz, CDCl3) δ 154.0, 131.4, 130.2, 115.2, 65.0, 38.8, 26.1, 18.5, −5.2 
ppm; 
b) Phenol 1.42 (24.4 g, 96.7 mmol) was dissolved in CH3CN (480 mL) and H2O (120 
mL) at room temperature.  The solution was cooled in an ice-water bath to an internal 
temperature of 2-3 °C and PhI(OAc)2 (37.5 g, 116.4 mmol) was added portion-wise 
over 3 minutes with vigorous stirring.  The mixture was stirred at 2-3 °C until TLC 
analysis indicated complete consumption of the starting material (20 minutes), then 
saturated aqueous Na2SO3 (300 mL) was added followed by Et2O (300 mL).  The 
organic layer was separated and the aqueous layer extracted with Et2O (2 × 200 mL).  
The organic layers were combined, dried with MgSO4 and concentrated under reduced 
pressure, giving a dark green/black oil.  Flash chromatography (silica gel, gradient 9:1 
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Petroleum Ether 40-60/EtOAc to neat EtOAc) gave 4-(2-((tert-
butyldimethylsilyl)oxy)ethyl)-4-hydroxycyclohexa-2,5-dienone 1.43 (15.1 g, 56.3 
mmol, 58% yield) as a pale yellow crystalline solid; All data matched that previously 
reported.44 
1H NMR (400 MHz, CDCl3) δ 6.97 (d, J = 10.1 Hz, 2H), 6.15 (d, J = 10.1 Hz, 2H), 
4.41 (s, 1H), 3.94 (t, J = 5.7 Hz, 2H), 1.94 (t, J = 5.7 Hz, 2H), 0.91 (s, 9H), 0.11 (s, 
6H) ppm;  





6.3.3 Alternative Experimental Procedure for Compound 3.49 
 
2-(4-aminophenyl)ethanol 2.15 (5.00 g, 36.5 mmol), iPr2NEt (13.2 mL, 76.0 mmol), 
NaI (2.28 g, 15.2 mmol) and a trace quantity of BHT were dissolved in anhydrous 
CH3CN (200 mL) at room temperature under a N2 atmosphere. Cis-1,4-dichlorobut-2-
ene 3.51 (3.20 mL, 30.4 mmol) was added and the mixture heated to 60 °C with 
stirring.  After 1.5 hours when TLC analysis indicated complete consumption of 
starting material, the reaction mixture was cooled to room temperature, water (250 
mL) added and extracted with EtOAc (4 × 150 mL).  The organic layers were 
combined, washed with brine, dried with Na2SO4 and concentrated under reduced 
pressure to give a brown solid.  Flash chromatography (silica gel neutralised with Et3N 
CH2Cl2 + trace BHT) gave 2-(4-(2,5-dihydro-1H-pyrrol-1-yl)phenyl)ethan-1-ol 37 
3.49 as pale yellow solid (5.00 g, 26.3 mmol, 87% yield). 
Rf 0.20 (CH2Cl2); 
1H NMR (500 MHz, CDCl3); δ 7.12 (d, J =8.6 Hz, 2H), 6.51 (d, J = 8.6 Hz, 2H), 
5.95 (s, 2H), 4.10 (s, 4H), 3.81 (q, J =6.5 Hz, 2H), 2.78 (t, J = 6.5 Hz, 2H), 1.39 (t, J 
= 6.0 Hz, 1H) ppm; 
13C NMR (126 MHz, CDCl3); δ 146.1, 130.1, 126.6, 125.0, 111.5, 64.2, 54.7, 38.4 
ppm; 
IR (cm−1) 3302(br), 2922, 2849, 2824, 1626, 1612, 1522, 1474, 1362, 1188, 1043, 
1015, 1003; 
HRMS (ESI+) 190.1240 (calculated [M+H]+ 190.1226); 
M.p. 121-123 °C.  
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6.3.4 Experimental Procedure for Compound 4.17 
 
2,5-dihydropyrrole 3.49 (1.51 g, 7.96 mmol) was placed in a single neck Schlenk flask.  
The flask was evacuated and flushed with N2 three times.  Anhydrous CH2Cl2 (20 mL) 
was added and the resulting solution degassed by three freeze-pump-thaw cycles.  
Anhydrous, degassed pyrrolidine (0.730 mL, 8.76 mmol) was added, followed by 
Rh(H)(CO)(PPh3)3 (5 mol%, 0.368 g, 0.398 mmol).   The tube was sealed and heated 
to 40 ºC with stirring.  After 2 hours, when 1H-NMR analysis showed complete 
conversion of starting material to aminal 4.16, (for an example of 1H NMR monitoring 
of this reaction, see 6.8) the solution was cooled to room temperature, water (0.3 mL) 
added followed by p-quinol 1.43 (5.36 g, 19.9 mmol).  The flask was re-sealed and 
stirred at room temperature.  After 20 hours at room temperature, when 1H-NMR 
analysis indicated consumption of starting material, the solvent was removed under 
reduced pressure to give a brown oil.  Flash chromatography (silica gel neutralised 
with Et3N, 4:1 → 1:1 petroleum ether/EtOAc) gave the desired compound 4.17 (2.81 
g, 6.13 mmol, 77% yield) as a brown oil and a small amount of the quinol dimer 4.18 
(0.580 g, 1.08 mmol, 11% yield) as a white solid. 
Compound 4.17 
Rf 0.26 (1:1 petroleum ether:EtOAc); 
1H NMR (500 MHz, CD2Cl2); δ 7.09 (d, J = 8.6 Hz, 2H, H-2ʹ, H-6ʹ), 6.75 (d, J = 8.6 
Hz, 2H, H-3ʹ, H-5ʹ), 6.50 (dd, J = 10.3, 1.7 Hz, 1H, H-6), 5.87 (dd, J = 10.3, 1.0 Hz, 
 
231 
1H, H-5), 5.69 (d, J = 6.2 Hz, 1H, H-1ʹʹ), 3.90 – 3.84 (m, 1H, H-8a), 3.80 – 3.73 (m, 
3H, H-8b, H-8ʹa, H-8ʹb), 3.26 (td, J = 8.9, 5.2 Hz, 1H, H-4ʹʹa), 3.19 – 3.11 (m, 2H, H-
2ʹʹ, H-4ʹʹb), 3.00 (ddt, J = 9.3, 7.2, 1.8 Hz, 1H, H-2), 2.80 – 2.73 (m, 3H, H-3a, CH2-
7ʹ), 2.62 (dt, J = 18.2, 1.4 Hz, 1H, H-3b), 2.03 – 1.93 (m, 2H, H-3ʹʹa, H-H-7a), 1.93 – 
1.87 (m, 1H, H-7b), 1.84 – 1.76 (m, 1H, H-3ʹʹb), 1.44 (d, J = 5.5 Hz, 1H, OH), 0.88 
(s, 9H, OTBS), 0.05 (d, J = 6.2 Hz, 6H, OTBS) ppm; 
13C NMR (126 MHz, CD2Cl2); δ 192.9 (C-4), 149.3 (C-6), 140.1 (C-4ʹ), 125.1 (C-2ʹ, 
C-6ʹ), 122.3 (C-1ʹ), 109.1 (C-3ʹ, C-5ʹ), 89.3 (C-1ʹʹ), 75.7 (C-1), 59.4 (C-8ʹ), 54.2 (C-8), 
43.6 (C-4ʹʹ), 43.0 (C-2ʹʹ), 39.3 (C-2), 37.7 (C-7), 33.9 (C-7ʹ), 31.2 (C-3), 21.2 (3C 
OTBS), 19.8 (C-3ʹʹ), 13.6 (C OTBS), −10.1 (2C OTBS) ppm;  
IR (cm−1) 3495, 2953, 2930, 2893, 2857, 2843, 1670, 1614, 1518, 1485, 1462, 1369, 
1248, 1088; 
HRMS (ESI+) 458.2742 (calculated [M+H]+ 458.2721); 
Quinol dimer 4.18 
Rf 0.22 (4:1 petroleum ether:EtOAc); 
1H NMR (601 MHz, CD2Cl2) δ 6.94 (d, J = 10.3 Hz, 1H, H-3), 6.14 (d, J = 10.3 Hz, 
1H, H-2), 4.12 (dt, J = 5.2, 0.9 Hz, 1H, H-3ʹ), 3.82 – 3.71 (m, 4H, CH2-8, CH2-8ʹ), 
3.26 (dd, J = 5.2, 4.2 Hz, 1H, H-2ʹ), 3.15 (ddd, J = 9.8, 4.2, 0.8 Hz, 1H, H-5), 3.12 (s, 
1H, OH), 2.70-2.67 (m, 1H, H-5ʹ), 2.61 – 2.54 (m, 2H, H-6, H-6ʹa), 2.24 (dd, J = 20.0, 
3.1 Hz, 1H, H-6ʹb), 2.00 – 1.89 (m, 2H, CH2-7), 1.66 (dt, J = 14.3, 6.1 Hz, 1H, H-7ʹa), 
1.48 (dt, J = 14.3, 6.3 Hz, 1H, H-7ʹb), 0.87 (s, 9H, OTBS), 0.87 (s, 9H, OTBS), 0.04 
(app. t, J = 2.4 Hz, 12H, OTBS) ppm; 
13C NMR (151 MHz, CD2Cl2) δ 210.5 (C-1ʹ), 197.3 (C-1), 146.7 (C-3), 130.7 (C-2), 
82.7 (C-3ʹ), 79.5 (C-4), 74.0 (C-4ʹ), 59.6 (C-8 or 8ʹ), 59.1 (C-8 or 8ʹ), 55.9 (C-2ʹ), 45.8 
(C-6), 44.7 (C-5ʹ), 44.4 (C-6ʹ), 42.6 (C-7), 42.6 (C-5), 41.1 (C-7ʹ), 26.2 (OTBS), 26.2 
(OTBS), 18.6 (OTBS), 18.6 (OTBS), −5.2 (OTBS), −5.3 (OTBS) ppm; 
IR (cm-1) 2953, 2928, 2857, 1719, 1668, 1254, 1090, 1051; 
HRMS (ESI+) 537.3085 (calculated [M+H]+ 537.3062).  
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6.3.5 Experimental Procedure for Compounds 4.19 and 4.14 
 
OTBS pre-incargranine A 4.17 (0.810 g, 1.77 mmol) was dissolved in anhydrous THF 
(20 mL) at room temperature.  TBAF (2.65 mL, 1.0 M in THF, 2.65 mmol) added with 
stirring at room temperature.  After 3 hours, additional TBAF (0.885 mL, 1.0 M in 
THF, 0.885 mmol) added and mixture stirred at room temperature for a further 30 
minutes.  When TLC analysis showed complete consumption of starting material (3.5 
hours total), saturated NH4Cl (25 mL) added and the resulting mixture extracted with 
CHCl3 (3 × 30 mL).  Organic layers combined, washed with brine, dried over Na2SO4 
and concentrated under reduced pressure to give a dark yellow oil.  Flash 
chromatography (silica gel 230-400 mesh 96:4 → 95:5 CHCl3/MeOH) gave the ring 
closed product 4.19 (0.344 g, 1.00 mmol, 56 % yield) allow with the ring opened 
product 4.14 (0.0628 g, 0.183 mmol, 10 % yield). 
Ring-closed 4.19 
Rf 0.30 (96:4 CH2Cl2:MeOH); 
1H NMR (500 MHz,CD2Cl2) δ 7.09 (d, J = 8.5 Hz, 2H, H-2ʹ, H-6ʹ), 6.77 (d, J = 8.6 
Hz, 2H, H-3ʹ, H-5ʹ), 5.59 (d, J = 6.4 Hz, 1H, H-1ʹʹ)), 4.14 (dd, J = 9.4, 5.5 Hz, 1H, H-
6), 4.01 – 3.93 (m, 2H, CH2-8), 3.74 (td, J = 6.5, 3.1 Hz, 2H, CH2-8ʹ), 3.47 – 3.38 
(m, 2H, CH2-4ʹʹ), 3.28-3.20 (m, 1H, H-2ʹʹ), 2.74 (t, J = 6.7 Hz, 2H, CH2-7ʹ), 2.68 – 
2.61 (m, 2H, H-5a, H-2), 2.47 (dd, J = 16.2, 5.8 Hz, 1H, H-3a), 2.34 (dd, J = 16.2, 
9.7 Hz, 1H, H-3b), 2.31 – 2.22 (m, 2H, H-5b, H-7a), 2.10 – 1.97 (m, 2H, H-7b, H-
3ʹʹa), 1.89 (ddt, J = 12.9, 7.3, 5.5 Hz, 1H, H-3ʹʹb), 1.58 (d, J = 5.2 Hz, 1H, OH) ppm; 
13C NMR (126 MHz, CD2Cl2) δ 209.4 (C-4), 145.1 (C-4ʹ), 130.1 (C-2ʹ, C-6ʹ), 128.5 
(C-1ʹ), 114.0 (C-3ʹ, C-5ʹ), 94.6 (C-1ʹʹ), 91.5 (C-1), 80.2 (C-6), 67.0 (C-8), 64.4 (C-8ʹ), 
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49.4 (C-4ʹʹ), 46.9 (C-2ʹʹ), 44.3 (C-5), 42.9 (C-2), 39.4 (C-3), 38.9 (C-7ʹ), 38.5 (C-7), 
24.8 (3ʹʹ) ppm; 
IR (cm-1) 3439, 2938, 2874, 1711, 1614, 1518, 1377, 1346, 1186, 1043; 
HRMS (ESI+); 366.1678 (calculated [M+Na]+ 366.1676); 
Ring-open 4.14 
Rf 0.20 (96:4 CH2Cl2:MeOH); 
1H NMR (601 MHz, CD3OD) δ 7.09 – 7.04 (m, 2H, H-2ʹ, H-6ʹ), 6.77 – 6.73 (m, 2H, 
H-3ʹ, H-5ʹ), 6.57 (dd, J = 10.4, 1.7 Hz, 1H, H-6ʹ), 5.91 (dd, J = 10.3, 1.0 Hz, 1H, H-6), 
5.72 (d, J = 6.2 Hz, 1H, H-5), 3.82 – 3.71 (m, 2H, CH2-8), 3.68 (t, J = 7.3 Hz, 2H, 
CH2-8ʹ), 3.27 (td, J = 9.0, 5.0 Hz, 1H, H-4ʹʹa), 3.21 (tt, J = 10.3, 5.6 Hz, 1H, H-2ʹʹ), 
3.12 (td, J = 8.5, 6.4 Hz, 1H, H-4ʹʹb), 2.96 (ddt, J = 9.5, 7.5, 1.7 Hz, 1H, H-2), 2.84 
(dd, J = 18.4, 7.3 Hz, 1H, H-3a), 2.72 (t, J = 7.3 Hz, 2H, CH2-7ʹ), 2.69 – 2.63 (m, 1H, 
H-3b), 2.06 (dt, J = 13.8, 6.8 Hz, 1H, H-7a), 2.02 – 1.97 (m, 1H, H-3ʹʹa), 1.94 (dt, J = 
14.2, 6.4 Hz, 1H, H-7b), 1.77 (ddt, J = 13.4, 8.1, 5.1 Hz, 1H, H-3ʹʹb) ppm; 
13C NMR (151 MHz, CD3OD) δ 200.3 (C-4), 155.9 (C-6), 145.7 (C-4ʹ), 130.4 (C-2ʹ, 
C-6ʹ), 129.3 (C-1ʹ), 127.5 (C-5ʹ), 114.7 (C-3ʹ, C-5ʹ), 95.1 (C-1ʹʹ), 81.3 (C-1), 64.7 (C-
8ʹ), 58.7 (C-8), 49.3, 49.1 (C-3ʹʹ and C-2ʹʹ overlap with solvent), 45.3 (C-2), 42.9 (C-
7), 39.4 (C-7ʹ), 36.5 (C-3), 25.2 (C-3ʹʹ) ppm; 
IR (cm-1) 3374, 2920, 2857, 1665, 1614, 1518, 1371, 1348, 1045, 1005; 




6.3.6 Experimental Procedure for Incargranine A 4.1 
 
Ring-open pre-incargranine A 4.14 (0.0069 g, 0.020 mmol) was dissolved in CD3OD 
(0.6 mL) in an NMR tube.  The resulting solution was heated to 40 °C and monitored 
by 1H NMR.  After 55 hours the reaction mixture was cooled to room temperature and 
purified by flash chromatography (silica gel 230-400 mesh 96:4 CHCl3/MeOH) to give 
incargranine A (4.1) (0.0023 g, 0.0067 mmol) in a 33% yield (43% brsm) along with 
unreacted starting material 4.14 (0.0014 g, 0.0041 mmol).  For characterisation data 




6.3.7 Alternative Experimental Procedure for incargranine A 4.1 
 
Compound 4.17 (2.10 g, 4.58 mmol) was dissolved in anhydrous MeOH (50 mL) at 
room temperature.  I2 (1 % w/v in MeOH, 11.6 mL, 0.459 mmol) was added and the 
resulting solution stirred at room temperature.  After 22 hours, when TLC analysis 
showed complete consumption of starting material, saturated aqueous Na2S2O3 (9 mL) 
was added.  The resulting suspension was concentrated under reduced pressure to 
remove the majority of the MeOH, then the aqueous residue was extracted with CHCl3 
(10 × 30 mL).  The organic fractions were combined, washed with brine, dried with 
Na2SO4 and concentrated under reduced pressure to give a brown foaming oil.  Flash 
chromatography (silica gel  CHCl3 + 5% MeOH → 7% MeOH) gave incargranine A 
(4.1) (1.33 g, 3.87 mmol, 84% yield) as a pale yellow, foaming amorphous solid.  All 
data matched that previously reported for isolated incargranine A.107 
Rf 0.15 (19:1 CHCl3:MeOH); 
1H NMR (600 MHz, CD3OD); δ 7.06 (d, J = 8.6 Hz, 2H), 6.63 (d, J = 8.6 Hz, 2H), 
4.06 (dd, J = 9.7, 3.0 Hz, 1H), 3.92 (td, J = 8.4, 1.7 Hz, 1H), 3.86 – 3.84 (m, 1H), 
3.84 – 3.80 (m, 1H), 3.68 (t, J = 7.2 Hz, 2H), 3.44 (ddd, J = 9.4, 7.9, 5.5 Hz, 1H), 
3.35 (dddd, J = 9.7, 8.1, 5.9, 1.9 Hz, 1H), 3.22 (dd, J = 3.9, 3.0 Hz, 1H), 3.14 (ddd, J 
= 9.5, 8.3, 6.4 Hz, 1H), 2.71 (t, J = 7.2 Hz, 2H), 2.49 (dd, J = 20.0, 3.4 Hz, 1H), 
2.39 – 2.35 (m, 1H), 2.35 – 2.26 (m, 2H), 2.19 (dddd, J = 13.5, 10.1, 8.3, 5.5 Hz, 
1H), 2.00 – 1.89 (m, 2H) ppm; 
 
13C NMR (151 MHz, CD3OD); δ 213.85, 146.82, 130.61, 129.12, 115.44, 86.76, 




IR (, cm−1); 3387(br), 2953, 2860, 1720, 1614, 1516, 1361, 1302, 1221, 1159, 1105, 
1047; 
HRMS (ESI+); 344.1844 (calculated [M+H]+ 344.1856); 




6.3.7.1 Comparison of NMR Spectra of Synthetic and Isolated Incargranine A  
A comparison of 1H and 13C NMR data reported for synthetic 
incargranine A (4.1) (in CD3OD) with the data for natural, 
isolated incargranine A (4.1), as reported by Zhang9.  Professor 
Zhang kindly provided the pdf copies of 1H and 13C spectra 
shown below.  Note that the spectrometer frequency differs 
between the tabulated data (as published 600MHz, 150MHz)107 and spectra provided 
in pdf form (300MHz, 75MHz). 
Atom # Synthetic incargranine A (CD3OD) Natural incargranine A (CD3OD)9 
δ 1H 
(600MHz) 
m, J (Hz) δ  13C 
(150MHz) 
δ  1H 
(600MHz) 
m, J (Hz) δ  13C 
(150MHz) 
1 -- -- 81.7 -- -- 81.7 
2 2.39-2.35 m 42.8 2.39-2.37 m 42.7 
3a 2.49 dd (20.0, 3.4) 36.7 2.49 dd (18.9, 3.3) 36.7 
3b 2.35-2.26 m (overlap) 2.31 dd (18.9, 3.1) 
4 -- -- 213.8 -- -- 214.1 
5 3.22 dd (3.9, 3.0) 53.9 3.21 dd (3.6, 3.3) 53.9 
6 3.86-3.84 m 86.8 3.83 d (3.6) 86.7 
7a 2.35-2.26 m (overlap) 39.6 2.00-1.97 m 39.6 
7b 2.00-1.89 m (overlap) 
8a 3.92 app. td (8.4, 1.7) 68.1 3.95-3.89 m 68.2 
8b 3.84-3.80 m 3.83-3.78 m 
1ʹ -- -- 129.1 -- -- 129.1 
2ʹ, 6ʹ 7.06 d (8.6) 130.6 7.05 d (8.4) 130.6 
3ʹ, 5ʹ 6.63 d (8.6) 115.4 6.61 d (8.4) 115.5 
4ʹ -- -- 146.8 -- -- 146.8 
7ʹ(CH2) 2.71 d (7.2) 39.4 2.70 t (7.2) 39.4 
8ʹ CH2) 3.68 t (7.2) 64.6 3.67 t(7.2) 64.6 
1ʹʹ 4.06 dd (9.7, 3.0) 60.1 4.06 dd (8.6, 3.0) 60.1 
2ʹʹ 3.39-3.32 m 36.1 3.36-3.34 m 36.1 
3ʹʹa 2.22-2.14 m 27.4 2.21-2.15 m 27.4 
3ʹʹb 2.00-1.89 m(overlap) 1.95-1.92 m 
4ʹʹa 3.44 ddd (9.4, 7.9, 
5.5) 
51.2 3.48-3.40 m 51.2 
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6.4 NMR SPECTRA CHAPTER 2 – INCARGRANINE B 




































































































































6.5 NMR SPECTRA CHAPTER 3 - MILLINGTONINE 



























































































































































































































































































































6.6 NMR SPECTRA CHAPTER 4 - INCARGRANINE A 




6.6.2 13C NMR Spectrum of Compound 4.7  
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6.7 X-RAY CRYSTAL STRUCTURES OF COMPOUNDS 2.7A AND 2.7B 
Anisotropic Displacement Ellipsoid Plot for 2.7b (CCDC 958613) 
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